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IV 
Abstract 
 
The analysis of molecular binding events is of great importance for both basic research 
and drug development. Several biophysical methods can be applied for the 
characterization of interactions, regarding affinity, kinetics or thermodynamic 
parameters. One commonly applied biophysical method is label-free MicroScale 
Thermophoresis (MST), which provides Kd determination under label-free and in-solution 
conditions. This method utilizes the intrinsic fluorescence of tryptophan, an amino acid 
incorporated in the vast majority of proteins. Up to now, label-free MST was restricted to 
quantification of interactions in which only one binding partner exhibits fluorescence in 
the detection wavelength. This excludes proteins as second binding partners, along with 
a significant number of small molecules or fragments. The reason for this is that preferred 
scaffolds used for the synthesis of small molecules and fragments often include indole 
or similar ring systems, which lead to fluorescence interference in label-free MST assays. 
Because of these reasons, the main goal of this thesis was to explore approaches which 
would enable a broader applicability of label-free MST and facilitate the quantification of 
intermolecular interactions under close-to-native MST-based experimental conditions.  
In a first approach, a modified emission filter was tested to potentially cut off any 
unwanted signal arising from interfering compounds to a higher extent compared to the 
established filter. The modified emission bandwidth indeed decreased the extent of 
fluorescence interference caused by compounds. However, as many compounds exhibit 
so-called privileged structures, such as indole motifs which are also present in tryptophan 
residues of proteins, the number of compounds that still interfere in label-free assays 
highly depends on the compound library used and remains hard to predict, as different 
chemical substituents can already drastically alter the emission spectrum of compounds. 
As this modification of the device´s optical system did not provide an overall solution for 
interfering compounds and in addition could not be used for the analysis of protein-
protein interactions (PPIs), a second strategy was developed. Here, a composition 
gradient titration strategy in combination with data analysis based on a least-mean-
square approximation was applied for the quantification of PPIs in a label-free MST 
approach. The obtained Kd values were in good agreement with data obtained from 
standard (= non-label-free) MST experiments. Although in general, this approach was 
suitable for the quantification of PPIs, simulations of various experimental conditions 
revealed several limitations and restrictions regarding proteins´ fluorescence intensities, 
Fnorm values and start concentrations in general.  
Due to the limitations of both strategies, a compromise strategy between preserving the 
proteins´ native structure as much as possible, while at the same time making use of the 
  V 
advantages of a fluorescent tag was applied. Therefore, target proteins were site-
specifically labeled at their His6-tag using tris-NTA fluorophores, which was found to 
provide robust results for both, protein-small molecule and PPIs. Using such a site-
specific labeling approach, the proteins´ native structure is highly preserved and 
interference of fluorophores with ligand binding is prevented. Among three different 
fluorophores tested, RED-tris-NTA proved to be the most suitable dye for this purpose. 
Furthermore, this approach offered the possibility to directly measure MST in crude cell 
lysate, which further increased the close-to-native format. In addition, such 
measurements wouldn´t be possible using label-free MST, which further highlights the 
advantages of the site-specific labeling approach.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VI 
Zusammenfassung 
 
Die Analyse molekularer Interaktionen ist von großer Bedeutung für die 
Grundlagenforschung und für die Entwicklung neuer Arzneistoffe. Für ihre 
Charakterisierung stehen verschiedene Methoden zur Verfügung, mit denen Affinität, 
Kinetik oder auch thermodynamische Parameter analysiert werden können. Eine dieser 
Methoden ist markierungsfreie mikroskalierte Thermophorese (MST), mit der Kds 
markierungsfrei und frei in Lösung bestimmt werden können. Dafür verwendet diese 
Methode die Fluoreszenz von Tryptophan, einer Aminosäure, die in den meisten 
Proteinen vorkommt. Bisher war diese Methode auf die Analyse von Interaktionen 
beschränkt, bei denen nur einer der beiden Bindungspartner in dem detektierten 
Wellenlängenbereich fluoresziert. Damit waren nicht nur Protein-Protein Interaktionen 
(PPI) von der Analyse ausgeschlossen, sondern auch eine große Anzahl an kleinen 
Molekülen und Fragmenten. Der Grund dafür ist, dass viele dieser kleinen Moleküle und 
Fragmente sogenannte privilegierte Strukturen wie Indole oder ähnliche Ringstrukturen 
aufweisen, was zur Fluoreszenzüberschneidung führt. Daher war das Hauptziel dieser 
Dissertation Möglichkeiten zu finden, die ein breiteres Anwendungsspektrum der 
markierungsfreien MST ermöglichen und dabei weiterhin die Quantifizierung von 
Interaktionen in einem nahezu nativen Zustand ermöglichen. 
In einem ersten Ansatz wurde ein veränderter Emissionsfilter getestet, der die 
ungewollte Detektion von Fluoreszenzsignalen der Interaktionspartner reduzieren sollte. 
Tatsächlich konnte durch diesen Filter der Grad an Fluoreszenzüberschneidung gesenkt 
werden. Allerdings weisen viele chemische Verbindungen privilegierte Strukturen wie 
Indole auf, die auch Teil des Tryptophans sind. Daher ist der Grad an Signalüberlappung 
stark von der Substanzbibliothek abhängig und die Vorhersagbarkeit über das Ausmaß 
an Signalüberschneidung bleibt schwierig, da kleinste Modifikationen der chemischen 
Struktur dieser Substanzen bereits drastisch deren Emissionsspektrum verändern 
können.  
Da der neue Filter also keine generelle Lösung darstellte und auch nicht für die Analyse 
von PPI verwendet werden kann, wurde eine zweite Strategie entwickelt. Dabei wurde 
eine Mischungsgradienten-Titration (Englisch: composition gradient titration (CGT)) 
zusammen mit einer auf den kleinsten mittleren Quadraten basierten Datenanalyse für 
die Charakterisierung von PPI angewandt. Obwohl dieser Ansatz prinzipiell dafür 
geeignet war PPI zu quantifizieren, zeigten Simulationen einer Vielzahl an 
experimentellen Bedingungen, dass dieser Ansatz Limitationen in Hinsicht auf 
Fluoreszenzintensität, Fnorm Wert und Startkonzentration der verwendeten Proteine hat.  
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Aufgrund der Nachteile beider Ansätze, wurde ein Kompromiss zwischen der Erhaltung 
der nativen Struktur des Proteins einerseits und den Vorteilen einer 
Fluoreszenzmarkierung andererseits gesucht. Um das zu erreichen wurde das Protein 
orts-spezifisch mit einem tris-NTA Farbstoff fluoreszenzmarkiert, was robuste 
Messungen von sowohl PPI als auch Protein-Ligand Interaktionen ermöglichte. Durch 
die orts-spezifische Markierung bleibt die native Struktur des Proteins erhalten und eine 
mögliche Beeinträchtigung der Ligandbindung durch Farbstoffmoleküle ist 
weitestgehend ausgeschlossen. Unter verschiedenen getesteten Fluorophoren erwies 
sich RED-tris-NTA als für diese Anwendung am besten geeignet. Darüber hinaus konnte 
dieser Ansatz für MST Messungen in Zelllysat verwendet werden, was zusätzlich den 
nahezu nativen Charakter dieses Ansatzes erhöht. Dies wäre mit markierungsfreier MST 
nicht möglich gewesen und stellt damit einen weiteren Vorteil dar.  
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General Introduction 
 
 
Every intra- and extracellular process depends on the interaction between different 
molecules, such as the binding of hormones to receptors, protein-protein interactions as 
part of a signaling cascade, protein-DNA interactions for gene regulation or antibody-
antigen interactions as part of the immune response. Thereby these molecular 
interactions are highly specific, mostly reversible and fulfill strictly defined biological 
functions. Miscommunication in any of these processes can lead to a diseased state. 
Thus, robust and reliable determination of the affinity between a target molecule and its 
interaction partner is a critical step in many areas of biological, biochemical and 
biomedical research and technology1. Here, a deep understanding of the physical forces 
governing molecular recognition, affinity and specificity, is a prerequisite for the 
development of new and effective drugs2. As the drug discovery process is a time 
consuming (10 or more years from a hit to the drug on the market) and highly expensive 
(currently around 1 billion €) process, it is of great importance that biophysical methods 
provide reliable and robust results already during the early stages of drug development3. 
Nowadays there are various methods available for the investigation of intermolecular 
interactions and for the determination of underlying binding affinities (Figure 1)4,5. All 
methods can be categorized into either label-based, surface-immobilization based, or 
label-free and in-solution techniques4,5. Additionally, all available methods have their 
advantages and disadvantages regarding sensitivity, sample-, and time-consumption 
and provided information content. Thus, it is in general recommended to use more than 
one technique to verify the data outcome from a single analytical binding assay4.  
 
 
Figure 1: Schematic principle of ligand-binding assays. Free target and ligand molecules are present. 
Molecules start to bind to each other and form complexes. This binding event is detected and transduced 
into a signal output that can further be quantified.  
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A comprehensive listing of all available assays is beyond the scope of this thesis. 
However, the most important techniques for the quantitative characterization of 
intermolecular interactions are briefly summarized below and categorized according to 
their basic measurement principles.  
 
1 Labeling-based methods  
 
For a label-based approach for the quantification of biomolecular interactions, different 
types of labels and methods are available. The earliest label-based experiments were 
carried out using radiolabels for radioimmunoassays6. Such radio-isotopic labels, like 3H, 
125I and 32P, exhibit several disadvantages like radioactive waste and its disposal, high 
costs, the requirement for special licenses, and general significant health and 
environmental hazards7. This led to the development of other technologies, which are 
not harmful but still provide high sensitivity, such as fluorescence-based methods8. For 
such fluorescence-based assay, the attachment of a specific fluorophore to the molecule 
of interest is required. The behavior of the labeled molecule and the changes observed 
upon ligand binding will then be recorded. These changes can be detected e.g., as a 
quenching of the fluorescence intensity upon binding, as a change in the movement of 
molecules in a temperature gradient, or as changes in fluorescence anisotropy9–12 (Table 
1). However, such assays typically require time-consuming fluorescent labeling steps 
that in addition can interfere with the native conformation of the target molecule and 
might alter binding energetics13. The fact, that most molecules are labeled with more 
than one fluorophore per molecule to increase sensitivity, can further contribute to 
destabilization or alteration of the labeled molecules. To exclude any unspecific binding 
and negative influence of the labeling approach, carefully designed control experiments 
are required. In addition, fluorescence-based assays have to deal with potential 
fluorescence-interference of compounds, for which alternative methods have to be 
applied14.  
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Table 1: Fluorescence-based methods. 
Method Strengths Limitations  Sample 
consumption 
Affinity 
range 
MST* 
MicroScale 
Thermophoresis 
Fast, low sample 
consumption, 
additional information 
on protein 
aggregation/precipita
tion, no instrument 
maintenance 
required, 
measurements in cell 
lysate and 
plasma15,16. 
Fluorescence label required 10 µL at nM 
concentration per 
data point 
pM to mM 
TSA** 
Thermal shift assay 
Fast4  Fluorophore binding involved, 
quenching or aggregation can 
cause experimental artifacts4, 
not applicable for hydrophobic 
proteins4 
40 µL of 2 µM4 1 nM to 
100 µM4 
FP/FA*** 
Fluorescence 
polarization/ 
anisotropy 
Highly reproducible17, 
high throughput/fast5, 
low cost18 
Fluorescence label required, 
requires large change in size 
upon binding5, 
autofluorescence/quenching/li
ght scattering interference18 
Several µL at 
nM 
concentration 
per data point5 
nM to mM5 
Protein-observed 
NMR**** 
Nuclear magnetic 
resonance 
High structural 
resolution 
(identification of 
binding epitopes)19 
Protein labeling required, high 
sample consumption4, 
complex data analysis5, low 
throughput, not possible for 
large proteins20 
Several mg per 
data point5 
100 nM to 
mM4 
*Quantifies the difference in thermophoresis and TRIC of the unbound and the bound state of a molecule. 
**Quantifies the shift in thermal unfolding of a protein upon ligand binding11. 
***Measures the polarization or anisotropy of light caused by changes in molecular size18.  
**** Follows 1H/15N/13C chemical shifts of specific residues in the protein21.   
 
 
2 Surface-immobilization based techniques 
 
Another class of biophysical methods for the investigation of binding affinities are 
surface-immobilization based techniques. These methods require the immobilization of 
one binding partner to a solid surface, which often is specifically functionalized for the 
immobilization procedure. The potential interaction partner will then bind to the 
immobilized molecule, whereby the binding event can either be detected due to changes 
in refractive index of light (surface plasmon resonance, back-scattering interferometry), 
changes in the vibration frequency (quartz crystal microbalance), or due to changes in 
the amplitude and phase of acoustic waves (surface acoustic wave)22–25. While surface-
immobilization techniques are highly sensitive and have provided valuable knowledge in 
the study of molecular interactions, they do not reflect a physiologically relevant 
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environment as one binding partner is fixed to the surface and cannot diffuse free in 
solution. This can, on the one hand, alter the molecular structure or it can also sterically 
hinder the ligand from binding if the active site is in close proximity to the surface26. In 
addition, immobilization-based assays are often time-consuming and might require 
challenging surface immobilization strategies. However, once a capture molecule is 
immobilized to the solid surface, it can be used for the quantification of several binding 
events, as surface regeneration strategies can be applied27. The most important 
immobilization-based techniques, their strengths, limitations, sample consumption and 
affinity range are listed in Table 2. 
 
Table 2: Immobilization-based methods. 
Method Strengths Limitations Sample 
consumption 
Affinity 
range 
SPR* 
Surface 
plasmon 
resonance 
Kinetics and 
thermodynamics5, high 
sensitivity22 
Surface-immobilization, long 
experimental time, signals 
altered by solvent effects4 
Sub-µg to µg5 Sub-nM 
to low 
mM5 
QCM** 
Quarz crystal 
microbalance 
Real-time determination of 
interactions with proteins 
and cells4 
Surface-immobilization 15 nmol protein 
(0.5 mg of 30 
kDa)4  
1 nM to 
500 µM4 
BSI*** 
Backscattering 
interferometry 
Simple and low-cost 
hardware and high 
sensitivity28, kinetics23 
Surface-immobilization 1µL of 5 µM 
protein28 
pM to 
µM23,28 
*Molecular interactions on the chip change the absorbed mass on the surface which directly lead to changes in the 
intensity of the reflected light. The intensity values are then converted into resonance signals by the optical detection 
unit22.   
**Monitoring vibration frequency of a quartz crystal upon interaction between a ligand and an immobilized protein or cell29. 
***Detects changes in refraction pattern of light, which passes through the sample in the channel of a microchip23. 
 
 
3 Label-free in-solution techniques 
 
The techniques described above require labeling (attachment of an isotope or 
fluorophore) or surface immobilization of one of the binding partners, which can lead to 
misleading results, as the incorporated dye or the solid surface can impair protein 
function. This can occur due to destabilization of the proteins upon the immobilization or 
labeling procedure, or due to a close proximity of the modifications to the active site, 
whereby the latter might sterically hinder the ligand from binding13,26. Hence, label-free 
in-solution determination of binding strength is more favorable because the risk of 
perturbing the system is significantly reduced. Some methods exist which use inherent 
properties of the molecules for binding detection, without the need for any label or 
surface immobilization. Examples are isothermal titration calorimetry, analytical 
ultracentrifugation, dynamic light scattering and label-free MicroScale Thermophoresis. 
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These techniques provide different advantages and disadvantageous regarding costs, 
efficiency and the type of information they provide (Table 3)4,5. Generally, label-free 
detection systems are not as sensitive as label-based methods and thus often require a 
higher quantity of sample, but they provide physiologically relevant results.  
 
Table 3: Label-free and in-solution based methods. 
Method Strengths Limitations Sample 
consumption 
Affinity 
range 
ITC* 
Isothermal 
titration 
calorimetry 
Label-free and in-solution, 
Thermodynamic parameters, 
high precision and 
reproducibility17 
Low throughput5, long 
preparation time17, buffer 
limitations5, high sample 
consumption4 
Several hundred 
µg per binding 
assay5 
nM to 
sub-mM5 
AUC** 
Analytical 
ultra-
centrifugation 
Label-free and in-solution, 
size-independent5 
Sedimentation equilibrium 
needs to be reached5  
Several hundred 
µL at nM to µM 
concentration per 
data point5 
nM to 
mM5 
DLS*** 
Dynamic light 
scattering 
Label-free and in-solution Requires defined difference in 
hydrodynamic radius of free 
and bound molecules5 
Several µL at pM 
concentration per 
data point5  
pM to 
mM5 
Label-free 
MST**** 
Label-free and in-solution, fast, 
additional information on 
protein 
aggregation/precipitation, no 
instrument maintenance 
required 
Requires strong intrinsic 
fluorescence, problems with 
autofluorescence, only one 
binding partner can fluoresce  
10 µL of nM 
concentration per 
data point 
nM to 
mM 
* Measures the heat which is released or absorbed during combining of two substances by titration30 
**Detects the separation of unbound and bound molecules using centrifugal force5.    
***Processes the time-dependent fluctuations in scattered light to yield the hydrodynamic radius of particles in solution, 
which will change upon binding31.  
****Quantifies the difference in thermophoresis and TRIC of the unbound and the bound state of a molecule.  
 
 
4 Theoretical background 
 
The following chapter provides theoretical background information on MicroScale 
Thermophoresis (MST) for Kd determination. As this method is based on fluorescence, 
the physical principles behind fluorescence will be described as well.      
 
4.1 Basic principles of fluorescence 
 
Fluorescence, whether those of fluorophores or intrinsic fluorescence of tryptophan (Trp) 
and tyrosine (Tyr), is the basis for MST investigations. For this reason, the phenomenon 
and the underlying physical principles of fluorescence will be described first. 
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Fluorescence occurs when an electron is excited by light with a distinct wavelength and 
then falls back to its ground state. More in detail, light excitation will cause a transition of 
an electron from its ground state to a higher energy electronic state, while the energy 
difference between the ground and the excited state reflects the required excitation 
energy32. In this excited state, the system will only remain for a few nanoseconds before 
the excited electron loses some of its energy due to heat or vibrational rotation32. The 
electron can then fall back to its ground state while emitting energy in form of a photon, 
a phenomenon called fluorescence32. Thereby, the fluorescence emission wavelength is 
always longer than the excitation wavelength, since it contains less energy33. The 
difference in excitation and emission wavelength is called Stokes shift and is of 
importance for all fluorescence-based assays, as it enables the excitation of 
fluorescence at one wavelength and its emission at another. Thereby, a large Stokes 
shift minimizes potential cross-talk between the excitation and emission of 
fluorescence32,34.  
 
Figure 2 shows a simplified Jablonski diagram, in which the process of fluorescence is 
illustrated.  
 
 
Figure 2: Jablonski diagram. Jablonski diagram for schematic illustration of fluorescence. Electronic states 
of a molecule are present as horizontal lines, while thicker lines being electronic energy levels and thinner 
lines are vibrational energy states. Absorption of photons from UV-light leads to a transition of the electron 
(blue) from the ground state to an excited state (here Sn). Loss of energy due to vibrational relaxation leads 
to an electron transition towards a lower energetic singlet state. Transition to its ground state leads to the 
emission of fluorescence. Figure was modified from Pingoud et al.35 and Sasaki et al.36.   
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4.2 Binding affinity of biomolecular interactions  
 
For the comprehensive understanding of the molecular mechanisms behind 
biomolecular interactions, different parameters can be quantified. Besides binding 
kinetics and thermodynamic parameters, binding affinity can be quantified by measuring 
the equilibrium dissociation constant (Kd), or the equilibrium association constant (Ka), 
respectively. Binding affinity is influenced by non-covalent intermolecular interactions 
such as hydrogen bonding, electrostatic interactions, hydrophobic and Van der Waals 
forces between involved molecules17. Thereby, the binding process itself is regarded as 
an equilibrium condition, which results from a balance between association and 
dissociation of two interacting molecules17. The equilibrium state is dynamic, as 
molecules constantly form a complex while in the same time complex dissociates 
again37.  
In case of an interaction, two mixed proteins A and B will at some point colloid and bind 
together to form a complex. Most biological binding reactions can be described by a 1:1 
interaction scheme. For such an interaction, the time-dependent association and 
dissociation can be expressed as shown in equation 117. 
(1) 
AB represents the protein–ligand complex and kon [M-1min-1, number of association 
events per minute and molar] and koff [min-1, number of dissociation event per minute] 
are the kinetic rate constants17. 
At equilibrium, the association reaction of the monomers towards the complex and the 
dissociation reaction of the complex are equal, as given by equation 217, 
,         (2) 
where the square brackets represent the equilibrium concentration of the single 
molecules ([A], [B]) or the complex ([AB]), respectively. The binding constants, Kd and 
Ka, are then defined by the law of mass action and can be expressed as17 
.         (3) 
The relation between Ka and Kd can be expressed as17 
.           (4) 
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The equations above form the basis for determining their values experimentally. Thereby 
the equilibrium constant characterizes the affinity of molecules for each other, by 
calculating how much ligand is bound by the protein at equilibrium. An interaction with a 
fast association and a slow dissociation rate will result in a high binding affinity and in a 
low dissociation constant. Thus, the lower the dissociation constant the stronger the 
binding. In biological systems “tight binding“ corresponds to a dissociation constant in 
the order of 1 nM or less38. For example, therapeutics should bind to their targets with 
high affinity as this will not only decreases costs but also the risk of potential side effects 
as lower doses can be applied39. The different dimensions of Kd-values are illustrated in 
Figure 3.  
 
 
Figure 3: Kd dimensions. Overview of Kd dimensions, ranging from low, medium to high affinity38.  
*40; **41; ***42 
 
 
4.3 MicroScale Thermophoresis  
 
Thermophoresis was first described in the 19th century by Carl Ludwig and Charles Soret. 
Here, thermophoresis was described as a directed movement of particles along a 
temperature gradient, typically from a hot to a cold region43. This leads to a change in 
concentration, which can be quantified by the Soret coefficient ST (the percentage of the 
concentration change per kelvin)44.  
(5) 
Several decades later, thermophoresis was further investigated by Philipp Baaske and 
Stefan Duhr, who used this thermophoretic effect for the quantification of molecular 
interactions on a micro scale45,46. Since the foundation of NanoTemper Technologies 
GmbH in 2008, MST developed into a well established biophysical tool for the rapid, 
sensitive and immobilization-free quantification of biomolecular interactions, ranging 
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from oligonucleotide interactions, like protein-DNA or RNA interactions, to protein-
protein, protein-small molecule and protein-lipid interactions free in-solution47–50. 
Thereby, both the binding of ions, as well as the interaction of high molecular weight 
molecules and multidomain complexes can be quantified51–53. In addition, MST 
experiments can be carried out in any buffer, even in plasma and cell lysate, which allows 
for the evaluation of interactions under close to native conditions15,16. Another advantage 
of MST is the low sample consumption and a large dynamic range of affinities that can 
be quantified (pM to mM).  
 
4.3.1 Theoretical background 
 
Theoretical background information was obtained from the User Starting Guide for the 
Monolith NT.115_V23 if no other reference information is provided. 
  
MST is used for the affinity quantification of molecular interactions. It is carried out in a 
Monolith instrument (NanoTemper Technologies GmbH), which consists of a 
fluorescence excitation and detection unit and an IR laser beam with 1480 nm 
wavelength (Figure 4 A)1. For the experiments, a serial dilution of the ligand is prepared, 
and a constant amount of a fluorescent target molecule is added to all dilution steps. 
Samples are then filled into glass capillaries with a maximal volume of 10 µL, placed on 
a tray and loaded into the Monolith device. At the beginning of the experiment, the 
fluorescence intensity of each capillary is recorded (capillary scan), to ensure sample 
homogeneity and accurate pipetting. Next, the IR laser is used to locally increase the 
temperature of the sample within a region spanning ~200 µm in diameter by 2 – 6 °C, 
depending on the MST power used (Table 4)1. This increase in temperature leads to a 
decrease of the observed fluorescence in the observation window, which comes from a 
change in fluorescence due to TRIC (temperature related intensity change) during the 
first seconds after laser activation and from a change in the concentration of the 
fluorescent molecule due to thermophoresis. Both parameters together, the 
thermophoretic movement and the TRIC are analyzed for MST quantification. Thus, the 
overall change in fluorescence 
𝜕
𝜕𝑇
(𝑐𝐹) after IR laser activation can be expressed as: 
   (6) 
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As the temperature sensitivity of the dyes, which are used for MST analysis, is highly 
sensitive towards changes in their local environment, ligand binding can be detected due 
to changes in the target conformation or in the intramolecular dynamics or because of a 
close proximity of the binding site and the dye. But not only TRIC, but also 
thermophoresis will change upon binding, as it depends on the size, charge and 
hydration shell44. Since at least one of these parameters will change upon binding, it is 
possible to quantify the thermophoretic change from an unbound to a bound molecular 
state.  
 
4.3.2 Calculation of normalized fluorescence and binding affinities 
 
MST is quantified by dividing the fluorescence intensity in the hot region by the 
fluorescence intensity in the cold region, which refers to the time after a defined MST-on 
time (Table 4) and the time before laser-on time, respectively. This value is normalized 
(Fnorm), converted into promille and plotted against the logarithmic ligand concentration, 
which then yields a dose-response curve, from which the affinity constant can be 
obtained, by fitting the following equation  
, (7) 
where f(c) is the fraction bound at a given ligand concentration c, unbound is the Fnorm 
signal of the target, bound is the Fnorm signal of the complex, Kd is the dissociation 
constant, and ctarget is the final target concentration in the assay.  
In case the fluorescence of the target molecule changes upon ligand binding without IR 
laser activation, this ligand-induced fluorescence change can be quantified as well. For 
this, it needs to be determined, if the fluorescence change is either a result of unspecific 
material loss or is ligand-binding specific. This can be done using the SD test, in which 
the samples are denatured using 4 % SDS and 40 mM DTT and heat, to then compare 
the fluorescence intensity of the samples prior and after denaturation. If the fluorescence 
counts are equal, the change in fluorescence was caused by the ligand-binding and thus 
the fluorescence scan can be evaluated.  
 
Figure 4 represents some general principles of the MST measurement. Thereby, the 
optical system and the sample containing glass capillaries (A), a standard MST trace 
together with illustrations of the processes inside the capillaries during the MST 
measurement (B), MST traces of a 16-step MST binding experiment, as well as the 
resulting dose-response curve are shown (D).   
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Figure 4: General MST measurement. A) Schematic illustration of MST optical system. Samples are 
loaded into glass capillaries and sample fluorescence is excited and recorded with the same objective. An 
implemented IR laser is used to heat a defined spot, leading to a temperature gradient in the capillaries.  
B) Illustration of an MST trace. At the beginning of the experiment, molecules are homogeneously 
distributed. After activation of the IR laser, molecules move out of the heated spot, leading to a steep 
decrease in detected fluorescence intensity due to the TRIC effect and thermophoresis. After around 10 sec, 
molecules reach a steady state, before they diffuse back ones the laser is switched off again. C) MST binding 
experiment. Normalized MST traces of unbound (black), intermediate state (grey) and bound molecule (red) 
are shown. Marked regions of Fcold and Fhot refer to fluorescence before (Fcold) and fluorescence after laser 
activation (Fhot). Cursor positions define fluorescence values that are used for data analysis. D) Dose-
response curve. Normalized fluorescence counts are plotted against the logarithmic ligand concentration. 
Fnorm refers to the normalized ratio of Fhot / Fcold *1000. The inflection point represents the Kd value. The 
figure was modified from Jerabek-Willemsen et al.47.  
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The following table summarizes basic MST background information and measurement 
parameters.   
 
Table 4: Overview of general MST measurement parameters. 
Capillary type  Glass capillaries are used for sample loading. 
Standard capillaries are physically treated to obtain 
high-quality surface properties. Premium capillaries 
are covalently coated with a polymer to prevent 
surface adsorption of molecules.  
LED power  Is used to excite the fluorophores. Intensity can be 
selected and should be high enough to detect 
sufficient fluorescence intensity.  
Capillary Scan At the beginning of the MST experiment, the 
fluorescence intensity of each capillary is detected. 
This provides already valuable information about 
sample adhesion to the capillary wall, 
inhomogeneous sample and incorrect pipetting.   
MST power Refers to the IR laser power and thus to the extent 
of the temperature gradient. Intensity can be 
selected, while the higher the MST power, the 
larger is the temperature increase.  
MST trace Defines the typical motion of a fluorescent molecule 
in a temperature gradient, that is recorded for 5 sec 
before laser-on time, 20 sec laser-on time and 5 sec 
after laser-on time.  
MST-on time Defines the time of IR laser activation, which is used 
for data quantification.  
Fnorm value Describes the normalized fluorescence of MST 
traces. 
 
 
4.3.3 Sample quality control using MST 
 
MST data will not only provide binding affinity data, but will also deliver direct feedback 
on sample quality regarding aggregation or sticking of the fluorescent molecule to the 
surface of the capillaries. As aggregates can be observed by irregular MST traces, 
broader shapes of scanned capillary fluorescence are an indication for sample 
adsorption to the capillary wall. To improve bad sample quality, an addition of detergents 
or centrifugation of the samples can be used to get rid of these effects. Figure 5 illustrates 
both phenomena.  
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Figure 5: MST sample quality control. A) Schematic illustration of MST traces. The upper trace shows an 
irregular bulky shape because of the presence of aggregates. B) Different shapes of capillaries are overlaid: 
very strong adsorption of samples to the capillary wall (red), adsorption and no adsorption. Capillary cross-
section is illustrated above and shows adsorption of molecules (red) to the capillary wall. Figure was modified 
from the MO.Control software.   
 
 
4.3.4 Different MST instruments 
 
NanoTemper Technologies GmbH provides Monolith instruments for the analysis of 
interactions in different spectral regions: blue (excitation 460 nm – 480 nm, emission  
515 nm – 530 nm), green (excitation 515 nm – 525 nm, emission 560 nm – 585 nm) and 
red (excitation 605 nm – 645 nm, emission 680 nm – 685 nm). For the measurements, 
covalently attached fluorescent dyes or fluorescent fusion proteins are required. The 
Monolith NT.115Pico detects low concentrations of red-emitting fluorophores, which 
allows analysis of high-affinity interactions with Kds in the low pM range. The Monolith 
NT.LabelFree detects intrinsic fluorescence of proteins, which originates from Trp and 
Tyr residues. Thus, label-free MST provides a label-free in-solution analysis method.  
 
5 Aims of the thesis 
 
Since MST quantifies the transition from an unbound to a bound state of a protein, by 
recording changes in the proteins thermophoretic signal, it cannot be addressed to 
interactions, in which both binding partners fluoresce in the detection wavelength. 
Regarding an interaction, in which both binding partners fluorescence in the same 
spectral region, it is no longer possible to distinguish between an unbound and a bound 
state of a protein, as all recorded MST time traces would be a mixture of ligand, target 
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and complex time trace with unknown distributions. In addition, the serial dilution of the 
ligand might exceed the detection range, resulting in nondetectable low ligand 
concentrations and in detector saturation for high ligand concentrations, as illustrated in 
Figure 6. 
 
 
Figure 6: Capillary Scan. Schematic representation of a capillary scan of a 16-step standard serial dilution 
of two fluorescent molecules. Red peaks indicate the lowest ligand concentration (right) that cannot be 
detected by the optical system and the highest ligand concentrations (two left), which lead to detector 
saturation.   
 
 
Fluorescence interference of compound is of special concern when planning label-free 
MST experiments. Many small molecules are based on privileged structures with indole 
motif, which is also present in the Trp residues of proteins. In addition, this method is not 
accessible to the analysis of protein-protein interactions (PPIs), which is a large scientific 
field of interest, comprising antibody-antigen interactions, among others.   
The main aim of this thesis was to establish new approaches that would expand the 
application range of label-free MST and near-native approaches for MST in general. This 
thesis is divided into three major aims, which are discussed in three separate chapters. 
Each chapter deals with a distinct strategy to overcome the limitations of label-free MST 
and to find options for MST affinity analysis under close to native physiological conditions 
without the limitations described above.  
The first aim was to increase the application range of the Monolith NT.LabelFree device 
for fragment and small molecules screenings. The assumption was that with the careful 
selection of an emission filter one could cut-off unwanted fluorescence signal from 
compounds, which otherwise leads to fluorescence interference in the assay.  
In Chapter 1 detailed analysis of factors determining the extent of fluorescence 
interference is presented and the influence of the emission filter selection is discussed.  
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The second aim was to establish an experimental approach that would enable the 
analysis of PPIs with label-free MST (Chapter 2). This chapter deals with the applicability 
of a composition gradient titration, combined with a least-mean-square fitting algorithm, 
for Kd determination without eliminating parts of the detected signal. Using this approach, 
label-free MST could, for the first time, be used to quantify PPIs. However, this approach 
was limited to proteins that exhibit similar fluorescence intensities and comparable Fnorm 
values. In addition, low affine interactions might require high protein concentrations, 
whereas ultra-low sensitivities are not easy to determine as the device´s sensitivity might 
not be high enough.  
Because the first two aims have not improved the applicability of label-free MST, an 
additional approach was considered. The main aim of Chapter 3 was to investigate and 
develop an MST approach that would enable the quantification of intermolecular affinities 
under near-native conditions. The combination of a site-specific labeling targeting the 
oligohistidine tag of proteins and an MST optimized fluorophore was investigated as a 
tool to achieve near-native experimental conditions.  
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Chapter 1  
 
 
1 Introduction 
 
The main goal of the pharmaceutical research is the specific manipulation or inhibition 
of disease-related targets using small molecular compounds. During early stages of drug 
discovery often very large compound libraries (up to 4 billion compounds) are screened 
against a target molecule in a single-point binding experiment54. In case the target and 
the natural ligand are known, these libraries mostly contain small molecules with highly 
similar structures, which match the targets active site and the structure of the natural 
ligand55. However, if this detailed information is missing, a highly diverse library is more 
favorable, as it increases the chance for a successful screening campaign55. Around 30 
years ago, Evans and his colleagues observed the potential of certain regularly occurring 
structural motifs as templates for defined modifications to generate novel and potent 
drugs56,57. These organic scaffolds are known as “privileged structures”56. Often, these 
scaffolds are derived from natural products and exhibit similar motifs than the peptide 
backbone56,58,59. In 2010, Welsch et al. published a broad list of privileged structures, 
such as indoles, quinolines, purines, and benzimidazoles, among others58–60. Table 5 
lists different privileged structures together with their therapeutic effects as structurally 
modified drugs.  
Among all privileged structures, the indole scaffold probably represents one of the most 
important structural subunits for the discovery of new drug candidates56. It is widely 
distributed in biological systems as it is an important constituent of the amino acid Trp, 
of alkaloids and of the neurotransmitter serotonin56. Furthermore, the indole scaffold is 
present in many drugs, such as GPCR agonists and antagonists, ion channel blockers 
and enzyme inhibitors56.  
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Table 5: Overview of different privileged structures.  Modified from Welsch et al.59  
Name Privileges structure Drug class 
Indole 
 
Anti-cancer, serotonin-reuptake 
inhibitors, anti-depressives 
Quinoline 
 
Anti-malarial, 
immunosuppressants, anti-
cancer 
Purine 
 
Anti-viral, anti-bacterial 
Quinoxaline 
 
Anti-glaucoma, anti-bacterial 
Benzodiazepine 
 
Anxiolytics, sedatives 
Arylpiperidine 
 
Anti-parkinsonian, anti-diabetic 
Benzylpiperidine 
 
Anti-parkinsonian, vasodilators 
Benzothiophene 
 
Anti-asthmatic 
Dihydropyridines 
 
Vasodilators 
Benzimidazole 
 
Anti-helmintic, anti-histaminic 
 
 
The aromatic systems incorporated in the privileged structure can lead to the 
fluorescence interference in any label-free technique that uses the intrinsic Trp 
fluorescence to quantify intermolecular interactions. This can cause misinterpretation of 
the signal output, leading to potential false negatives and false positives61–64. Different 
strategies can be applied to overcome this problem. One way is simply to increase the 
concentration of fluorescently labeled target in an assay because the degree of 
fluorescence interference is directly related to the ratio between the concentration of the 
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compound and the concentration of the labeled target61,63. However, the concentration 
of labeled target used in many assays is in the nM range, whereas screened compounds 
are typically tested at µM – mM concentrations, making this approach not generally 
applicable65. Especially in MST experiments the target concentration used in the assay 
needs to be below the Kd, whereas the ligands are used in concentrations 20 to 50-fold 
above the Kd. With this, the free ligand concentration is similar to the total ligand 
concentration and ligand depletion is avoided66. This ensures maximum resolution and 
highest precision when determining dissociation constants44.  
Another described strategy for the avoidance of fluorescence interference results from 
the observation that lower wavelength dyes, like Fluorescein, Cyanine 3 or Rhodamine 
110, are particularly prone for compound interference, since the percentage of 
fluorescent compounds is on average inversely proportional to the recorded emission 
wavelength63,67. Thus, many fluorescent compounds show emission below  
530 nm61,62,68,69. Consequently, longer wavelength, red-shifted dyes, like Alexa 647 or 
Cyanine 5, are often preferred and can be successfully applied to reduce fluorescence 
interference61–63. Simeonov et al. analyzed a large chemical library with compound 
concentrations that are typically used in HTS for their fluorescence interference in 
different spectral regions14. About 5 % of the library was more fluorescent than 10 nM of 
the fluorophore 4-methylumbelliferone, but by red-shifting the emission wavelength, this 
number could be decreased14. Again, this solution strategy cannot be applied for label-
free MST, as the fluorescence of Trp is recorded, which cannot be red-shifted. Another 
solution strategy would be to separate each recorded time trace into all underlying time 
traces, to then only analyze the transition from an unbound protein to its bound state, 
while excluding the time trace that arises from the ligand. A similar approach for signal 
separation can be found in literature, in which linear unmixing is used for fluorescence 
multichannel microscopy images, with which regions of overlapping fluorescence signals 
are reassigned to the different fluorophores used, regarding both their color and their 
intensity70. However, this is only possible as reference spectra of all underlying dyes can 
be recorded, which is not the case for label-free MST, for which the time trace of a pure 
complex is missing. Hence, another strategy to overcome fluorescence interference is 
required. The simplest possibility would be to separate the fluorescent signal which 
arises from the protein from the signal that arises from the compound upon detection. In 
principle, this is possible when protein and compound exhibit significant differences in 
any detectable output signal, ranging from fluorescence excitation, emission to 
fluorescence lifetime. Signal separation using different fluorescent lifetimes is already 
used in TR-FRET (time-resolved fluorescence resonance energy transfer) assays and in 
FCS (fluorescence correlation spectroscopy) measurements71,72. These techniques are 
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based on the observation that compound fluorescence often displays very short lifetimes, 
whereas that of the fluorophores such as Trp is longer65. Using such a time-resolved 
method can reduce interference by measuring the emission of the fluorophore right after 
the compound autofluorescence has vanished65,73,74. The main issue of this approach is 
that Trp itself can have very different fluorescent lifetimes. Thus, depending on its local 
environment, if it is in contact with other residues or if it is exposed to the solvent, its 
fluorescence lifetime can vary to a significant extent75. Thus the fluorescence lifetime of 
proteins can range from 0.5 to 5.5 ns75,76. Moreover, compounds can show diverse 
fluorescence lifetimes ranging from less than 0.2 to 1.4 ns and thus not always exhibit a 
shorter fluorescence lifetime compared to proteins77. To conclude, the variation of 
fluorescence lifetimes is too high to be used for detection in label-free MST. 
In contrast, the emission of proteins in the UV-Vis spectral region is highly conserved, 
while depending on the compound library used, emission profiles of compounds can vary 
to a significant extent. Thus, the fluorescence emission could be used for a spectral 
separation of protein and compound.  
The following will describe the efforts to separate the fluorescence signal that arises from 
the protein from that of the compound using appropriate emission filter. The 
spectrofluorometric profiling of several proteins and compounds was performed and the 
applicability of a new emission filter for label-free MST was tested. Obtained data showed 
that although the new filter can significantly reduce the fluorescence interference, the 
success rate highly depends on the chemical composition of the compound library used.  
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2 Materials 
 
Table 6: Chemicals 
Chemicals Company 
DMSO (≥ 99.8 %) 
Carl Roth GmbH + Co. KG, Karlsruhe, DE, cat.no. 
A994.2 
DTT 
Carl Roth GmbH + Co. KG, Karlsruhe, DE, cat. no. 
6908.2 
GlcNAc Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. T2144 
H2O AnalaR NORMAPUR® 
VWR Prolabo Chemicals, Darmstadt, DE, cat. no. 
102927G 
HEPES 
Carl Roth GmbH + Co. KG, Karlsruhe, DE, cat. no. 
HN78.2 
Maltose Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. M5885 
MST buffer NanoTemper Technologies GmbH  
NaCl 
Carl Roth GmbH + Co. KG, Karlsruhe, DE, cat. no. 
0962.1 
Pluronic® F-127 Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. P2443 
Roti®-Stock 10x PBS 
Carl Roth GmbH + Co. KG, Karlsruhe, DE cat. no. 
1058.1 
SDS 
Carl Roth GmbH + Co. KG, Karlsruhe, DE, cat. no. 
4360.1 
Tween®-20  Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. 93773 
 
 
Table 7: Buffers and solutions 
Buffers and solutions Composition 
MST buffer   50 mM Tris-HCl, 250 mM NaCl, 10 mM MgCl2, pH 7.8 
MSTP buffer 0.1 % Pluronic® F-127 in MST buffer 
MSTT buffer 0.05 % Tween® 20 in MST buffer 
PBSP  0.1 % Pluronic® F-127 in PBS buffer 
PBST 0.05 % Tween® 20 in PBS buffer 
SD mixture 4 % SDS, 40 mM DTT 
 
 
Table 8: Proteins 
Proteins Company 
BI09 IgG Boehringer Ingelheim, Ingelheim, DE 
BLIP DBV1  CRELUX GmbH, Munich, DE 
BRD4 CRELUX GmbH, Munich, DE 
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CREBBP CRELUX GmbH, Munich, DE 
His6-MBP 
Was kindly provided by Susanna v. Gronau and Dr. 
Sabine Suppmann from the biochemistry core facility 
of the Max Planck Institute of Biochemistry, Munich, 
DE 
His6-p38α MAPK  CRELUX GmbH, Munich, DE 
His6-Ca II  
Sino Biological Inc., Beijing, CN, cat.no. 10478-H08E-
50 
MEK1 CRELUX GmbH, Munich, DE  
Protein A Thermo Fisher Scientific, Rockford, US, cat. no. 21181 
SNF CRELUX GmbH, Munich, DE 
TEM DBV1 and TEM P107A CRELUX GmbH, Munich, DE 
α-Amylase 
Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. 
10102814001 
 
 
For the characterization of compound emission spectra, in total 1513 compounds were used. This set 
comprised compounds out of 7 different screening campaigns and 8 commercially available inhibitors. All 
compounds were diluted in 100 % DMSO upon arrival and were stored at -20 °C.  
 
Table 9: Compound libraries 
Target (number of compounds) Supplier 
(±)-Sulpiride against carbonic anhydrase Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. S8010 
AGI-6780 against IDH2 
Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. 
SML0895 
BIRB 796 against p38α LC Laboratories®, Woburn, US, cat. no. D2744 
Commercially available compounds (8):  
Compounds against MCAD (245) 
LMU Medical Center, Dr. von Hauner Children’s 
Hospital, Munich, DE  
Fragments against Fyn (18) CRELUX GmbH, Munich, DE 
Fragments against MEK1 (193) Sanofi Aventis, Paris, FR 
Fragments against PAH (56)  
LMU Medical Center, Dr. von Hauner Children’s 
Hospital, Munich, DE 
Furosemide against Ca II Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. F4381 
I-CBP112 against CREBBP 
Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. 
SML1134 
IDH-C227 against IDH1 
Xcess Biosciences, Inc., San Diego, US, cat. no. 
M60043 
IDH-C35 against IDH1 
Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. 
SML0839 
PHGDH inhibitors (349)  Astra Zeneca, Cheshire, UK  
SB203580 against p38α  Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. S8307 
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small molecules against ATAD-3 (298) Astra Zeneca, Cheshire, UK 
TANK inhibitors (346)  Astra Zeneca, Cheshire, UK 
 
 
Table 10: Devices 
Device Company 
Calibration Thermostat (Ecoline ER 207) LAUDA GmbH & CO. KG, Lauda-Königshofen, DE 
FP-8300 Fluorescence Spectrometer  JASCO Germany GmbH, Gross-Umstadt, DE 
NanoDropTM One  Thermo Fisher Scientific Inc., Wilmington, US 
NanoPhotometer Implen GmbH, Munich, DE 
NT.LabelFree (339 – 380 nm and 320 – 340 nm 
emission filter) 
NanoTemper Technologies GmbH, Munich, DE 
 
 
Table 11: Centrifuges and rotors 
Centrifuges and rotors Company 
Centrifuge 5424 Eppendorf AG., Hamburg, DE 
Centrifuge 5430 R  Eppendorf AG., Hamburg, DE 
Rotor FA-45-24-11-HS Eppendorf AG., Hamburg, DE 
 
 
Table 12: Online tools and software 
Online tools and software Company 
NT.Control 2.0.2.29 NanoTemper Technologies GmbH, Munich, DE 
PyMOL(TM) 1.7.4.5 Edu - Educational Product Schrödinger, LLC, New York, US 
MO.Control_x86_1.5.3.6096 NanoTemper Technologies GmbH, Munich, DE 
MO.AffinityAnalysis_x86_2.2.7.6056 NanoTemper Technologies GmbH, Munich, DE 
Chemograph Plus 6.4  DigiLab Software GmbH, Altenholz, DE 
 
 
Table 13: Further material 
Material Company 
320 – 340 nm filter (AHF F47-330) AHF analysetechnik AG, Tübingen, DE 
330 – 380 nm filter (Semrock FF01-357 / 44-25) Semrock Inc., New York, US 
Glass capillaries with autofluorescence NanoTemper Technologies GmbH, Munich, DE 
Label-free emission filters:  
Monolith NT.LabelFree Zero Background MST 
Premium Coated Capillaries 
NanoTemper Technologies GmbH, Munich, DE 
Monolith NT.LabelFree Zero Background 
Standard Treated Capillaries 
NanoTemper Technologies GmbH, Munich, DE 
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SPROUT® MINI CENTRIFUGE 12V  Heathrow Scientific®, Vernon Hills, US 
Ultra-micro-cuvette (quartz glass SUPRASIL®), 
1.5x1.5 mm 
Hellma GmbH & Co. KG, Müllheim, DE  
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3 Methods 
 
3.1 Fluorometric profiling of proteins and compound libraries 
 
A three-dimensional fluorescence spectra of the protein p38α was recorded on a Jasco 
FP-8300 spectrofluorometer equipped with a Xenon lamp. The protein p38α was diluted 
in MSTP buffer to a final concentration of 168 µM. 20 µL of the solution was then filled 
into a quartz cuvette and loaded into the device. Fluorescence was excited using 
excitation wavelengths that range from 230 to 350 nm using a wavelength interval of  
2 nm. The emission wavelengths were recorded between 260 and 600 nm. The 
excitation and emission bandwidths were both fixed at 5 nm, and the scan speed was 
5000 nm per min. Measurements were performed at room temperature in the quartz 
cuvettes with a path length of 1.5 mm. Quartz cuvettes were cleaned between sample 
measurements using ddH2O and dried with compressed air. Obtained spectral data were 
analyzed using Microsoft Excel 2016.   
The same device was used to record two-dimensional fluorescence emission spectra of 
selected compounds (fragment against Fyn kinase, CBP112, fragment against MEK1, 
SB203580) and proteins (IgG BI09, BRD4, amylase, carbonic anhydrase, CREBBP, 
MBP, p38α). Therefore, samples were diluted in MSTP buffer to a final concentration of 
1 µM for the proteins or of 100 µM or 132 µM for the compounds. 20 µL of the samples 
were then filled into quartz cuvettes and loaded into the device. A 280 nm excitation 
wavelength was used for the fluorescence measurements, while emission spectra were 
recorded between 290 nm and 750 nm using a wavelength interval of 0.2 nm. The 
excitation and emission bandwidths were both set to 5 nm, and the scan speed was  
1000 nm per min. Measurements were done at room temperature in quartz 1.5 mm path 
length cuvettes. The quartz cuvettes were cleaned as described above. Obtained 
spectral data were analyzed using Microsoft Excel.    
The PMT voltage was kept at 500 in all measurements; the intensity values of the overall 
spectra were in between 200 and 10000 fluorescence counts.  
To estimate the proportion to which the given compound interferes with the fluorescence 
intensity readout, the data of two-dimensional compound emission spectra were used 
and all fluorescence intensity values were added to a sum, which lie between the filter 
bandpass borders determined. To enable better comparison between the compounds, 
their fluorescence intensity was first normalized by defining the maximum fluorescence 
intensity as 100 %.  
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3.2 Determination of fluorescence interference by compounds 
 
The fluorescence intensities of in total 1513 compounds were determined with two 
different NT.LabelFree devices, one equipped with a 330 – 380 nm emission filter and 
one with a 320 – 340 nm emission filter, respectively. Data were recorded with the cap 
scan routine in the NT.Control 2.0.2.29 software. Depending on the stock concentration, 
the samples were diluted with MSTP buffer to reach a final concentration of 0.1 to 1 mM. 
More in detail, compounds were diluted in MSTP buffer to final concentrations of 1 mM 
(fragments against MEK1) or of 0.1 mM (PHGDH-, TANK-, and ATAD-3 inhibitory 
compounds). Compounds against PAH and MCAD were diluted to a final concentration 
of 500 µM using 20 mM HEPES, 200 mM NaCl, 0.1 % Pluronic, pH 7.0. All other 
compounds were diluted 1:200 in MSTP buffer to reach a final concentration of 0.1 to 
0.75 mM. In addition, three different concentrations of MEK1 were prepared using MSTP 
buffer: 0.5 µM, 1 µM and 2 µM. Those served as reference samples and were used for 
later data analysis.  
All samples were loaded into Monolith NT.LabelFree Zero Background MST Premium 
Coated Capillaries and loaded into the NT.LabelFree instrument. Probes were excited at 
280 nm using an LED power of 15 %. MST experiments were recorded using 1 sec 
before IR-laser-on time, 1 sec IR-laser-on time and 1 sec IR-laser off time as a 
workaround to record the cap scan data. Measurements were carried out at 25 °C.  
For data analysis, fluorescence intensities of the compounds were compared to the 
fluorescence counts of MEK1 (reference samples). Therefore, the fluorescence intensity 
of the three MEK1 measurements was set to 100 % and the compounds proportion to 
this fluorescence intensity was calculated. Obtained values were then distributed into 
two groups: Less than 30 % MEK1 fluorescence and more than 31 % MEK1 
fluorescence. 
 
3.3 Proteins fluorescence intensity in both emission filters 
 
A set of different proteins (p38α, CREBBP, BRD4, IgG BI09, carbonic anhydrase, MBP, 
ProtA, SNF, BLIP, TEMP107A, MEK1, amylase) was diluted in MSTP buffer to a final 
concentration of 1 µM. Samples were then filled into Monolith NT.LabelFree Zero 
Background MST Premium Coated Capillaries and loaded into the Monolith 
NT.LabelFree device, equipped with the 330 – 380 nm or with the 320 – 340 nm emission 
filter, respectively. The probes were excited at 280 nm using 10 % LED power. MST 
experiments were recorded using 1 sec before IR-laser-on time, 1 sec IR-laser-on time 
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and 1 sec IR-laser off time to record the cap scan data. Measurements were carried out 
at 25 °C. Raw fluorescence counts were compared using Microsoft Excel.   
 
3.4 Label-free MicroScale Thermophoresis Assay 
 
For MST affinity analysis of MBP against maltose or (GlcNAc)3, a 16-step serial dilution 
of maltose or (GlcNAc)3 was prepared, starting from 1 mM highest concentration with a 
final volume of 10 µL in each titration step. MSTP buffer was used as assay buffer and 
was sterile filtered prior usage. Afterward 10 µL of 500 nM MBP was added to all vials 
and the reaction was incubated for 15 min at room temperature in the dark. Samples 
were then filled into Monolith NT.LabelFree Zero Background MST Premium Coated 
Capillaries and measurements were carried out at 25 °C, using 20 % LED and 80 % MST 
power. Data was evaluated after 5 sec laser-on time using the 330 – 380 nm emission 
filter, and after 10 sec laser-on time using the 320 – 340 nm emission filter.    
For the binding affinity quantification of p38α against SB203580, a 16-step serial dilution 
of SB203580 was prepared using sterile filtered MSTP buffer (supplemented with 2 % 
DMSO). Thereby, the highest ligand concentration was set to 40 µM, with 10 µL in each 
dilution step. Afterward 10 µL of 220 nm p38α was added to all dilution steps and the 
reaction was incubated for 15 min at room temperature in the dark. Samples were then 
filled into Monolith NT.LabelFree Zero Background Standard Treated Capillaries and 
loaded into the two Monolith NT.LabelFree devices (equipped with 320 – 340 nm or with 
330 – 380 nm emission filter). MST was recorded at 25 °C using 20 % LED power. After 
running the SD test (see below), data were analyzed using the raw fluorescence counts.  
 
3.5 SDS denaturation (SD) test 
 
If a ligand-dependent fluorescence change is detected during the cap scan, the SD test 
needs to be performed to identify the reason for this observation. This test allows 
discriminating between binding-specific fluorescence quenching and nonspecific loss of 
material. For this, the vials 1 to 3, which contain the highest ligand concentrations, and 
the vials 14 to 16, which contain the lowest ligand concentrations, are mixed 1:1 with the 
2 x SD mixture (4 % SDS and 40 mM DTT in ddH2O). Samples are then incubated for  
5 min at 95 °C for protein denaturation. Afterward samples are filled into the same type 
of glass capillaries as the original samples were measured in. The SD test routine of the 
MO.Control software is then used to record the fluorescence intensities of each sample 
and to compare it to the fluorescence counts prior addition of the SD mixture. In case of 
specific ligand-induced fluorescence change, the fluorescence intensity of all six 
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samples should be nearly identical after denaturation. Consequently, the fluorescence 
intensity can be used for Kd determination. No changes in fluorescence intensity between 
the probes before and after the SD test are indicators of nonspecific loss of material. In 
this case, the experimental data is not valid; further optimization of assays conditions is 
required (like the use of low-binding tubes, a different labeling strategy or the addition of 
buffer additives).  
As the interaction analysis of p38α against SB203580 showed ligand-induced 
fluorescence change in the device equipped with the 320 – 340 nm emission filter, the 
SD test was performed. For this, samples were prepared as described above, filled into 
Monolith NT.LabelFree Zero Background Standard Treated Capillaries and loaded into 
the device. The fluorescence was then recorded at 20 % LED power and 25 °C.  
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4 Results 
 
With the intention to select the most appropriate emission filter for the reduction of 
fluorescence interference originating from the compounds used in the screening, the 
spectrofluorometric profiling of several proteins and compounds was performed and the 
applicability of new emission filter in the label-free MST was tested. Overall, 7 proteins 
and 7 different compound libraries were analyzed, which contained 1513 compounds in 
total. Moreover, label-free MST experiments were carried out using both emission filter 
sets. Obtained data were compared regarding fluorescence interference, S/N ratio, 
fluorescence intensity and determined dissociation constant. 
 
4.1 Fluorescence profiling of proteins and compounds 
 
Fluorescence profiling of proteins and compounds was performed to determine the 
spectral overlap. The regions which do not overlap can be used for detection by a 
selection of a filter with an appropriate bandwidth. To determine the typical fluorescence 
excitation and emission wavelengths of a protein, first a three-dimensional spectrum of 
p38α was recorded. For this, p38α was diluted in MSTP buffer and a three-dimensional 
protein spectrum and the corresponding contour map, showing the bird´s eye view of the 
spectrum, were recorded using spectrofluorometry (Figure 7). The protein spectra show 
two emission peaks, one at λex = 280 nm and λem = 350 nm and the second peak at  
λex = 230 nm and λem = 350 nm. The first peak refers to the Trp residues of the protein, 
while the second peak shows the peptide bond (absorption below 240 nm) 78.  
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Figure 7: Fluorimetric profiling of p38α. Three-dimensional fluorescence spectrum (A) and corresponding 
contour diagram (B) were recorded on a JASCO spectrofluorometer, using 168 µM p38α diluted in MSTP 
buffer. Emission wavelengths were recorded between 260 nm and 600 nm using excitation wavelengths of 
230 nm to 350 nm, with 10 nm steps in between.  
 
The Monolith NT.LabelFree device excites the Trp fluorescence of the protein at 280 nm 
and detects it at 330 – 380 nm. As the three-dimensional spectra of p38α exhibits 
maximum emission at 330 nm after excitation at 280 nm, the protein can efficiently be 
detected using label-free MST. However, as the fluorescence properties of Trp are highly 
sensitive towards its local environment, Trp emission can vary among different proteins. 
Thus, Trp residues which are directed towards the hydrophobic core of a protein will 
exhibit emission maximum at 330 nm, while Trp amino acids that are directed towards 
the solvent will have a maximum emission at 350 nm. To gain insides into the variation 
of protein emission profiles, a set of representative proteins was chosen, and the 
fluorescence spectroscopic profile was recorded. For this, proteins were diluted in MSTP 
buffer and emission was recorded at an excitation of 280 nm, using spectrofluorometry 
(Figure 8). Obtained emission profiles were normalized to their maximum fluorescence 
intensity of the Trp residues. The normalized emission spectra show only slight variations 
in the maximum peak of emission, ranging from 320 to 350 nm. These slight deviations 
arise from the Trp sensitivity described above. Although there are few exceptions that 
show different emission spectra, such as an emission maximum of ~ 308 nm for azurin 
or ~ 355 nm for glucagon, the pharmaceutically most relevant proteins, like enzymes or 
antibodies show similar spectra as shown in Figure 879. 
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Figure 8: Emission spectra of different proteins. Spectra were recorded on a JASCO spectrofluorometer. 
Excitation wavelength was set to 280 nm, while the emission wavelength ranged from 270 nm to 600 nm.  
 
 
Knowing that the emission maximum of proteins typically varies between 320 – 350 nm, 
a new emission filter can be designed covering this part of the spectrum. However, 
before the exact bandwidth of the filter could be selected, emission properties of a 
representative set of compounds were analyzed. To record the spectra, samples were 
diluted in MSTP buffer and spectrofluorometric analysis was carried out on a JASCO 
spectrofluorometer. Figure 9 shows the normalized emission spectra of ten compounds. 
As the structural motifs and scaffolds of those compounds are more diverse than the 
peptide backbone of proteins, their emission profiles vary to a significantly higher extent 
than those of proteins. 
 
 
Figure 9: Emission spectra of compounds after excitation at 280 nm.  Fluorescence spectra were 
recorded at a fixed excitation wavelength of 280 nm and an emission range from 280 nm to 600 nm using a 
JASCO spectrofluorometer. Names of compounds are listed on the right (from the top down refers to from 
left to right). Their emission maxima range from 310 nm to 425 nm. 
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New emission filter should thus enable the transmission of Trp fluorescence to guarantee 
strong and stable signal originating from the protein and at the same time cut-off the 
signal which arises from the compounds.    
To fulfill mentioned requirements, the emission filter with the bandwidth of 320 – 340 nm 
was chosen, as most proteins emit in this spectral region (Figure 8). At the same time, 
the chosen bandwidth cuts-off most of the interfering fluorescence originating from 
compounds. As a comparison, the bandwidth of the current filter is 330 – 380 nm. The 
transmission spectra of both emission filters are illustrated in Figure 10.  
 
 
Figure 10: Two different filter sets for the NT.LabelFree device.  A) The emission filter is implemented 
in NT.LabelFree devices for detection of Trp fluorescence. It spans a bandwidth from 330 – 380 nm. B) The 
emission filter was designed to reduce fluorescence interference from compounds in label-free MST assays. 
It spans a bandwidth from 320 – 340 nm.  
 
While both filter sets can detect sufficient protein fluorescence, compounds interference 
is significantly higher for the broad emission filter (Figure 11). Here, all four compounds 
overlap the region of detection, while less compound interference can be observed for 
the filter with narrower bandwidth.  
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Figure 11: Emission spectra of compounds, IgG BI09 and position of emission filters.  A) Chemical 
structures of CBP112, fragment against MEK1 and SB203580 (from top to bottom). Structure for fragment 
against Fyn was not available. Structures are illustrated in the same color code as corresponding emission 
profiles in B and C. If available, compounds chemical structures were re-drawn using Chemograph Plus 6.4 
software. B and C) Fluorescence emission spectra of four compounds (purple to blue) and IgG BI09 (black) 
are shown. Spectra were recorded at a fixed excitation wavelength of 280 nm and an emission range from 
280 to 600 nm using a JASCO spectrofluorometer. Spectral profiles are overlapped with a 330 – 380 nm (B) 
or with a 320 – 340 nm (C) emission filter, illustrated as black boxes. 
 
To quantify the extent of fluorescence interference of each compound, their two-
dimensional emission spectra were used. First, their spectra were normalized to their 
maximum emission. Then, all fluorescence intensity values that lie either between  
320 – 340 nm or between 330 – 380 nm emission wavelength, were added to a sum. 
This way, a comparison of both filter sets was obtained (Table 14). Here, the relative 
fluorescence of each compound in both filter sets is listed separately. Thereby, only one 
compound (fragment against Fyn kinase) has higher fluorescence intensity with the filter 
320 – 340 nm than with the filter 330 – 380 nm. Thus, all the other compounds exhibit 
significantly higher fluorescence in the 330 – 380 nm emission filter.  
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Table 14: Relative fluorescence intensity of each compound in both filter sets.  The fluorescence 
interference of each compound in the emission filter was defined as the sum of all normalized intensity 
values in between 320 – 340 nm and 330 – 380 nm, respectively. 
Compound Sum of normalized fluorescence intensities 
 320 – 340 nm 330 – 380 nm 
Fragment against Fyn 513.8 430.9 
IDH-C227 770.9 1886.6 
Sulpiridine 850.0 2048.4 
I-CBP112 571.0 2163.5 
Small molecule against MEK1 506.7 2191.0 
Small molecule against Fyn 386.1 2084.4 
Small molecule against MEK1 506.8 2190.1 
BIRB 796 3.0 576.1 
Small molecule against ATAD-3 0.6 173.9 
SB203580 2.1 386.1 
 
 
In detail, the fluorescence interference of nine compounds was lower in the narrower 
emission filter. In addition, three compounds showed no interference for the  
320 – 340 nm emission filter. For the other compounds, up to 5-fold less interference 
was observed. Only the fragment against Fyn shows slightly stronger interference in the 
smaller emission filter set. The emission profile of this compound exhibits maximum 
close to 300 nm as seen in Figure 11.  
 
4.2 Quantitative comparison of emission filters for the NT.LabelFree device 
 
Based on the results obtained above, it was assumed that the narrower emission filter 
should significantly reduce the autofluorescence from compounds in label-free MST 
experiments. In order to verify this assumption, the fluorescence intensity of compounds 
and chemical fragments out of 7 compound libraries (in total 1513 compounds and 
fragments) was analyzed using the cap scan routine in the Monolith NT.LabelFree device 
equipped with the 330 – 380 nm emission filter and in a prototype label-free device 
equipped the 320 – 340 nm emission filter. Therefore, all compounds were diluted in 
MSTP buffer, filled into glass capillaries and separately loaded into both devices. The 
fluorescence intensity of each sample was then recorded using the cap scan routine of 
the device. As reference for data analysis the fluorescence intensity of two different 
MEK1 concentrations (0.5 µM and 2 µM) was recorded. For this, the fluorescence 
intensity of MEK1 was set to 100 %, while the fluorescence counts of each compound 
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were then calculated as their percental proportion to this. All compounds exhibiting less 
than 30 % MEK1 fluorescence were counted and are summarized in Table 15. 
 
Table 15: Summary of fluorescence intensity screening of 1513 compounds.  Seven compound 
libraries and eight commercially available substances were analyzed for their fluorescence intensity 
compared to the fluorescence counts of two different MEK1 concentrations, using two emission filters. 
Number of compounds, showing less than 30 % of MEK1 fluorescence are listed as absolute numbers and 
as percentage values. 
 Target 
Number of 
compounds 
320 – 340 emission filter 330 – 380 nm emission filter 
  0.5 µM MEK1 2 µM MEK1 0.5 µM MEK1 2 µM MEK1 
PAH 56 
14 
(25.0 %) 
34 
(60.7 %) 
4 
(7.1 %) 
24 
(42.9 %) 
ATAD-3 298 
162 
(54.4 %) 
257 
(86.2 %) 
80 
(26.8 %) 
212 
(71.1 %) 
Fyn  18 
2 
(11.1 %) 
10 
(55.6 %) 
2 
(11.1 %) 
7 
(38.9 %) 
MEK1  193 
74 
(38.3 %) 
124 
(64.2 %) 
14 
(7.3 %) 
76 
(39.4 %) 
PHGDH 349 
229 
(65.6 %) 
311 
(89.1 %) 
187 
(53.6 %) 
280 
(80.2 %) 
TANK 346 
222 
(64.2 %) 
295 
(85.3 %) 
102 
(29.5 %) 
222 
(64.2 %) 
MCAD 245 
5 
(2.0 %) 
14 
(5.7 %) 
15 
(6.1 %) 
109 
(44.5 %) 
diverse 
targets 
8 
3 
(37.5 %) 
6 
(75.0 %) 
1 
(12.5 %) 
4 
(50.0 %) 
 
 
As seen in Table 15, in seven out of eight libraries, the narrower filter reduced the number 
of interfering compounds to a significant extent. Especially for the screening against 
TANK, 35 % less compounds interfered with the detection, which refers to around 120 
compounds for a screening of this size. Interestingly, compounds of the screening 
campaign against MCAD are probably more prone to interfere in the region of  
320 – 340 nm, making the narrower emission filter less suitable for this screening project, 
compared to a broader filter bandwidth. 
In general, data from Table 15 illustrate, that the number of interfering compounds could 
be lowered with higher concentrations of MEK1. Thus, depending on the Kd of the 
interaction and with this on the required compound concentrations, more or less 
fluorescence interference of compounds will be observed.   
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4.3 Determination of fluorescence interference by compounds 
 
In order to investigate the influence of the narrower filter bandwidth on the fluorescence 
intensity emitted by proteins, a set of different proteins was diluted in MSTP buffer and 
loaded into the Monolith NT.LabelFree devices, equipped with either the 330 – 380 nm 
or with the 320 – 340 nm emission filter. Protein fluorescence was recorded after 
excitation at 10 % LED power. Results are illustrated in Figure 12. For all proteins, the 
narrower emission filter reduced the overall fluorescence counts to ~ 50 %.  
 
 
Figure 12: Fluorescence intensity of proteins in both emission filters.  Proteins fluorescence was 
excited at 280 nm and at 10 % LED power using two Monolith NT.LabelFree devices (emission filter  
330 – 380 nm (black), 320 – 340 nm (grey)). Fluorescence was recorded at 25 °C. Measurements were 
done in duplicates.  
 
 
4.4 Influence of filter bandwidth on the quality of label-free MST 
measurements 
 
As the narrower bandwidth of the emission filter reduces the sensitivity of the device to 
around 50 %, the impact on data quality of label-free MST measurements was 
investigated. Therefore, affinity analysis of two already MST approved interactions were 
carried out on both devices. Therefore, the interaction between MBP and maltose is 
known to show high binding amplitudes and high S/N ratios using standard label-free 
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MST, whereas the interaction of p38α against SB203580 was so far not accessible by 
label-free MST due to fluorescence interference caused by SB203580.  
MBP is part of the periplasmic transport system of E.coli. Here, MBP binds the 
disaccharide and translocate it across the inner membrane 80. Figure 13 shows the 
structure of MBP together with maltose.  
 
 
Figure 13: Crystal structure of MBP and maltose.  Once MBP binds to maltose (colored orange), it 
undergoes a conformational change. Structural alignment of unbound structure (blue; PDB 1OMP) and 
bound conformation (grey; PDB 1ANBF) was performed using PyMol. 
 
 
The re-purified MBP (Supplementary data Figure 2) was used for the label-free MST 
experiments. Briefly, a serial dilution of maltose was prepared, starting from 1 mM as the 
highest concentration. MSTP buffer served as assay buffer. Afterward 500 nM of MBP 
was added to all dilution steps. As a negative control, N,N',N''-triacetylchitotriose, also 
known as (GlcNAc)3, was titrated against MBP using the same experimental conditions. 
Samples were measured in both NT.LabelFree devices, equipped either with the 
emission filter 330 – 380 nm (Figure 14 A), or with the emission filter 320 – 340 nm 
(Figure 14 B). Measurements with the 330 – 380 nm emission filter exhibit a higher S/N 
ratio and more homogeneous MST traces than those obtained by the narrower filter 
(Figure 14). However, obtained binding affinities of 9.7 ± 1.2 µM and 6.6 ± 1.0 µM for the 
broader and narrower emission filter, respectively, are in good agreement with literature 
values, where the Kd is around 2 μM81.  
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Figure 14: MST affinity analysis of MBP against maltose.  A & B): Comparison of the MST traces (left) 
and the dose-response curves (right) of maltose (black) and (GlcNAc)3 (orange) titrated against MBP using 
the NT.LabelFree device equipped with the 330 – 380 nm emission filter (A) or with the 320 – 340 nm 
emission filter (B). All graphs display merged data from three independent experiments. MST experiments 
were carried out at 20 %LED and 80 % MST power at 25 °C.   
 
 
Next, the interaction between p38α and a commercially available inhibitor, SB20358, was 
analyzed. P38α belongs to the class of mitogen-activated protein kinases (MAPK) and 
plays a major role in the regulation of cell cycle processes and in the inflammatory 
response, what makes this kinase a well-known therapeutic target for many 
pathologies82. The mentioned interaction was previously not accessible by label-free 
MST (Figure 17 A).  
 
 
Figure 15: Crystal structure of p38α and SB203580.  Structure of p38α alone (grey) and in a complex 
(blue) with the SB203580 inhibitor (orange) (PDB code: 1A9U).  
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Figure 16 shows the emission spectra of p38α (black) and the compound SB203580 
(blue). The transmission width of both filters is depicted with black boxes. With the use 
of the broader 330 – 380 nm filter, the fluorescence interference of SB203580 negatively 
influences the MST measurements (Figure 16, red region). The use of a narrower filter 
should cut-off the fluorescence of SB203580 and thus enables determination of binding 
affinity in the label-free MST assay.  
 
 
Figure 16: Emission profiles of p38α and SB203580.  Emission spectra were recorded using a JASCO 
spectrofluorometer. The emission spectrum of p38α shows two emission peaks at an extinction of 280 nm. 
The first peak at 280 nm is residual excitation light, while the second is caused by aromatic amino acids, 
especially Trp (black). In blue, the emission spectrum of SB203580 inhibitory compound is shown, with its 
chemical structure illustrated on the right. The two black boxes show the emission filters that were used for 
label-free MST affinity analysis. Using the 320 – 340 nm emission filter, the fluorescence signal of the 
compound is eliminated, whereas there is fluorescent interference with the 330 – 380 nm filter. Region of 
interference is marked in red.  
 
 
Figure 17 shows the MST results for the interaction described above. Here, with the 
broad emission filter (Figure 17 A) the fluorescence interference of SB203580 prevented 
determination of the binding affinity. However, the same interaction could be analyzed 
using the narrower emission filter (Figure 17 B). The SD test confirmed that the ligand-
induced fluorescence change is binding-specific (Figure 18). Thus, this change in 
fluorescence was used for Kd quantification, which was in good agreement with literature 
values83.  
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Figure 17: Binding of SB203580 to p38α.  In both experiments, the concentration of p38α was kept 
constant at 110 nM, while the concentration of SB203580 was varied from 1.2 nM – 40 000 nM. Experiments 
were performed at 20 % LED power and at 25 °C (n = 2). A) Raw fluorescence counts of the measurements 
using the 330 – 380 nm emission filter. Quantification of the Kd was not possible. B) Raw fluorescence counts 
of Monolith device with a narrower emission filter (320 – 340 nm). Binding specific ligand-induced 
fluorescence change was used for data analysis.  
 
 
 
Figure 18: SD test for p38α against SB203580.  Fluorescence intensity of samples was recorded prior and 
after denaturation using the cap scan routine in the Monolith NT.LabelFree device.   
 
 
The observed reduction in fluorescence upon binding can be explained by the existence 
of a Tyr residue in the SB203580 binding site of p38α, as illustrated in Figure 19. As not 
only Trp, but also Tyr residues contribute to the signal in label-free MST measurements, 
the binding of ligands near those amino acid residues can lead to changes in the 
detected fluorescence intensity. This decrease in fluorescence cannot be detected using 
the broader emission filter, as here the fluorescence of SB203580 overlays any change 
in Trp or Tyr fluorescence. In addition, Tyr emission maximum lies at around 330 nm, 
which makes the 320 – 340 nm emission filter more prone to changes in the Tyr 
fluorescence84.  
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Figure 19: Crystal structure of p38α binding pocket and SB203580.  Structure of the binding site of p38α 
alone (grey) and in a complex (blue) with the SB203580 inhibitor (orange) (PDB code: 1A9U). Tyr35 amino 
acids are illustrated as sticks.  
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5 Discussion  
 
Nowadays, drug discovery mostly starts with the screening of thousand potential drug 
candidates against a disease-related target molecule in an HTS campaign. Thereby, 
label-free and in-solution methods are the techniques of choice, as they provide close to 
native experimental conditions. One example of such a technique is label-free MST. It 
uses the proteins intrinsic Trp and Tyr fluorescence to track the movement of molecules 
in a temperature gradient. As all other fluorescence-based techniques, label-free MST 
must deal with fluorescence interference caused by certain compounds. To increase the 
applicability of the NT.LabelFree device, I therefore first tested the assumption that it is 
possible to reduce the fluorescence interference by separating the fluorescence signal 
that arises from the protein from that of the compound by using appropriate emission 
filter.   
To address the first question, I analyzed the fluorescence interference of 1513 small 
molecules and fragments out of seven different libraries and 8 commercially available 
inhibitors. Experimental data showed that this simple optical modification could decrease 
the percentage of interfering compounds from 70 to 36 %, depending on the compound 
library. However, it is important to note that the number of interfering compounds highly 
depends on the composition of the compound library. Although many libraries are based 
on privileged structures like indoles, that are also part of Trp. These compounds don´t 
necessarily interfere with the detection as already slight modifications of chemical 
substitutes in the compound structure can significantly alter the respective emission 
profile. Thus, it remains hard to predict how many compounds will interfere with the MST 
assay in an HTS, even if their basic structure is known.   
An additional disadvantage of the narrower filter bandwidth is the reduced fluorescence 
intensity (down to ~ 50 %), depending on the location and amount of Trp residues in the 
protein. As this reduction in overall sensitivity can cause lower S/N ratio, as shown for 
MBP maltose interaction, the implementation of a smaller emission filter requires 
additional adjustments in the optical system of the device to compensate this loss of 
intensity. This could be achieved using different detection systems or stronger LED 
power.  
 
Nevertheless, the use of narrower emission filter allowed characterization of selected 
interactions, that were previously not accessible to label-free MST because of high 
fluorescence interference. As an example, the interaction between p38α and SB203580 
was used, as the narrow emission filter completely blocked the compound´s 
fluorescence. Here, the determination of a Kd was possible by analyzing binding specific 
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ligand-induced changes in the fluorescence of the titration series. This measurement 
revealed an additional weak point of the narrower emission filter. With the use of this 
filter, one can easily see slight changes in the Trp or Tyr fluorescence shift caused by 
the ligand binding. For the analysis of this data, the ligand-induced fluorescence change 
is used to determine the binding affinity. Such data mostly exhibit lower S/N ratios, 
because data normalization is missing. Also, an additional verification step by performing 
SD test is required to determine the specificity of observed fluorescence change.  
Based on these findings it was concluded that although changes in the bandwidth of the 
emission filter can improve the number of compounds analyzed by label-free MST, this 
improvement does not generally suffice. Also, this approach is only applicable for the 
quantification of interactions between small molecule compounds and fragments. The 
analysis of interactions where both of the interacting species are proteins is still not 
possible by label-free MST, because of the too high similarity in the emission spectra of 
proteins. Thus, for the analysis of protein-protein interactions by label-free MST, a novel 
approach is required.  
In the following chapter, I describe the development and validation of a label-free 
approach for the determination of the binding affinity between two proteins.  
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Chapter 2 
 
 
1 Introduction 
 
Most biological functions in a cell are controlled by proteins. Over 80 % of proteins do 
not function as independent cellular components but interact with other proteins to fulfill 
a large variety of cellular functions85. Those range from gene expression, cell proliferation 
and apoptosis, to signal transduction and transport31,86. Thus, protein-protein interactions 
(PPIs) play a major role in nearly every biological process. Regarding the human body, 
it has been estimated that around 170 000 PPIs exist, of which most are still unexplored5. 
Since abnormal PPIs, such as loss of interactions or gain of inappropriate interactions, 
can cause several diseases, the study of PPIs is of huge interest for pharmaceutical 
research87,88. In this regard, the inhibition of PPIs, using small molecular inhibitors has 
emerged as a field of interest during the last few years, leading to the investigation of 
PPI modulators as potential therapeutic agents89–92.  
Molecular forces, that are involved in PPIs, are a combination of hydrophobic bonding, 
van der Waals forces and salt bridges, where the surface which is involved in the binding 
process can span only view amino acids, or can comprise large surface areas93. In 
addition, there is a direct correlation between binding affinity and the amount of surface 
area buried at the interface, while no relationship between binding affinity and the 
chemical composition of the interface could be observed93. Binding affinities can span a 
wide range from pM to the mM range93. To study binding affinities, different methods can 
be applied, as already discussed in the general introduction of this thesis. MST offers 
the advantage of being a fast and reliable technique for the in-solution quantification of 
molecular binding events, with only low amounts of sample required. In addition, it offers 
the possibility for label-free measurements, that so far is restricted to interactions, in 
which only one binding partner exhibits intrinsic fluorescence. As the highly conserved 
nature of proteins does not allow for signal separation as it was applied in the previous 
chapter, another solution strategy is required. Thus, it was tested whether the ligands 
fluorescence contribution can be used for data analysis rather than being eliminated from 
the overall signal. Therefore, the concept of data analysis in dynamic light scattering 
(DLS) was chosen as a model system, as there also all involved particles contribute to 
the detected signal when molecular interactions are analyzed94.  
In general, DLS analyses the diffusion behavior of macromolecules to establish the size, 
shape, and molecular weight of macromolecules in solution95. Therefore, it records time-
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dependent fluctuations in scattered light, which arise from Brownian motion of scattering 
molecules31. This information is used to calculate the diffusion coefficient and the 
hydrodynamic diameter, using the Stokes-Einstein equation31. Thereby, the diameter 
that is measured refers to how a particle diffuses within a fluid. The larger a particle is, 
the slower the diffusion speed will be96. As both, the diffusion coefficient and hence the 
hydrodynamic radius depend on the size and shape of macromolecules, changes in the 
average molecular radius or molecular mass provide a direct indication of the formation 
or dissociation of complexes97. 
For sample preparation for DLS binding studies, a variation of the experimental method 
known in the literature as the method of continuous variation, or the Job Plot, is used, 
referred to as composition gradient titration (CGT)31,98. Thereby, the total molar 
concentration is kept constant, while their ratio of interacting partners is varied31. In DLS, 
the average hydrodynamic radius is then plotted against the mole fraction of two 
analyzed molecules. For the case of an interaction, measured values will increase to a 
higher extent than expected for a solution of two non-interacting monomers31. This 
increase can then be quantified and used for Kd determination.  
At first sight, this approach is not intuitive, as usually binding studies are carried out by 
holding the concentration of one binding partner fixed while varying the concentration of 
the other molecule99. Such experiments can then be illustrated as saturation curves, from 
which the Kd can easily be gathered, as illustrated in Figure 20. In contrast, instead of 
varying the concentration of one component at a time, the method of continuous variation 
holds the total concentration of both molecules constant, while varying the relative 
proportions of both species31. Having such a titration scheme, the Kd cannot easily be 
taken from the graph but can be quantified with a nonlinear least mean square fit37. 
However, the shape of the curve provides already qualitative information about the 
binding affinity of the regarded interaction, as strong binding results in a more triangle-
shaped graph, whereas lower affinities show a more curved form (Figure 20)100. 
Moreover, this approach can be used to determine binding stoichiometry, if both binding 
partners exhibit the same starting concentration. Here, the position of the peak maximum 
is then used for binding stoichiometry determination, whereby a simple 1:1 interaction 
will have a maximum increase in the measured parameter at equal amount of both 
proteins, whereas 1:2 or 2:1 interactions exhibit maximum change at below or above 
equal concentration, respectively100.  
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Figure 20: Saturation curve and CGT data. Results of a protein-protein interaction analysis from a 
saturation experiment (A) and from a DLS experiment, in which the method of continuous variation was 
applied (B). While the Kd of the interaction can be obtained from the plot in A, only a qualitative value for the 
underlying Kd can be gained from the experiment in B. Here, quantification of the interaction requires further 
fitting of the measurement to simulated data.   
 
In the following chapter, I examined whether the same approach, namely CGT for Kd 
determination, can also be applied for label-free MST affinity analysis of two fluorescent 
species. Therefore, the general applicability of this titration for label-free affinity analysis 
of PPIs will be investigated and limitations of this approach will be discussed. In 
summary, a novel approach to analyze PPIs by MST in a label-free format will be 
implemented.  
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2 Materials 
 
Table 16: Chemicals 
Chemicals Company 
EDTA 
Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. 
1233508 
H2O AnalaR NORMAPUR® 
VWR Prolabo Chemicals, Darmstadt, DE, cat. no. 
102927G 
HEPES 
Carl Roth GmbH + Co. KG, Karlsruhe, DE, cat. no. 
HN78.2 
MST buffer NanoTemper Technologies GmbH  
NaCl 
Carl Roth GmbH + Co. KG, Karlsruhe, DE, cat. no. 
0962.1 
Pluronic® F-127 Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. P2443 
Roti®-Stock 10x PBS 
Carl Roth GmbH + Co. KG, Karlsruhe, DE cat. no. 
1058.1 
TRIS PUFFERAN® Carl Roth GmbH + Co. KG, Karlsruhe, DE 4855.1 
Tween®-20  Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. 93773 
 
 
Table 17: Buffers and solutions 
Buffers and solutions Composition 
MST buffer   50 mM Tris-HCl, 250 mM NaCl, 10 mM MgCl2, pH 7.8 
MSTP buffer 0.1 % Pluronic® F-127 in MST buffer 
MSTT buffer 0.05 % Tween® 20 in MST buffer 
NHS labeling buffer 130 mM NaHCO3, 50 mM NaCl, pH 8.2–8.3 
PBSP  0.1 % Pluronic® F-127 in PBS buffer 
PBST 0.05 % Tween® 20 in PBS buffer 
 
 
Table 18: Proteins and oligonucleotides 
Proteins and oligonucleotides Company 
BLIP DBV1  CRELUX GmbH, Munich, DE 
DNA oligo strands: 
5´-Cy5-ATAT TTA CGA TCT GAT CCT T -3´)  
3´-AAT GCT AGA CTA GGA A (TATA-Cy5)-5´ 
3´-AAT GCT ACA CTA GGA A (TATA-Cy5)-5´ 
3´-AAT GCT ACT CTA GGA A (TATA-Cy5)-5´ 
Metabion, Planegg, DE 
IL6 antigen 
Was kindly provided by Dr. Patrick Kunz from the 
functional genome analysis department of the german 
cancer research center, Heidelberg, DE 
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IL6 nanobody 
Was kindly provided by Dr. Patrick Kunz from the 
functional genome analysis department of the german 
cancer research center, Heidelberg, DE 
MBP 
antibodies-online GmbH, Atlanta, US, cat. no. 
MBP0801 
MBP binding protein ChromoTek GmbH, Planegg, DE 
TEM DBV1  CRELUX GmbH, Munich, DE 
 
 
Table 19: Fluorophores 
Fluorophores Company 
ATTO647-NHS ester 
MW:811 g/mol; ε: 120 000 M-1cm-1 
Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. 07376 
NT647-NHS ester 
MW: n.a.; ε: 250 000 M-1cm-1  
From NanoTemper Technologies MO-L001 labeling 
kit, NanoTemper Technologies GmbH, Munich, DE 
 
 
Table 20: Kits 
Kits Company 
Monolith Protein Labeling Kit RED-NHS (Amine 
Reactive)  
MO-L001, NanoTemper Technologies GmbH, Munich, 
DE 
 
 
Table 21: Devices 
Machines and devices Company 
Monolith NT.115 (RED/BLUE, BLUE/GREEN, 
RED/GREEN), Monolith NT.115.Pico 
NanoTemper Technologies GmbH, Munich, DE 
NanoDropTM One  Thermo Fisher Scientific Inc., Wilmington, US 
Monolith NT.LabelFree  NanoTemper Technologies GmbH, Munich, DE 
 
 
Table 22: Centrifuges and rotors 
Centrifuges and rotors Company 
Centrifuge 5424 Eppendorf AG., Hamburg, DE 
Centrifuge 5430 R  Eppendorf AG., Hamburg, DE 
Rotor FA-45-24-11-HS Eppendorf AG., Hamburg, DE 
 
 
Table 23: Online tools and software 
Online tools and software Company 
MO.AffinityAnalysis_x86_2.2.7.6056  NanoTemper Technologies GmbH, Munich, DE 
MO.Control_x86_1.5.3.6096 NanoTemper Technologies GmbH, Munich, DE 
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Table 24: Further materials 
Further material Company 
10 mL (12 mL) NORM-JECT®,  Henke Sass Wolf, Tuttlingen, DE  
CHROMAFIL® RC-20/25, pore size: 0.2 µm MACHEREY-NAGEL GmbH & Co. KG, Düren, DE 
Monolith NT.115 MST Premium Coated 
Capillaries  
NanoTemper Technologies GmbH, Munich, DE 
Monolith NT.115 Standard Treated Capillaries  NanoTemper Technologies GmbH, Munich, DE 
Monolith NT.LabelFree Zero Background MST 
Premium Coated Capillaries 
NanoTemper Technologies GmbH, Munich, DE 
Monolith NT.LabelFree Zero Background 
Standard Treated Capillaries 
NanoTemper Technologies GmbH, Munich, DE 
SPROUT® MINI CENTRIFUGE 12V Heathrow Scientific®, Vernon Hills, US 
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3 Methods 
 
3.1 Discrimination between binder and non-binder molecules 
 
To investigate, whether an interaction can be distinguished from a non-binding event 
when both molecules emit in the detection wavelength, binding check experiments were 
carried out using exemplary samples for both devices, NT.115 and NT.LabelFree. For 
experiments on the NT.115, two red-emitting fluorophores (ATTO647-NHS ester and 
NT647-NHS ester) were chosen as an example for a non-binding, whereas RED-tris-
NTA against NT647-labeled His6-p38α was selected as an example of an interaction. 
For label-free measurements, His6-p38α against TEM1 was chosen as an example for 
no-binding, while BLIP against TEM1 was selected for two interacting molecules.  
 
3.1.1 No interaction on NT.115  
 
NT647-NHS ester and ATTO647-NHS ester were diluted to 100 nM using 20 mM Tris 
buffer pH 7.5, supplemented 100 mM NaCl and 0.05 % Tween. Solutions were stored 
overnight at room temperature to let the NHS ester groups hydrolyze. Un-reactive dyes 
were then mixed in a 1:1 ratio. Afterward both dyes alone and as a 1:1 mixture were filled 
into Monolith NT.115 Capillaries and MST traces were recorded at 25 °C, 20 % LED and 
medium MST power. Measurements were carried out in triplicates.  
 
3.1.2 Interaction on NT.115  
 
RED-tris-NTA and NT647-labeled His6-p38α were diluted to 50 nM in PBST buffer and 
then mixed 1:1. After incubating the reaction mixture for 30 min at room temperature 
away from light, RED-tris-NTA, NT647-labeled-His6-p38α and the mixture of both 
samples were filled into Monolith NT.115 Premium Capillaries and loaded into the 
NT.115 device. MST traces were recorded at 25 °C, 20 % LED and medium MST power. 
Samples were measured in triplicates.  
 
3.1.3 No interaction on NT.LabelFree 
 
His6-p38α and TEM1 were both diluted to 1 µM using sterile filtered MSTP buffer. After 
centrifugation at 14 000 g, 4 °C for 10 min, samples were mixed 1:1. After incubation for 
15 min at room temperature, both proteins separately and as 1:1 mixture were filled into 
Monolith NT.LabelFree Premium Capillaries and loaded into the NT.LabelFree device. 
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MST traces were recorded at 20 % LED and high MST power at 25 °C. Samples were 
measured in triplicates.  
 
3.1.4 Interaction on NT.LabelFree 
 
BLIP and TEM1 were both diluted to 1 µM using sterile filtered MSTP buffer. After 
centrifugation at 14 000 g, 4 °C for 10 min, samples were mixed 1:1 and reaction was 
incubated for 15 min at room temperature. Afterward both proteins alone and the 1:1 
mixture were filled into Monolith NT.LabelFree Premium Capillaries and loaded into the 
device. MST traces were recorded at 25 °C, 20 % LED and high MST power. 
Measurements were carried out in triplicates.  
 
3.2 Correlation between fluorescence intensity and Fnorm value 
 
To test, whether the Fnorm value is independent of the fluorescence intensity of a sample, 
three different proteins were titrated against PBSP or MSTP buffer using the CGT 
pipetting scheme below. Therefore, TEM1 was diluted to 300 nM using MSTP buffer, 
while IL6 nanobody and IL6 antigen were both diluted to 300 nM using PBSP buffer. 
After titration of the CGT against the corresponding buffer, samples were filled into 
Monolith NT.LabelFree Premium Capillaries and MST was recorded at 20 % or 40 % 
LED power for TEM1 and IL6 antigen and nanobody, respectively and at high MST 
power. Measurements were carried out at 25 °C. Data was evaluated after 20 sec laser-
on time.  
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Table 25: CGT pipetting scheme 
Vial number MBP-3xMyc PBSP 
1 25.2 µL 0.0 µL 
2 23.4 µL 1.8 µL 
3 21.6 µL 3.6 µL 
4 19.8 µL 5.4 µL 
5 18.0 µL 7.2 µL 
6 16.2 µL 9.0 µL 
7 14.4 µL 10.8 µL 
8 12.6 µL 12.6 µL 
9 10.8 µL 14.4 µL 
10 9.0 µL 16.2 µL 
11 7.2 µL 18.0 µL 
12 5.4 µL 19.8 µL 
13 3.6 µL 21.6 µL 
14 1.8 µL 23.4 µL 
15 0.0 µL 25.2 µL 
 
 
3.3 Standard MST experiments 
 
To verify obtained Kd values using the CGT approach, the same interactions were 
quantified using standard MST affinity analysis, as described below: 
 
3.3.1 DNA hybridization  
 
DNA hybridization was quantified using a Cy5-labeled single-stranded DNA template (5´-
Cy5 – ATAT TTA CGA TCT GAT CCT T -3´) against one of three unlabeled single 
stranded DNA molecules: perfect match: 3´-AAT GCT AGA CTA GGA A-5´, mismatch 
1: 3´-AAT GCT ACA CTA GGA A-5´, or mismatch 2: 3´-AAT GCT ACT CTA GGA A-5´. 
For the experiments, unlabeled DNA strands were diluted in 20 mM HEPES buffer, pH 
7.4, supplemented with 100 mM NaCl, 5 mM EDTA and 0.05 % Tween. Starting from  
2 µM highest concentration, a 16-step serial dilution was prepared. Afterward 2 nM Cy5-
labeled template strand was then added to the dilution series and the reaction was 
incubated for 10 min at room temperature in the dark. Samples were then filled into 
Monolith NT.115 Capillaries and loaded into the Monolith NT.115Pico device. 
Measurements were carried out at 5 % LED, medium MST power and at 25 °C. Data 
was quantified after 5 sec laser on-time. Measurements were carried out in triplicates.  
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3.3.2 IL6 nanobody against IL6 antigen or against BIRC75 antigen 
 
Labeling of IL6 and BIRC75 antigen was carried out according to the Monolith Protein 
Labeling Kit RED-NHS (Amine Reactive) from NanoTemper Technologies GmbH. 
Briefly, 20 µM of antigen was mixed with 60 µM of RED-NHS dye using NHS labeling 
buffer. Reaction mixture was incubated for 30 min at room temperature before unreacted 
dye was removed using size-exclusion chromatography. For this, a B column was 
equilibrated using MSTT buffer, which was also used for elution of labeled antigen. 
Protein was then aliquoted and stored at -80 °C.  
 
For the MST experiment of RED-NHS IL6 antigen or RED-NHS BIRC75 antigen against 
IL6 nanobody, a serial dilution of L6 nanobody was prepared, starting from 10 µM highest 
concentration using MSTT buffer. Afterward 40 nM RED-NHS-labeled antigen was 
added to all dilutions and reaction was incubated for 15 min at room temperature away 
from light. Samples were then filled into Monolith NT.115 Premium Capillaries and 
loaded into the Monolith NT.115 device. The MST measurement was carried out at  
40 % LED and at 80 % MST power at 25 °C. Data was quantified after 10 sec laser-on 
time and measurements were carried out in triplicates.  
 
3.3.3 MBP binding protein against MBP 
 
His6-MBP-binding protein was diluted to 200 nM in PBST buffer. RED-tris-NTA dye was 
diluted in PBST buffer to a final concentration of 100 nM. 100 µL of protein was then 
mixed with 100 µL of dye and the reaction mixture was incubated for 30 min at room 
temperature in the dark.  
For the serial dilution, 5 µM of MBP diluted in PBST buffer was used as the highest ligand 
concentration of the 16-step dilution series, with a final volume of 10 µL in each reaction 
tube.  
Then 10 µL of 100 nM labeled protein was added to all 16 vials and samples were mixed 
by pipetting up and down. Reactions were incubated for 30 min at room temperature 
away from light and then filled into Monolith NT.115 Capillaries. Using the Monolith 
NT.115 device, MST was carried out at 40 % LED and high MST power. Data were 
evaluated at 15 sec MST-on time. Measurements were carried out in triplicates.  
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3.4 Composition gradient titration (CGT) 
 
3.4.1 Pretest to check for fluorescence difference between both molecules 
 
For the CGT experiment the molecules concentrations need to be adjusted in a way, that 
both exhibit the same fluorescence intensities. Therefore, a pretest was carried out, in 
which molecules are diluted in MSTP buffer to a final concentration of 100 nM and were 
then filled into Monolith NT.LabelFree Premium Capillaries. Then capillaries were 
scanned to record the fluorescence intensity of both molecules, using 20 % LED power.    
 
3.4.2 Titration scheme 
 
For the CGT, both proteins were concentrated at least ~10 to 100-fold above the Kd, in 
a volume of 200 µL each. Prior titration of the CGT, samples were centrifuged at  
14 000 g for 10 min at 4 °C. Afterward samples were titrated according to the following 
pipetting scheme: 
 
Table 26: CGT pipetting scheme 
Vial number Molecule A Molecule B 
1 25.2 µL 0.0 µL 
2 23.4 µL 1.8 µL 
3 21.6 µL 3.6 µL 
4 19.8 µL 5.4 µL 
5 18.0 µL 7.2 µL 
6 16.2 µL 9.0 µL 
7 14.4 µL 10.8 µL 
8 12.6 µL 12.6 µL 
9 10.8 µL 14.4 µL 
10 9.0 µL 16.2 µL 
11 7.2 µL 18.0 µL 
12 5.4 µL 19.8 µL 
13 3.6 µL 21.6 µL 
14 1.8 µL 23.4 µL 
15 0.0 µL 25.2 µL 
 
 
Samples were then filled into Monolith NT.LabelFree (Premium) Capillaries, and loaded 
into the NT.LabelFree device to record Fnorm values for each capillary.  
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3.4.3 CGT data analysis 
 
Analysis was done using Microsoft Excel. First, measurements were transferred to the 
MO.Affinity Analysis software, in which an appropriate laser-on time was selected. 
Corresponding Fnorm values were then exported to Microsoft Excel and plotted against 
the capillary position. Afterward Fnorm values for an interaction and for the case of no-
interaction were simulated and plotted into the same graph. By minimizing the difference 
between the measured data and the simulated data for an interaction, while altering the 
Kd and the complex Fnorm value using the solver function, the Kd was determined.  
 
In principle, this fitting consists of four parts, which will be described below: 
 
1) Modeling the complex- and the free concentrations in solution: 
 
Regarding the reversible interaction between protein A and B, 
 
 ,         (8) 
 
the equilibrium dissociation constant (Kd) can be expressed using the law of mass action 
 
or   ,      (9) 
 
whereby [A] and [B] are the free concentrations of protein A and B, respectively and [AB] 
is the concentration of the complex.  
 
The known total molar concentrations of two proteins [Atot] and [Btot] can be expressed 
as 
         (10) 
or as 
 
.        (11) 
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Equalizing the two equations (I) and (II) or (I) and (III) and solving them for [A] will give 
the equations (IV) and (V): 
 
 
.        (12) 
 
Equalizing the two equations (IV) and (V) and solving it for [B] with the quadratic equation 
yields: 
 
.  (13) 
 
Knowing the total concentrations of A and B in each titration step, their free 
concentrations and the complex concentration could be calculated, using an assumed 
Kd and the following equations, derived from the law of mass action as described above:   
 
         (14) 
.  (15) 
 
2) Modeling Fnorm values for an interaction and for the case of no-interaction, using 
the following equations with an estimated complex Fnorm and an assumed Kd. 
 
   (16) 
 
3) Fitting modeled results to measurements by minimizing the difference between 
both graphs, using the solver function in Microsoft Excel.  
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Therefore, for each Fnorm value of the titration series, the difference between the 
measured and the simulated Fnorm value for the case of an interaction was calculated and 
squared. All squared deviations were then taken to a sum. This sum was then minimized, 
by adjusting the Kd and the complex Fnorm value, using the solver function. To estimate 
the quality of the fit, a quadratic error was calculated as well. Therefore, the square root 
of the minimized sum was calculated and divided by the number of titration steps, in this 
case,15.  
 
3.5 Quantified interactions using the CGT 
 
3.5.1 DNA Hybridization 
 
All DNA single strands (template strand: 5´-Cy5 – ATAT TTA CGA TCT GAT CCT T -3´, 
perfect match single strand: 3´-AAT GCT AGA CTA GGA A TATA-Cy5-5´, mismatch 1 
single strand: 3´-AAT GCT ACA CTA GGA A TATA-Cy5-5´, mismatch 2 single strand: 
3´-AAT GCT ACT CTA GGA A TATA-Cy5-5´), were diluted in 25 mM HEPES buffer, pH 
7.4, supplemented with 100 mM NaCl, 5 mM EDTA, 0.1 % Pluronic, to reach a final 
concentration of 100 nM. These stock solutions were centrifuged at 14 000 g for 10 min 
at 4 °C before they were used for CGT. After titrating the samples, they were filled into 
Monolith NT.115 Capillaries and loaded into the device. MST traces were recorded at  
20 % LED and medium MST power. Fnorm values after 5 sec laser-on time were taken for 
analysis. Measurements were carried out in triplicates.  
 
To investigate the influence of the start concentration on the obtained Kd, perfect match 
DNA hybridization was used. Therefore, 100 nM, 50 nM and 5 nM solutions were 
prepared for CGT, as described above. Fnorm values were recorded using 2 % / 20 % and 
100 % LED power of 100 nM / 50 nM / 5 nM, respectively and medium MST power at  
25 °C. Data was evaluated after 10 sec laser-on time.  
 
3.5.2 IL6 Nanobody against IL6 antigen or against BIRC75 antigen 
 
Proteins were diluted in MSTP buffer to reach a final volume of 100 nM. Samples were 
then filled into Monolith NT.LabelFree Premium Capillaries and loaded into the 
NT.LabelFree device. Fluorescence intensity was recorded using the expert function of 
the MO.Control software and a LED power of 20 %. As the fluorescence intensity of IL6 
nanobody was 1.4 times higher than that of the antigens, the concentrations were 
adjusted to exhibit the same fluorescence intensity. Therefore, 250 nM of IL6 nanobody 
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and 350 nM antigens were prepared using MSTP buffer and samples were centrifuged 
at 14 000 g, for 10 min at 4 °C, before CGT was carried out. Samples were then 
incubated for 15 min at room temperature and were filled into Monolith NT.LabelFree 
Premium Capillaries and loaded into the NT.LabelFree device. MST was recorded at  
25 % LED and medium MST power. Data was evaluated after 5 sec MST-on time. Fnorm 
values were exported into Microsoft Excel, for data analysis as described above.  
 
3.5.3 MBP binding protein against MBP 
 
Both proteins were diluted in MSTP buffer to reach a final volume of 100 nM. Samples 
were then filled into Monolith NT.LabelFree Premium Capillaries and loaded into the 
Monolith NT.LabelFree device. Fluorescence intensity was recorded using the expert 
function of the MO.Control software and a LED power of 20 %. As the fluorescence 
intensity of MBP was 2 times higher than that of MBP binding protein, the concentrations 
were adjusted to exhibit the same fluorescence intensity. Therefore, 100 nM and 200 nM 
were prepared using MSTP buffer and samples were centrifuged at 14 000 g, for 10 min 
at 4 °C, before CGT was carried out. Samples were then incubated for 15 min at room 
temperature and were filled into Monolith NT.LabelFree Premium Capillaries and loaded 
into the Monolith NT.LabelFree device. MST was recorded at 10 % LED and high MST 
power. Data was evaluated after 15 sec MST-on time. Fnorm values were exported into 
Microsoft Excel, for data analysis as described above.  
 
To investigate the influence of the start concentration on the obtained Kd using MBP 
against MBP binding protein, 100 nM / 200 nM / 400 nM MBP was titrated against  
200 nM / 400 nM / 800 nM of MBP binding protein, respectively as described above. 
Fnorm values were recorded using 10 % LED and high MST power at 25 °C. Data was 
evaluated after 15 sec laser-on time. Experiments were carried out in triplicates. 
   
Excel sheets with the complete CGT data analysis for all investigated interactions are 
provided in the supplementary data.  
 
3.6 Simulations to determine the limitations of the CGT 
 
Simulations were carried out using Microsoft Excel. For the simulations, Fnorm values for 
the case of an interaction were simulated, using the following equation: 
   (17) 
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The Fnorm value of A was fixed to 725 and the Fnorm value of the complex was fixed to 
825. All other values were varied. Parameters are listed in the table below:  
 
Table 27: Parameters for CGT simulation. Parameters for simulation of CGT label-free MST 
measurements of the interaction of A and B.   
Parameter Values used for simulation 
Kd 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1 µM, 10 µM, 100 µM, 1 mM, 10 mM 
Fnorm value of A 
/ B 
725 / 725, 725 / 750, 725 / 775, 725 / 825  
Start 
concentration of 
A / B 
10 nM / 10 nM, 10 nM / 15 nM, 10 nM / 25 nM, 10 nM / 50 nM, 10 nM / 100 nM 
100 nM / 100 nM, 100 nM / 150 nM, 100 nM / 250 nM, 100 nM / 500 nM, 100 nM / 1000 nM 
1 µM / 1 µM, 1 µM / 1.5 µM, 1 µM / 2.5 µM, 1 µM / 5 µM, 1 µM / 10 µM 
10 µM / 10 µM, 10 µM / 15 µM, 10 µM / 25 µM, 10 µM / 50 µM, 10 µM / 100 µM 
100 µM / 100 µM, 100 µM / 150 µM, 100 µM / 250 µM, 100 µM / 500 µM, 100 µM / 1000 µM 
1 mM / 1 mM, 1 mM / 1.5 mM, 1 mM / 2.5 mM, 1 mM / 5 mM, 1 mM / 10 mM 
10 mM / 10 mM, 10 mM / 15 mM, 10 mM / 25 mM, 10 mM / 50 mM, 10 mM / 100 mM 
 
3.7 Fluorescence intensity of p38α and SB203580 
 
To compare the intrinsic fluorescence intensity of p38α and SB203580, both molecules 
were diluted in PBSP buffer to reach a final concentration of 1 µM. Samples were then 
filled into Monolith NT.LabelFree Premium Capillaries and loaded into the Monolith 
NT.LabelFree device. Fluorescence was excited at 20 % LED power.  
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4 Results 
 
This chapter deals with the quantification of PPIs using label-free MST. Therefore, 
composition gradient titration will be used, which on the one hand prevents detector 
saturation, while on the other hand, it allows the determination of Kd using a least mean 
square approximation. The fitting algorithm is based on the assumption that one can 
clearly distinguish a binding from a non-binding event. Therefore, it was tested whether 
binder and non-binder molecules can be discriminated using MST, if both molecules 
exhibit fluorescence in the same spectral region. This should be possible as in theory 
the measured time trace of a 1:1 mixture of two not-interacting molecules is simply the 
meantime trace of the two single time traces. This principle can further be applied to all 
different molecule to molecule ratios, as the recorded time trace would be a mixture of 
the single time traces, each weighted by the relative amount of each molecule in the 
mixture. In case of an interaction, the measured time trace would be a mixture of the 
single time traces plus the unknown time trace of the formed complex. The extent to 
which all three single time trace species contribute to the resulting time trace is unknown 
as long as the dissociation constant is not known. Figure 21 illustrates the two scenarios, 
in which (A) shows the case for no interaction and (B) represents two interacting 
molecules. 
 
 
Figure 21: MST traces for binder and non-binder molecules. Illustration of sample filled capillaries with 
corresponding MST time traces. A) Two not-interacting molecules are shown together with their MST time 
traces, which are represented in the same color. The red time trace represents the recorded one from a 1:1 
mixture of both molecules. B) Two interacting molecules are shown as single molecules as well as formed 
complex. The MST time traces on the right illustrate the time traces of each single species. The red time 
trace represents the recorded time trace.   
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To confirm these theoretical ideas, MST time traces of two single molecules as well as 
of a 1:1 mixture of both molecules were recorded. This was done for different sets of 
samples, including binder and non-binder molecules. According to the theory described 
above, no interaction occurred if there is an overlap between the measured “mixed” time 
trace and the “mean” time trace of the single-molecule time traces. If there is a difference 
between both, then an interaction occurred.   
For these experiments, I first used the NT.115 device to prevent any issues from dust or 
other fluorescent artifacts. Therefore, two not-reactive red fluorescent dyes, ATTO647 
and NT647, were chosen as an example for “no interaction”. As expected, the measured 
time trace clearly is the mean of both single time traces, and thus no interaction occurred 
(Figure 22). As example for an interaction, red-NHS labeled His6-p38α was mixed with 
RED-tris-NTA. Here, the measured time trace of the mixture of both molecules can 
clearly be distinguished from a mean time trace of the single molecules, and thus an 
interaction took place.  
 
 
Figure 22: Differentiation of binder and non-binder molecules. Differentiation of binder and non-binder 
molecules on the NT.115. A) MST time traces of ATTO647, NT647 and a 1:1 mixture of both. Single dyes 
and the mixture were loaded into Monolith NT.115 Capillaries. Thermophoresis was recorded at 20 % LED, 
medium MST power and 25 °C. B) MST time traces of red-NHS labeled His6-p38α, RED-tris-NTA and both 
molecules together, in a 1:1 ratio. Samples were loaded into Monolith NT.115 Premium Capillaries 
separately and as 1:1 mixture. Thermophoresis was recorded at 20 % LED, medium MST power and at  
25 °C. Legend) The grey and black traces represent the single molecular time traces, while the red one 
shows the time trace of the mixture and of the mean value of the single time traces. Measurements were 
carried out in triplicates. 
 
 
Next, similar experiments were done using the NT.LabelFree device. For this, TEM1 and 
His6-p38α was chosen as an example for no interaction, while TEM1 and BLIP served 
as an example for an interaction. Figure 23 shows the results for these experiments. The 
grey and black traces represent the single molecules, while the red trace shows the 1:1 
mixture. Here, the MST trace of the combined sample of TEM1 and His6-p38α lie in-
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between the single time traces, indicating that no interaction took place. In contrast, the 
time trace of TEM1 and BLIP mixture can nicely be distinguished from the mean of both 
single traces. This is an indication for an underlying binding event.  
 
 
Figure 23: Discrimination of binder and non-binder molecules. Discrimination of binder and non-binder 
molecules on the NT.LabelFree device. A) MST time traces of TEM1, His6-p38α and of both molecules 
together. B) MST time traces of TEM1, BLIP and of both molecules together. A&B) Molecules were loaded 
into Monolith NT.LabelFree Premium Capillaries separately and as 1:1 mixture. Each sample was measured 
in triplicates at 20 % LED, high MST power and at 25 °C. Legend) The grey and black traces represent the 
single molecular time traces, while the red one shows the time trace of the mixture and of the mean value 
of the single time traces. Measurements were carried out in triplicates. 
 
 
The referencing approach described above, offers an easy and straightforward way to 
discriminate between binder and non-binder molecules. However, it has the potential to 
generate false positives, because small changes in the thermophoretic time trace of both 
molecules already implies that an interaction occurred. To prevent such false positives 
and as a prove of value it is best to run several different compositions to increase the 
number of samples and to validate the data.   
 
4.1 From discriminating binder and non-binder molecules to Kd quantification   
 
The fact that it is possible to discriminate binder from non-binder molecules can be 
applied to a whole titration series, were different compositions of both molecules are 
used to then later extract the dissociation constant. This is possible as the time traces 
for every single titration step would be a superposition of the time traces of the two 
unbound proteins and of the complex time trace, all weighted by their relative amount in 
the sample.  
After recording Fnorm values from the titration series, cases for no interaction and for 
interaction were simulated using the following equations for each capillary:  
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   (18) 
 
The difficulty for this simulation was the unknown Fnorm value of the formed complex and 
the unknown Kd value, which is required for calculating the free and the complex 
concentrations. Hence, a Kd from a standard experiment was used as a first guess. For 
the complex Fnorm value an assumption was generated. These formulas were then used 
to calculate a preliminary Fnorm value for each capillary, for the case of an interaction and 
for the case of no interaction. These values were then plotted in one graph, together with 
the measured data. The dissociation constant was then obtained by a least mean square 
fitting approach that minimizes the square difference between the measured Fnorm values 
and the calculated ones for the case of an interaction. Therefore, the deviation between 
the calculation and the measurement was squared and all squared deviations were 
added to a sum. This sum of squared deviations was minimized by a least mean square 
approximation through varying the initial guess of the complex Fnorm value and the Kd. 
The quadratic error of this least mean square approximation, describes the quality of the 
fit and is defined as the square root of the sum of squared deviations, divided by the 
number of composition gradient steps, here 15.  
 
4.2 Implementation of the CGT for label-free MST 
 
Regarding an interaction with two fluorescent molecules, the application of a standard 
16-step serial dilution for MST would be problematic because of the high fluorescent 
range that needs to be covered by the optical system. This explains the need for a 
different titration strategy, that keeps the overall fluorescence intensity constant. For this, 
the composition gradient titration, short CGT, was used. This method is based on the 
method of continuous variation, also known as the Job Plot100. This technique keeps the 
total molar concentration of the two molecules constant, while systematically varying the 
ratio of both molecules31. Therefore, different compositions of both molecules are 
obtained by titrating the molecules against each other, whereby the overall fluorescence 
intensity is kept constant. Figure 24 illustrate this titration procedure. 
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Figure 24: Illustration of CGT. Schematic representation of the composition gradient titration of two 
fluorescent molecules. The tube on the left only contains molecule P (protein), while the tube on the right 
only contains molecule L (ligand). The amount of P and L decreases by 1.8 µL per titration step, from left to 
right and reverse, respectively. The overall fluorescence intensity is kept at one level.  
 
Regarding a CGT series over 15 different compositions with non-interacting molecules, 
the resulting Fnorm values will be the sum of the single Fnorm values, weighted by their 
relative amounts in the mixture (Figure 25 red). Whereas in case of an interaction, there 
will be a greater change in the measured Fnorm values, due to the presence of complexed 
species with a different Fnorm value. Schematically, the sample with equal molarity will 
result in the highest change in Fnorm, leading to a peak in the measured Fnorm values 
(Figure 25 blue). This is illustrated in Figure 25.  
 
 
Figure 25: Fnorm values after CGT. Schematic representation of Fnorm values after a 15-step CGT of 
interacting molecules (blue) and of non-interacting (red) molecules, if both molecules start with the same 
concentration (A) or if one molecule exhibits a 3-fold higher starting concentration, than the other one (B). 
For this simulation, complex Fnorm was set to 800, and Kd was fixed at 0.1 nM, with starting concentrations 
of 10 nM / 10 nM (A) or 10 nM / 30 nM (B).  
 
 
4.3 Correlation between fluorescence intensity and Fnorm value 
 
Before preparing whole CGTs, it is important to clarify to which extend the fluorescence 
counts of a CGT can vary without generating different background fluorescence 
contributions. Therefore, the correlation between the fluorescence intensity and the Fnorm 
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value was investigated. In theory, the Fnorm value is independent from the fluorescence 
intensity, but especially in the label-free device different contributions from the 
background are possible and need to be taken into account.   
In order to define the degree of fluorescence, which exhibit the same Fnorm values, 
different proteins were titrated against buffer, using a 15-step CGT. Fluorescence was 
detected using a LED power of 20 % for TEM1 or of 40 % for the IL6 proteins to cover a 
broad spectrum of fluorescence intensities. Fnorm values were recorded at high MST 
power. Results are shown in Figure 26. Here, the grey values are below the 
recommended fluorescence intensity of about 2500 fluorescence counts and thus the 
Fnorm values need to be neglected from the analysis. As illustrated in Figure 26, the Fnorm 
values change upon variations in the fluorescence intensity, although the fluorescence 
is well above the detection minimum. Hence, the fluorescence intensities of a CGT need 
to be constant throughout the whole titration series, to prevent capillary and buffer 
artifacts.  
 
 
Figure 26: Fluorescence intensity and Fnorm value. Correlation between fluorescence intensity and Fnorm 
value for different proteins, IL6 antigen, IL6 nanobody and TEM1 (from left to right). CGT of proteins against 
PBSP or MSTP buffer was prepared. Fluorescence intensities (top) over 15 capillaries and corresponding 
Fnorm values (bottom) are presented. Capillaries with fluorescence intensities below the detection minimum 
of 2500 fluorescence counts are illustrated in grey.  
 
 
4.4 Composition gradient titration for Kd determination 
 
In a first approach the general applicability of the CGT for MST experiments with two 
fluorescent molecules was tested. I decided to first run an exemplary measurement on 
the NT.115 device, to prevent any fluorescent artifacts from sample impurities, for which 
the NT.LabelFree device is highly sensitive. Thus, the first CGT experiment for Kd 
determination was done using DNA hybridization, with two fluorescent single stranded 
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DNA molecules. This interaction was chosen as this DNA hybridization is already deeply 
characterized by MST and is a robust and high affine interaction101. Furthermore, DNA 
hybridization allows for systematic alterations in the affinity, by introducing base pair 
mismatches102. Hence, the template strand was kept the same for all measurements, 
while the complementary single strand was either a perfect match oligo (Figure 27 black), 
a single-strand comprising one mismatch (Figure 27 grey) or a single strand with two 
mismatches (Figure 27 purple). These three interactions were quantified using the CGT 
approach on the NT.115 instrument. Obtained data out of three independent 
experiments are shown in Figure 28. Simulated Kd values are illustrated in the Table 
below. Here, the Kd decreases with higher number of mismatched base pairs. In addition, 
the height of the curve decreases with lower affinities. In general, obtained curves exhibit 
low quadratic error of the fits (0.14 – 1.16).   
 
Template:  5´-Cy5-ATAT TTA CGA TCT GAT CCT T-3´ 
Perfect match:  3´-   AAT GCT AGA CTA GGA A TATA-Cy5-5´ 
Mismatch 1:  3`-   AAT GCT ACA CTA GGA A TATA-Cy5-5´ 
Mismatch 2:  3´-   AAT GCT ACT CTA GGA A TATA-Cy5-5´ 
 
Figure 27: Nucleotide sequences. Nucleotide sequences of single stranded DNA molecules. Template 
DNA strand and perfect match (black), mismatch 1 (grey) and mismatch 2 (purple). Mismatch nucleotides 
are shown in red. Location of Cy5-fluorophore is illustrated as red star. 
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Figure 28: CGT of DNA Hybridization.  Composition Gradient titration of two Cy5-labeled DNA strands 
using the NT.115 device. A) Perfect match DNA oligo pair, mismatch 1 DNA oligo pair and mismatch 2 DNA 
oligo pair (from left to right). Experiments were carried out using starting concentrations of 100 nM for both 
single-stranded DNA molecules, 20 % LED and medium MST power. All interactions were measured in 
triplicates. Values obtained from the least mean square fitting of the corresponding CGT experiments are 
stated in the table below.  
 
 
To next validate obtained Kd values, all three interactions were quantified using a 
standard MST approach, with only the template strand being fluorescently labeled. 
Results are shown in Figure 29. Here, data exhibit high S/N ratios and a shift in Kd with 
higher amounts of mismatch base pairs to lower Kd values.  
 
 
Figure 29: Standard MST for DNA Hybridization. Standard MST analysis of Cy5-labeled template DNA 
strand against unlabeled perfect match DNA single-strand (black), mismatch 1 DNA single-strand (grey) and 
mismatch 2 DNA single-strand (purple). Therefore, unlabeled DNA single-strands were diluted from 1 µM 
highest concentration, while labeled DNA template strand was added at 1 nM constant concentration. MST 
was carried out at 5 % LED and medium MST power. Data were quantified after 5 sec laser-on time. 
Interactions were measured in triplicates.   
 
DNA Oligo Pair 
Complex Fnorm value 
for simulation 
Simulated Kd Quadratic error 
Perfect match 874.9 17.9 nM 1.16 
Mismatch 1 880.3 19.3 nM 0.14 
Mismatch 2 946.8 85.1 nM 0.15 
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In general, for both, the standard MST data and the CGT results, the Kd decreases with 
higher amounts of mismatches. However, the Kds for the perfect match and mismatch 1 
are over-estimated in the CGT experiment, while the obtained affinity for mismatch 2 is 
in good agreement with data gained by standard-MST experiments. Despite slight 
deviations in the obtained Kd, data showed that the general principle of the CGT can also 
be applied for MST affinity analysis, in which two fluorescent molecules are present.   
 
In a next step, its applicability for label-free MST experiments was investigated. 
Therefore, I first analyzed the interaction between IL6 nanobody against its antigen. 
BIRC75 antigen served as negative control. As the fluorescence intensity of the 
nanobody was 1.4 times higher than the intensity of the antigens, the concentrations had 
to be adjusted for the GCT. Thus, 250 nM IL6 nanobody was titrated against 350 nM 
antigen.  
Figure 30 shows the results of the CGT experiments for IL6 nanobody against IL6 
antigen (A) and for IL6 nanobody against BIRC75 antigen (B), respectively. As can be 
seen, the binding event in A can nicely be discriminated from the non-binding event in 
B. As the fitting algorithm could precisely determine the Kd of this interaction, the 
quadratic error of the fit is with 0.11 low. This indicates the good quality of the fit. The 
table below summarizes the data obtained with the least mean square fitting approach.  
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Figure 30: CGT of IL6 nanobody antigen.  Results of a CGT of IL6 nanobody against IL6 antigen or against 
BIRC75 antigen. A) CGT of IL6 nanobody against its specific antigen (A) or against BIRC75 antigen (B) was 
carried out. Fnorm values were recorded at 25 % LED and medium MST power. Fnorm values after 5 sec laser-
on time were exported to Microsoft Excel for data analysis. A) Measured Fnorm values are illustrated in black, 
with corresponding error bars indicating the standard deviation out of three independent experiments. Fnorm 
values in blue represent the fitted values for the case of an interaction and red illustrate the Fnorm values for 
the case of no interaction. Experiments were carried out in triplicates. B) Measured Fnorm values are shown. 
Error bars indicate the standard deviation from three independent experiments. The Table below 
summarizes the values that were obtained using the least mean square fit for the interaction between IL6 
nanobody against IL6 antigen.   
 
 
The interaction was verified using standard MST. Therefore, both the IL6 antigen and 
the BIRC75 antigen were analyzed against IL6 nanobody. Results are shown in Figure 
31. Here, only for IL6 nanobody against IL6 antigen binding could be detected, exhibiting 
a Kd of 26.7 +/- 9.4 nM. Obtained Kd values for IL6 nanobody against its specific antigen 
were in good agreement with data acquired in the CGT experiment.  
 
 
 
Interaction 
Complex Fnorm value 
for simulation 
Simulated Kd Quadratic error 
IL6 nanobody against 
IL6 antigen 
928.8 55.4 nM 0.11 
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Figure 31: Standard MST for IL6 nanobody antigen. Standard MST experiment of IL6 nanobody against 
NT647-IL6 antigen (black) or against NT647-BIRC75 antigen (red). MST was carried out using 40 % LED 
and 80 % MST power. Data were analyzed after 10 sec laser-on time. Experiments were performed in 
triplicates.  
 
 
The next interaction that was analyzed was MBP binding protein against MBP. 
Therefore, 200 nM MBP binding protein was titrated against 100 nM MBP. MST 
experiments of this CGT approach are illustrated in Figure 32 A. Here, the noise level of 
triplicate measurements is quite high, however, the fitting algorithm could nicely solve 
the underlying Kd of 5.5 nM, which is in good agreement with data gained from a standard 
MST approach (Figure 32 B).  
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Figure 32: CGT of MBP binding protein against MBP. MBP binding protein against MBP. A) CGT of 
unlabeled MBP binding protein (200 nM) and unlabeled MBP (100 nM). MST traces were recorded at 10 % 
LED and high MST power. Fnorm values after 5 sec laser-on time are shown in black, with corresponding 
error bars out of three independent experiments. Data for no-interaction (red) and for interaction (blue) were 
simulated using chemical equilibrium relations and least mean square fitting. Table below summarizes the 
values obtained by the least mean square fitting of the GCT data. B) Standard MST experiment of RED-tris-
NTA labeled MBP binding protein against titrated unlabeled MBP. MST was carried out at 40 % LED and 
high MST power, n=3. Data were analyzed after 15 sec laser-on time.  
 
 
4.5 Effect of the starting concentration on the simulation output 
 
Since molecular interactions are commonly concentration-dependent, it is important to 
estimate the appropriate start concentrations that must be high enough to produce a 
significant amount of complex and at the same time low enough to still leave some free 
monomer (avoiding the saturation).  
In order to clarify to which extend the starting concentration affects the calculated Kd, two 
well-characterized model systems were used, MBP binding protein against MBP and 
perfect match DNA hybridization. For latter interaction, the starting concentration could 
be reduced to 5 nM, as the sensitivity of the NT.115 device allows such low 
concentrations for labeled DNA oligos. In contrast, the range of starting concentrations 
that could be tested in the NT.LabelFree device was limited through the detection system 
of the device, which does not allow the sample concentrations below 100 nM, for proteins 
with an average amount of Trp residues, which refers to around 2.2 % of Trp amino acids 
in a eukaryotic protein103. Thus, for the DNA hybridization CGT experiments, 5 nM,  
50 nM and 100 nM were used as starting concentrations for both molecules. For the 
MBP experiments, 100 nM, 200 nM and 400 nM of MBP was titrated against 200 nM, 
Interaction 
Complex Fnorm value 
for simulation 
Simulated Kd Quadratic error 
MBP binding protein 
against MBP 
739.7 5.5 nM 1.69 
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400 nM and 800 nM of MBP binding protein, respectively. Results from those six 
experimental conditions are illustrated in the Tables below. Here, the higher the starting 
concentration is, the higher the obtained Kd value will be. However, regarding the 
complex Fnorm value, that was selected by the solver tool in Microsoft Excel, variable 
numbers are obtained, although the reaction that is regarded is the same and thus should 
exhibit the same complex Fnorm value. Hence in a next approach, the complex 
concentration was fixed for all three different starting concentrations and the 
corresponding Kds were calculated. With this, obtained Kd values were independent of 
the starting concentration. In addition, the quadratic error of the fit reduced to an 
acceptable extent, except for 400 nM MBP against 800 nM MBP binding protein. Here 
the error of the fit increased from 1.2 to 2.13, which can be explained by the starting 
concentration being ~160-fold higher than the Kd.  
 
Table 28: Effect of start concentration on CGT data analysis. 
Perfect match DNA 
Start 
concentrations 
Fnorm 
complex 
Kd 
Quadratic 
error 
Fix 
complex 
Fnorm to: 
816.3 
Kd 
Quadratic 
error 
100 nM both 821.7 10.2 nM 0.30 6.7 nM 0.32 
50 nM both 809.7 4.9 nM 0.26 6.9 nM 0.27 
5 nM both 816.3 1.7 nM 0.20 - - 
 
MBP binding protein against MBP 
Start 
concentrations 
Fnorm 
complex 
Kd 
Quadratic 
error 
Fix 
complex 
Fnorm to: 
739.7 
Kd 
Quadratic 
error 
400 vs 800 nM 794.5 46.7 nM 1.20 4.3 nM 2.13 
200 vs 400 nM 783.6 22.6 nM 1.72 3.7 nM 1.79 
100 vs 200 nM 739.7 5.5 nM 1.69 - - 
 
 
As illustrated by the experiments above, the obtained Kd is independent of the start 
concentrations, as long as they are close enough to the underlying Kd and as long as the 
freedom for complex Fnorm value selection is restricted. Thus, the differences in Kd does 
not result from different starting concentrations but arise from the too high tolerance in 
the fitting algorithm for the complex Fnorm selection.  
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4.6 Simulation of different experimental conditions for the CGT   
 
As only a small set of interactions does permit the in-depth analysis of limitations of the 
CGT approach, a set of 1400 experiments was virtually simulated and findings are 
summarized in the matrix below (Figure 35).  
For the simulations, an interaction between two molecules A and B was selected. The 
Fnorm value of free A was set to 725 and the Fnorm value of the complex was set to 825. 
All other parameters, like the Kd, the starting concentrations, the difference in starting 
concentration and the difference in the Fnorm value of free molecules, were systematically 
varied (Figure 35). This provides a general idea of the limitations of the CGT for label-
free MST. In addition, when the conditions are met, this analysis shows the great value 
of the CGT approach for label-free MST, which enables reliable estimation of the Kd 
value for a given PPI. 
In order to explain the results illustrated in the matrix in Figure 35, exemplary simulations 
are shown in Figure 33. Here, the interaction between 2 arbitrary molecules A and B with 
a Kd of 10 nM is analyzed. Figure 33 shows the simulated CGT MST results of this 
interaction with a starting concentration for both molecules of 10 nM (A), 100 nM (B) or 
100 µM (C) for both proteins. The case was chosen in a manner at which both proteins 
have the same fluorescence intensity at the same concentration. Knowing that the Fnorm 
value of free A and the Fnorm value of the complex AB is 825, Fnorm values for 10 different 
Kds and for the case of no interaction, were simulated (Figure 35). As can be seen, the 
yellow traces belong to a Kd of 10 nM. In Figure 33, the starting concentrations chosen 
in B are best suited to analyze the interaction, as the yellow graph can nicely be 
distinguished from a no-binding flat line and from the more triangular shaped curves of 
higher affine interactions. In contrast, the starting concentration in A is too low to clearly 
separate the trace from a non-binding event, especially if higher noise levels of a real 
experiment are taken into account. Further, the starting concentrations in C are too high. 
Thus, they are suitable to discriminate between Kd values between 1 µM and 100 µM but 
are not conclusive for Kd values lower than 1 µM.  
 
All simulations were then divided into the following categories: distinct Kd determination, 
no distinct Kd determination, distinct Kd determination for high S/N ratio and false 
negative. This is illustrated in Figure 34. Using this color code, data for all simulations 
were summarized in a matrix, which is presented in Figure 35.  
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Figure 33: CGT simulation with different start concentrations. Simulations of the same interaction with 
three different starting concentrations. In this case study, both molecules have the same fluorescence 
intensity at the same concentration, and thus can be used in equal molar starting concentrations: 10 nM (A), 
100 nM (B) or 100 µM (C). Fnorm value of A was set to 725, Fnorm value of the complex was fixed to 825. Both 
proteins exhibit a difference in Fnorm value of 25 counts. For each Kd, a plot was simulated. Simulated Kd 
values are illustrated below in the corresponding colors. 
 
 
 
Figure 34: Ranking of simulated data. These simulated CGT data arise from an interaction between A 
and B, with a starting concentration of 100 nM for both proteins. Different Kd values were simulated, using a 
fixed Fnorm value for A of 725 counts and a fixed complex Fnorm of 845 counts. Each curve is then assigned 
to “distinct Kd determination”, “no distinct Kd determination”, distinct Kd for high S/N ratio” or “false negative”.  
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Figure 35: Matrix. Summary of 1400 simulated CGT experiments for a PPI on the NT.LabelFree device. 
Red squares represent false negative results, orange squares illustrate interactions that can be quantified if 
the S/N ratio is high enough, yellow squares represent interactions, that can be detected as binding events, 
but distinct Kd determination is not possible, and green squares represent those interactions, that can be 
assigned to a distinct Kd value.  
 
 
As can be seen in the matrix above, the Kd quantification requires starting concentrations 
of ~10 to 100-fold above the Kd. Whereas lower concentrations can lead to false negative 
results, as the amount of complex is too low to change the recorded Fnorm value to a 
significant extent. However, also too high starting concentrations should be avoided, as 
the underlying Kd might be overestimated.   
In general, red areas also belong to those interactions, in which the starting 
concentrations of both proteins and / or the Fnorm values of both vary to a too high extent. 
Figure 36 illustrates the GCT data for a high affine interaction of 0.1 nM with a 10-fold 
difference in starting concentration. This high difference shifts the peak maximum to the 
left, resulting in less data points in which the complex concentration is high enough to 
lead to a quantifiable change in the Fnorm value. Furthermore, a difference in the Fnorm 
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values between both binding partners will, in addition, lower the amplitude of the binding 
curve, which is illustrated in Figure 36 B.  
 
 
Figure 36: Effect of fluorescence intensity discrepancy for CGT. Simulation of CGT experiment with a 
Kd of 0.1 nM and with a 10-fold difference in starting concentration. A) Both binding partners exhibit the same 
Fnorm value in the unbound state. B) The Fnorm values of both interacting molecules exhibit a difference of 50 
counts. 
 
 
As a too high difference in start concentrations can make data quantification and 
interpretation more difficult, as illustrated above, the GCT is not easy to implement for 
protein – small molecule interaction analysis. The reason is, that the fluorescent 
intensities of proteins and compounds can be highly different, as shown in Figure 37. 
Here, p38α and SB203580 were diluted to 1 µM, leading to a difference in fluorescence 
intensity of 20-fold. Hence, regarding a CGT experiment in which the concentration of 
both molecules needs to be adjusted to exhibit the same fluorescence intensity, this 
interaction could not be quantified, as nearly all titration steps would contain high 
amounts of SB203580 and only negligible amounts of p38α. Thus, the signal of free 
compound would dominate in mostly all capillaries, leaving no detectable change in Fnorm 
due to complex formation. Thus, although the compound shows fluorescence 
interference in standard MST experiments, as shown in the previous chapter, its 
fluorescence intensity for a CGT experiment is still too low.  
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Figure 37: Fluorescence intensity of protein and small molecule. Fluorescence intensity of p38α and its 
inhibitory compound SB203580. Both samples were diluted to 1 µM using PBSP buffer. Fluorescence was 
excited with 20 % LED power.    
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5 Discussion 
 
Several methods are available for the characterization of PPIs, such as surface-
immobilization based techniques (e.g. SPR), fluorescence based methods (e.g. FP) or 
truly label-free and in-solution methods (e.g. MST)5. Label-free MST allows 
determination of dissociation constants in a label-free and free in-solution manner and 
thus under close-to-native conditions. However, this approach was so far not applicable 
for the determination of binding affinities between two proteins, as in established 
methodology only one binding partner may fluoresce in the detection wavelength.  
Here, for the first-time, label-free MST was applied for the quantification of PPIs. To that 
end, the method of continuous variation (Job´s method), that is also applied for PPI 
analysis in DLS, was used100. This method keeps the total concentration of both 
molecules constant, while systematically varying the relative proportions of both 
species31. To achieve this, both molecules are titrated against each other, which is 
referred to as CGT. Applying this titration strategy together with data analysis based on 
a least mean square approximation, first hybridization of two Cy5-labeled DNA single 
strands was used as proof of concept experiments. Results showed that the CGT is 
capable for the dissection of hybridization affinities, while Kd values of analyzed single-
stranded DNA pairs spanned around three orders of magnitude. In addition, the same 
experimental workflow allowed for affinity quantification of two nanobody antigen 
interactions in the NT.LabelFree device, while obtained Kd values were in good 
agreement with data obtained from standard MST experiments. Further, limitations of 
the CGT for label-free MST experiments were systematically simulated. This analysis 
revealed that in theory the CGT and the applied fitting algorithm are capable to determine 
a broad range of Kd values, ranging from pM to mM affinity. However, the algorithm 
cannot be applied if the start concentrations and Fnorm values of both interacting partners 
simultaneously differ around 10-fold and 100 counts or more, respectively. Thus, it works 
best at nearly equal Fnorm values and similar start concentrations of both molecules. 
Furthermore, the chosen absolute start concentrations were shown to highly affect the 
data output. Thus, in case the start concentrations are too high, the signal of free 
monomers will always overlay the signal of formed complex. On the other hand, using 
too low start concentrations, the amount of formed complex is too low to change the Fnorm 
value to a quantifiable extend. In addition, as the detection system of the label-free 
device requires a minimum protein concentration of ~100 nM, Kds in the pM range cannot 
be precisely determined. A general rule of thumb would be to use start concentrations of 
~10 to 100-fold above the Kd. This also implies that weak interactions will require a high 
amount of sample, which might cause protein aggregation or unspecific self-association, 
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which can lead to false results104. In general, a pretest, in which the fluorescence 
intensities and Fnorm values of both molecules are recorded, can be used to simulate GCT 
traces using an assumed Kd and complex Fnorm value. This will help to estimate the most 
suitable start concentrations for the binding assay. Notably, the listed considerations and 
limitations are not MST specific, but arise from the CGT approach in general. Thus, not 
only MST, but also DLS must deal with the challenge to find the most suitable start 
concentrations. For DLS, the fitting algorithm works best if both molecules exhibit a 
similar light scattering signal at the chosen start concentrations, while at the same time 
the start concentrations are not allowed to vary too much, shifting the peak of equal 
concentrations too far to one side of the titration curve97. In addition, the selection of 
appropriate start concentrations becomes further challenging if the molar masses of both 
proteins differ more than 3-fold97. Furthermore, not only the ratio of start concentration 
needs to be carefully selected for DLS measurements, but also the absolute 
concentrations of both molecules, to allow for precise Kd determination97. Thus, the 
provided matrix of limitations for label-free MST analysis of PPIs, could be transferred to 
DLS measurements, in which similar restrictions are observed. Nevertheless, CGT 
experiments in DLS allow for the analysis of binding stoichiometries and protein self-
association, which is not the case for label-free MST experiments, as here the 
fluorescence intensities of all samples need to be the same. Thus, neither information 
about binding stoichiometries can be obtained, for which equal start concentrations are 
required, nor a dilution series of one single protein can be analyzed for self-association. 
Despite these drawbacks in this approach, MST provides advantages like no instrument 
maintenance and small sample consumption. DLS requires tedious instrument 
maintenance and higher amounts of sample (around 2 – 20 mL compared to 200 µL for 
MST, with being concentrated around 10-fold the Kd)104. 
In conclusion, this chapter showed that label-free MST analysis of PPIs is possible if 
certain conditions are met. In addition, the fitting algorithm turned out to require further 
improvements regarding its too high tolerance for the selection of the complex Fnorm value 
and the Kd. Here, defined limitations for the two unknown parameters need to be 
implemented. However, as this chapter is focused on the general implementation of the 
CGT approach for MST affinity analysis and on the definition of its overall limitations, 
fitting optimization was beyond the scope of this dissertation. Because of observed 
restrictions of the CGT approach regarding the fluorescence intensities and Fnorm values 
of involved molecules, this approach is not generally applicable for the quantification of 
PPIs. Thus, a need for an approach combining the advantages of the close-to-native 
conditions and red-shifted fluorescence tag was obvious.  
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To that end, I implemented a site-specific labeling approach for the analysis of both, 
protein-protein and protein-small molecule interactions, in which the protein structure is 
kept in a close-to-native state. This strategy will be presented in the following chapter. 
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Chapter 3 
 
 
The following chapter contains results from recently published data in Scientific Reports. 
Images are used with permission of the respective Journal. The synthesis of analyzed 
dyes was performed in the working group of Prof. Dr. Jacob Piehler (University 
Osnabrück), the experiments with the cell lysates were performed by Dr. Katarzyna 
Walkiewicz and Dr. Christian Kleusch. The cell lysates were a generous gift from  
Prof. Dr. Yves Müller (University Erlangen/Nürnberg) and from Prof. Dr. Dirk Daelemans 
(Rega Institute for Medical Research, Leuven).  
 
 
1 Introduction 
 
Reliable determination of binding affinity between a target molecule and its interaction 
partner is a critical step in many areas of biological, biochemical and biomedical research 
and technology. For example, early phases of drug discovery include steps such as 
target identification and validation, hit discovery and lead optimization. During all of these 
steps, quantitative characterization of intermolecular interaction affinity is highly 
necessary to develop novel and effective drugs for therapeutic interventions105. MST is 
a versatile method to quantify binding affinities in solution that is increasingly applied for 
interaction analysis4. In this technique an infrared laser is used to induce a local 
temperature gradient, causing molecules to migrate out of the heated spot47. This 
phenomenon is termed thermophoresis and strongly depends on molecular properties 
such as size, charge, hydration shell and conformation10. As at least one of these 
parameters will change upon binding, MST can be used to quantify the interaction and 
to determine equilibrium dissociation constants (Kd). One notable advantage of MST over 
other routinely used methods for the quantification of molecular binding events, such as 
SPR and ITC, is that it can also be used for the determination of Kd values in complex 
sample matrices like cell lysate and serum16,47,106. Although MST measurements can be 
performed using intrinsic fluorescence of proteins, labeling of the target proteins with a 
suitable fluorophore is required when using such complex samples. Unfortunately, in 
routine labeling techniques, the fluorophore is covalently attached to lysine residues 
using NHS- or to cysteine residues using maleimide chemistry. These labeling strategies 
are limited to purified proteins and cannot be applied in a mixture of several proteins or 
in complex biological matrices such as cell lysate or blood serum107. The generation of 
purified protein can be challenging, time-consuming and expensive, sometimes not even 
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applicable for the protein of interest108. Moreover, it is not possible to predict where the 
fluorophore will bind to the protein. Hence, covalent labeling of a protein with NHS or 
maleimide conjugated dye can lead to inhomogeneous protein-dye conjugates, some of 
which might even display destabilization or loss of functionality109. Fortunately, in 
contrast, site-specific protein modification strategies allow structurally and 
stoichiometrically well-defined labeling with minimal perturbation of structural and 
functional integrity. Two things that have conquered modern life cell fluorescence 
imaging are the genetic fusion of fluorescent proteins and enzymes specifically 
engineered for posttranslational labeling110, but such relatively large tags are not always 
desired for quantitative interaction analysis. With the use of bioorthogonal conjugation 
reactions, labeling of non-purified proteins with high selectivity is possible, allowing rapid 
and cost-effective labeling111. Different site-specific labeling strategies have been 
proposed and applied, including the co-translational introduction of unnatural or modified 
amino acids, or labeling via specific amino acid sequences, such as His-tag sequences 
and tetracysteine motifs107,112–116. Among these sequences, the His-tag is the most 
popular and widely used affinity tag for purification, immobilization or detection of 
proteins117–120. 
 
The tris-NTA / His-tag system comprises one of the smallest high-affinity recognition 
elements known to date121. This interaction is based on the capacity of the histidine’s 
imidazole groups to form coordinative bonds with transition metal ions such as Ni(II). 
Chelators such as nitrilotriacetic acid (NTA)122 stably bind Ni(II) ions via three oxygen 
atoms and one nitrogen atom. The two remaining coordination sites of Ni(II) can each 
bind one histidine moiety of a His-tag (Figure 38)107, yielding a molecular binding affinity 
of ~10 µM123. Tris-NTA is comprised of three NTA moieties coupled to a cyclic scaffold 
and thus can simultaneously bind six Histidine residues of a His6-tag, yielding 
subnanomolar binding affinity and a well-defined 1:1 stoichiometry123. Fast, 
stoichiometric binding of tris-NTA conjugates enabled in situ protein labeling of His-
tagged proteins124–127 that was compatible with complex sample matrices including living 
cells121,124,128–130. These unique features make tris-NTA / oligohistidine interaction 
labeling an attractive candidate for quantitative protein interaction analysis by MST.  
 
In this work, the application of tris-NTA-based labeling of His-tagged proteins for MST 
measurements will be presented. For this purpose, tris-NTA was conjugated to three 
different fluorescent dyes: RED (NT647), GREEN (NT547) and BLUE (Oregon Green® 
488), providing fluorophores from different spectral regions (Figure 38 A).  The dyes 
NT647 and NT547 are MST-optimized dyes, which are commercially available as NHS 
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or maleimide derivatives for MST measurements. Our data highlights the versatility, 
robustness and superiority of the novel tris-NTA labeling approach for MST. Overall, the 
RED-tris-NTA conjugate (NT647-tris-NTA) arose as the optimal dye conjugate for this 
approach. This conjugate is characterized by a high affinity for His-tags, a high 
fluorescence signal and the best S/N ratio of all investigated DYE-tris-NTA conjugates. 
Owing to its red emission spectrum, it enables reliable measurements in complex 
biological matrices such as cell lysates, which display substantial autofluorescence in 
the blue and green part of the spectrum. 
 
 
Figure 38: Labeling of His-tagged proteins via tris-NTA conjugates.  A) Chemical structure of the tris-
NTA moiety conjugated to a fluorophore via a linker. Fluorophores are illustrated on the right: RED (NT647), 
GREEN (NT547) and BLUE (Oregon Green® 488). B) Schematic representation of DYE-tris-NTA bound to 
a His-tagged protein. The conjugate is loaded with Ni(II) ions for the site-specific labeling of histidine-tagged 
proteins. Two remaining coordination sites of the NTA-complexed Ni(II) ions interact with histidine moieties 
of the protein´s His-tag. Figure adapted with permission from ref.131, Scientific Reports.  
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2 Materials  
 
Table 29: Chemicals 
Chemicals Company 
AGI-5198 / IDH-C35 
Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. 
SML0839 
DMSO (≥ 99.8 %) 
Carl Roth GmbH + Co. KG, Karlsruhe, DE, cat.no. 
A994.2 
H2O AnalaR NORMAPUR® 
VWR Prolabo Chemicals, Darmstadt, DE, cat. no. 
102927G 
HEPES 
Carl Roth GmbH + Co. KG, Karlsruhe, DE, cat. no. 
HN78.2 
PD169316 Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. P9248 
Roti®-Stock 10x PBS 
Carl Roth GmbH + Co. KG, Karlsruhe, DE cat. no. 
1058.1 
SB203590 Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. S8307 
TCEP Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. C4706 
Tween®-20  Sigma-Aldrich Co. LLC, St. Louis, US, cat. no. 93773 
 
 
Table 30: Fluorophores 
Coupling of listed fluorophores to tris-NTA moiety was done by Piehler et al. 
Fluorophores Company 
NT547 NHS ester 
NanoTemper Technologies GmbH, Munich, DE, cat. 
no. MO-L002 
NT647 NHS ester 
NanoTemper Technologies GmbH, Munich, DE, cat. 
no. MO-L001 
Oregon Green® 488 NHS ester 
Thermo Fisher Scientific Inc., Wilmington, US, cat. no. 
06149 
 
 
Table 31: Proteins and peptide 
Proteins and peptide Company 
His6-MBP-binding protein ChromoTek GmbH, Munich, DE, cat. no. mbt-250 
His6-p38α MAPK CRELUX GmbH, Munich, DE 
His6-peptide Apexbt Technology LLC, Houston, US, cat. no. A6006. 
His6-pUL53 containing E.coli cell lysate and 
purified His6-pUL53 
Was kindly provided by Sebastian Weigert, Prof. Dr. 
Yves Muller, Division of Biotechnology, Department of 
Biology Friedrich-Alexander University 
Erlangen/Nuremberg, Erlangen, DE 
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MBP 
antibodies-online GmbH, Atlanta, US, cat. no. 
MBP0801 
p38α-mNeonGreen-His6 and mNeonGreen-
His6 in HeLa cell lysate 
Was kindly provided by Prof. Dr. Dirk Daelemans, Dr. 
Thomas Vercruysse, KU Leuven, Department of 
Immunology and Microbiology, Laboratory of Virology 
and Chemotherapy, Rega Institute for Medical 
Research, Leuven, BEL 
 
 
Table 32: Devices 
Devices Company 
Monolith NT.115 (RED/GREEN or BLUE) NanoTemper Technologies GmbH, Munich, DE 
 
Table 33: Further material 
Material Company 
Monolith NT.115 Capillaries NanoTemper Technologies GmbH, Munich, DE 
Monolith NT.115 MST Premium Capillaries NanoTemper Technologies GmbH, Munich, DE 
SPROUT® MINI CENTRIFUGE 12V  Heathrow Scientific®, Vernon Hills, US 
 
 
Table 34: Software 
Software Company 
MO.AffinityAnalysis_x86_2.2.7.6056 NanoTemper Technologies GmbH, Munich, DE 
MO.Control_x86_1.5.3.6096 NanoTemper Technologies GmbH, Munich, DE 
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3 Methods 
 
3.1 Synthesis and preparation of tris-NTA conjugated fluorophores 
 
OregonGreen® 488-tris-NTA was prepared as previously published124. NT647 and 
NT547-tris-NTA conjugates were synthesized and characterized as following: tris-NTA 
modified by an aminocaproic acid (tris-NTA, MW: 1048 g/mol) was synthesized as 
previously described123 to yield tris-NTA-ACA. 5.9 mg tris-NTA-ACA was dissolved in 
100 µL dry DMF, followed by addition of 12 µL EDIPA. 3.0 mg NHS ester of fluorophores 
was separately dissolved in 100 µL dry DMF. Solutions were mixed and stirred overnight 
(20 h) at room temperature under the protection of N2 atmosphere in darkness.  After 
addition of 100 µL H2O, the reaction mixture was continuously stirred for 1 h to quench 
unreacted NHS groups. The mixture was diluted in 20 mL of 0.1 % TFA / water and was 
loaded on a C18 reverse phase HPLC column (Vydac 218TP, 250 mm × 4.6 mm) for 
purification using a 0–70 % acetonitrile gradient in 0.1 % TFA / water (1/6 of the reaction 
per run). The DYE-tris-NTA conjugates were eluted at ~45 % acetonitrile. The purified 
DYE-tris-NTA fractions of each dye were pooled together and lyophilized as blueish, 
orange or pink powder and stored at -20 °C. Obtained products were verified by the MS-
ESI analyses.  
For the nickel loading, the obtained DYE-tris-NTA- were dissolved in 20 to 50 mL of  
10 mM HEPES buffer pH 7.5 to a final concentration of 0.1 mM or less. NiCl2, in a final 
concentration of 5 mM was added to this solution for loading Ni(II) ions on the NTA 
groups. After 15 min, the solution was loaded onto a 1 mL anion-exchange column 
(Hitrap Q, GE Healthcare) and eluted with a gradient of 0-600 mM sodium chloride in  
10 mM HEPES buffer, pH 7.5. The Ni(II)-loaded tris-NTA-fluorophores were eluted at 
~300 mM sodium chloride. For each dye, the fractions from the elution peak were 
combined, and the concentrations were determined photometrically at 647 nm and  
547 nm using an extinction coefficient of 250000 M-1cm-1 and 150000 M-1cm-1, 
respectively. The final products were aliquoted in black Eppendorf tubes and stored at -
20 °C. 
 
3.2 Determination of DYE-tris-NTA binding affinity for oligohistidine tags 
 
His6-peptide or His6-p38α (expression construct CJA3) were diluted in PBST buffer to a 
final concentration of 10 µM and 2 µM, respectively. This solution was used for a 16-step 
serial dilution in PBST buffer (137 mM NaCl, 2.5 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4, pH 7.4, 0.05 % Tween-20) with 10 µL volume in each sample. Next, 10 µL of 
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50 nM dye, dissolved in PBST buffer, was added to all vials of the serial dilution. Samples 
were mixed by pipetting up and down and the reaction was incubated for 30 min at room 
temperature in the dark before samples were loaded into Monolith NT.115 Capillaries. 
Samples were then transferred into the Monolith NT.115 device and MST experiments 
were carried out at 40 % (RED) / 20 % (BLUE) / 100 % (GREEN) LED and medium MST 
power for the His6-peptide measurements and at 40 % (RED) / 60 % (BLUE) / 100 % 
(GREEN) LED and medium MST power for the His6-p38α studies.  
 
3.3 Labeling and MST measurements of purified His6-tagged proteins  
 
Proteins (His6-p38α and His6-MBP-binding protein were diluted to 200 nM in PBST buffer 
(137 mM NaCl, 2.5 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4, 0.05 % Tween-
20). Tris-NTA dyes were diluted in PBST buffer to a final concentration of 100 nM.  
100 µL of protein was then mixed with 100 µL of each dye separately and the reaction 
mixtures were incubated for 30 min at room temperature in the dark.  
Ligand dilution series: Small molecule inhibitors were stored in 100 % DMSO at -20 °C. 
For the dilution series, a 10 µM solution of PD169316 or of AGI-5198 (IDH-C35) was 
prepared using PBST buffer (2 % final DMSO concentration). This stock solution was 
used for the preparation of a 16-step serial dilution in PBST buffer, supplemented with  
2 % DMSO, with a final volume of 10 µL in each vial of the dilution series. For the protein-
protein interaction, 5 µM of MBP diluted in PBST buffer was used as the highest ligand 
concentration of the 16-step dilution series, with a final volume of 10 µL in each reaction 
tube.  
Then 10 µL of 100 nM RED / GREEN or BLUE labeled protein (p38α or MBP-binding 
protein) was added to all 16 vials and samples were mixed by pipetting up and down. 
Reactions were incubated for 30 min at room temperature away from light and then 
loaded into Monolith NT.115 Capillaries. Using the Monolith NT.115 device, MST was 
carried out at 20 % (RED) / 60 % (BLUE) / 100 % (GREEN) LED and high MST power 
for p38α, and at 40 % (RED) / 60 % (BLUE) / 100 % (GREEN) LED and high MST power 
for MBP-binding protein.  
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3.4 Labeling and MST measurements of oligohistidine-tagged proteins in 
crude cell lysate  
 
3.4.1 p38α against SB203580 
 
The p38α protein sequence was obtained through reverse transcription on mRNA from 
A549 cells. Using In-Fusion Cloning technology (Takara Bio USA, Inc.) this p38α coding 
sequence was cloned into a pcDNA3.1 mammalian expression vector behind a CMV 
promotor and separated from the mNeongreen-His6-tag by the linker sequence 
ESGSGS. A pcDNA3.1 vector coding for only mNeongreen-His6 was used as a control. 
These two plasmids expressing mNeongreen-His6 with and without the p38α sequence 
were transfected into 3*10^6 HeLa cells using separate T-75 flasks. Cells were grown 
for 24 h reaching approximately 10*10^6 cells. Cells were pelleted by centrifugation and 
resuspended in 1 mL PBST buffer, supplemented with protease inhibitors. At this step, 
the cells were disrupted using a Dounce homogenizer and centrifuged again at 14 000 x 
g for 30 min at 4 °C to remove cell debris. Obtained supernatant was diluted 1:10 in 
PBST, supplemented with protease inhibitors.  
Concentration of His6-tagged protein in cell lysate was determined by the MST 
experiment as described in the Supplemental information, Figure 4. The labeling of p38α-
mNeonGreen-His6 and mNeonGreen-His6 in HeLa cells was carried out by mixing  
100 µL of about 100 nM p38α-mNeonGreen-His6 or mNeonGreen-His6 with 100 µL of 
100 nM NT647-tris-NTA dye in PBST buffer. Reaction mixture was incubated for 30 min 
at room temperature.  
 
For the MST binding experiment, the stock solution of SB203580 (stored at 2.65 mM in 
100 % DMSO at -20 °C) was diluted 1:50 in PBST, reaching a concentration of 53 µM 
with 2 % DMSO. This solution was used for a 1:1 serial dilution using 16 dilution steps 
and a final volume of 10 µL for each point of the dilution series. Afterward 10 µL cell 
lysate was added to all steps of the dilution series, giving a final ligand concentration of 
26.5 µM with 1 % DMSO. Reaction was incubated for 30 min at room temperature, 
centrifuged at 14 000 g for 10 min at 4 °C and loaded into Monolith NT.115 MST Premium 
Capillaries. MST experiment was carried out using 100 % or 20 % LED power for the 
p38α containing sample and for the negative control, respectively, and high MST power 
for the NT.115 RED instrument. For the NT.115 blue device, 20 % LED and high MST 
power was used.  
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3.4.2 pUL53 against pUL50 
 
For protein expression, a plasmid encoding a His6-tagged protein variant of pUL53 
(residues 50 to 292 of human cytomegalovirus ORF-UL53 1-376)132 was transformed 
into BL21(DE3) cells and grown in LB medium in the presence of 100 mg/mL ampicillin 
and 32 mg/mL kanamycin at 33 °C until OD600 of 0.4. When the required OD was 
reached, 0.25 mM isopropyl -D-thiogalactopyranoside was added to induce protein 
expression. The culture was further incubated overnight at 20 °C. Cells were harvested 
by centrifugation, disrupted by sonication and resuspended in lysis buffer (50 mM 
phosphate buffer, pH 7.4, 300 mM NaCl) containing protease inhibitors, lysozyme, and 
DNase. 
 
For affinity determination of His6-pUL35 against RED-tris-NTA, pUL53-containing cell 
lysate was diluted 1:10 in PBST buffer and a 16-step serial dilution was prepared. RED-
tris-NTA was then added to all dilution steps with a final concentration of 25 nM. Samples 
were incubated for 30 min at room temperature in the dark before they were loaded into 
Monolith NT.115 MST Premium Capillaries and loaded into the Monolith NT.115 device. 
MST experiment was carried out at 40 % LED and high MST power.  
 
Labeling of His6-pUL53 in E. coli lysate was carried out by diluting the lysate 1:10 in 
PBST buffer and adding RED-tris-NTA dye at a final concentration of 50 nM. The mixture 
was incubated for 30 min at room temperature. For the labeling of purified His6-pUL53, 
the protein was first purified from the E.coli cell lysate via a Ni-NTA affinity 
chromatography followed by a size exclusion chromatography step. After purification, 
His6-pUL53 was labeled by mixing100 µL of a 200 nM protein solution with 100 µL of 50 
nM RED-tris-NTA using PBST as reaction buffer. Mixture was incubated for 30 min at 
room temperature in the dark.  
For affinity analysis of purified and non-purified RED-tris-NTA His6-pUL53 against pUL50 
(obtained as previously described)132, HEPES buffer (200 mM, 25 mM HEPES, 1 mM 
TCEP, pH 8.0) was used. The highest ligand concentration in the 16-step serial dilution 
series was 1 µM, with 10 µL volume in each titration step. 10 µL labeled protein was then 
added to all dilutions at a final concentration of 100 nM. Samples were mixed and loaded 
in Monolith NT.115 MST Premium Capillaries. MST experiments were carried out at 40 
% LED and high MST power.  
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3.5 Data acquisition and analysis 
 
The data were acquired with MO.Control 1.5.3 (NanoTemper Technologies GmbH). 
Recorded data were analyzed with MO.Affinity Analysis 2.2.7 (NanoTemper 
Technologies GmbH). The MST on-time yielding the highest S/N ratio was used for the 
Kd determination. The data were fitted using a Kd fit model that describes a molecular 
interaction with a 1:1 stoichiometry according to the law of mass action. The Kd is 
estimated by fitting the equation 19: 
f(c) = Unbound + (Bound − Unbound) ×
c+ctarget+Kd−√(c+ctarget+Kd)2−4cctarget
2ctarget
    (19) 
Where f(c) is the fraction bound at a given ligand concentration c, Unbound is the Fnorm 
signal of the target, Bound is the Fnorm signal of the complex, Kd is the dissociation 
constant or binding affinity, and the ctarget is the final concentration of target in the assay. 
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4 Results 
 
For the MST experiments in this study, the MST optimized dyes NT647 and NT547 were 
conjugated to tris-NTA. For the blue channel, the dye Oregon Green® 488124 was 
chosen. BLUE (OregonGreen® 488) is a derivate of fluorescein, the dyes RED (NT647) 
and GREEN (NT547) have distinct structures. The synthesis of DYE-tris-NTA constructs 
and the loading of the dyes with Ni(II) ions was performed according to previously 
described protocols123,124. Concentrations of DYE-tris-NTA conjugates were determined 
photometrically and the dyes were stored at -20 C until further use. 
   
4.1 The affinity of DYE-tris-NTA for oligohistidine sequences 
 
A high affinity of DYE-tris-NTA for oligohistidines is a prerequisite for labeling of proteins 
for the quantification of intermolecular interactions with MST. I therefore determined the 
affinity between the DYE-tris-NTA and two oligohistidine sequences: a His6-peptide and 
the MAP kinase p38α fused to an N-terminal His6-tag. As expected123, BLUE-, GREEN- 
and RED-tris-NTA displayed high affinity for the His6-peptide (6.7 ± 4.1 nM, 4.4 ± 3.7 nM 
and 3.8 ± 0.5 nM, respectively, Figure 39). Comparable affinities were measured for the 
His6-tag fused to the N-terminus of p38α, yielding Kd values of 2.7 ±1.7 nM for BLUE-
tris-NTA, 6.3 ± 1.7 nM for GREEN-tris-NTA and 2.1 ± 0.8 nM for RED-tris-NTA, 
respectively (Figure 40). These binding affinities are in excellent agreement with 
previously published Kd values of tris-NTA / His-tag interaction123. Slight differences in 
the Kd values between His6-peptide and His6-p38α can be explained with differences in 
the accessibility and the electrostatics due to structural characteristics of the protein and 
the fluorophores. 
 
Notably, the binding of BLUE-tris-NTA and GREEN-tris-NTA to His6-p38α resulted in a 
ligand-induced fluorescence change. To exclude the possibility of nonspecific 
interactions between these dyes and the ligand, I performed an EDTA / His6-peptide 
(ECP) test, which quantifies ligand-induced fluorescence changes while using DYE-tris-
NTA labeling. It consists of two subtests that must be performed to unambiguously 
distinguish between fluorescence changes caused by interaction and those caused by 
non-specific effects. In the case of His-tag labeling, non-specific effects can be caused 
by the interaction of a ligand with the His-tag bound tris-NTA dye (His6-peptide test) or 
by ligand-induced aggregation or adsorption to labware (EDTA test). The nonspecific 
interaction between BLUE-tris-NTA and GREEN-tris-NTA and the ligand was excluded 
based on this test (Supplementary data Figure 3). Hence, the fluorescence signal was 
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used for evaluation of binding data (Figure 40 B and C). In addition, for the p38α protein 
lacking His6-tag, no binding was detected with any DYE-tris-NTA (Figure 40).   
 
 
Figure 39: MST interaction analysis of His6-peptide against different tris-NTA fluorophores.  A) 
Schematic representation of DYE-tris-NTA interaction with His6-peptide. B) C) D) MST traces (top) and dose-
response curves (bottom) of His6-peptide titrated against tris-NTA conjugated dyes. B) BLUE-tris-NTA C) 
GREEN-tris-NTA and D) RED-tris-NTA. 25 nM of DYE-tris-NTA was added to a 16-step serial dilution of 
His6-peptide. Mean values of three independent experiments are shown. Error bars indicate the standard 
deviation. MST experiments were carried out at medium MST power at 25 °C. LED power was set to 20 % 
(B), 100 % (C) and 40 % (D). The resulting dose-response curves were fitted to a one-site binding model to 
extract Kd values; the standard deviation was calculated using the Kd values from each independent 
experiment. Fnorm = normalized fluorescence. Figure adapted with permission from ref.131, Scientific Reports. 
 
 
Figure 40: MST analysis of tris-NTA fluorophores interacting with p38α.  A) Schematic representation 
of tris-NTA-fluorophores and p38α (PDB: 1A9U). B) C) Dose-response curves for BLUE-tris-NTA and 
GREEN-tris-NTA against His6-p38α (black) and p38α (grey) (n=2). D) MST traces (top) and dose-response 
curve (bottom) of His6-p38α (black) and p38α (grey) towards RED-tris-NTA (n=3). All resulting dose-
response curves were fitted to a one-site binding model to obtain Kd values. Error bars indicate the standard 
deviation. MST experiments were performed at a LED power of 60 % (A), 100 % (C) and 40 % (D) and at 
medium MST power. Fnorm = normalized fluorescence. Figure adapted with permission from ref.131, Scientific 
Reports. 
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4.2 Stability of DYE-tris-NTA binding to His-tags  
 
The Ni(II) / His-tag interaction is reversible upon addition of competitor substances such 
as histidine or imidazole. This feature is useful in some contexts since it enables removal 
of immobilized molecules from microarray surfaces or elution of purified proteins from 
column-chromatography133,134. However, in the context of protein labeling for binding 
studies, disruption of the Ni(II) / His-tag interaction should be avoided, since it results in 
dissociation of the dye. To investigate potentially interfering buffer components, I 
systematically screened a set of common additives with respect to their effects on tris-
NTA labeling. To this end, His6-peptide was titrated against RED-tris-NTA, while varying 
the concentration of different additives in the assay buffer PBST. These additives are 
listed in Supplementary Table 20, together with the highest concentration tested and 
their maximum tolerable concentration for the tris-NTA labeling approach. The maximum 
allowed assay concentration was defined as the highest concentration that did not alter 
the Kd value, whereas a slight decrease in the S/N ratio or in the binding amplitude was 
tolerated. In general, chelating agents such as ethylenediaminetetraacetic acid (EDTA) 
and ethylene glycol-bis(aminoethyl ether) (EGTA) or the ionic detergent sodium dodecyl 
sulfate (SDS) should be avoided. In addition, Tris-based assay buffers are known to 
exhibit some ion-complexing capacities135,136, therefore a caution and additional pretests 
are recommended when used for DYE-tris-NTA labeling. The use of divalent metal ions 
as Zn(II), Co(II) and Ni(II) as additives is not recommended because they interfere with 
the labeling.  Bovine serum albumin (BSA) and various proteins without His-tag showed 
no interference at any of the tested concentrations. In general, the tris-NTA labeling 
method turned out to be highly robust toward buffer additives, even regarding competitor 
substances such as imidazole or histidine. Here, only concentrations higher than 1 mM 
showed interference with the labeling reaction. Additionally, reducing agents such as 
tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and dithiothreitol (DTT) can be 
used in the labeling buffer as well. This insensitivity and robustness of DYE-tris-NTA thus 
mostly allows labeling of proteins directly in their storage buffers, without the need for 
buffer exchange.  
 
4.3 Determination of ligand binding affinity using DYE-tris-NTA labeled target 
proteins 
 
A high affinity of DYE-tris-NTA for His-tags is a prerequisite for efficient stoichiometric 
labeling of His-tagged proteins for MST measurements. Because of all our DYE-tris-NTA 
candidates showed an affinity in the low nM range, I proceeded with the determination 
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of ligand binding affinity using DYE-tris-NTA labeled target proteins. For a protein-small 
molecule interaction, His6-p38α was labeled with all three DYE-tris-NTA candidates 
separately. To ensure that virtually all dye is bound to the protein, I labeled the protein 
at a ratio of 1:2 (dye:protein) and incubated the protein / dye mixture for 30 min at room 
temperature to enable complete binding of the DYE-tris-NTA to the protein. As evident 
from the experiment depicted in Figure 40, when I use 25 nM of DYE-tris-NTA, the 
binding of the DYE-tris-NTA reaches the saturation at the concentration of p38α of about 
50 nM. With further increase of the protein concentration, no additional increase in the 
binding of the dye is observed. This means that all dye is bound to the protein at a ratio 
of about 1:2. Based on this finding, efficient labeling was achieved and no separation of 
unbound dye was required. I proceeded immediately to the next step and added the 
labeled target protein to a dilution series of PD169316, a known selective inhibitor of 
p38α137,138. The ligand AGI-5198 (IDH-C35), a potent inhibitor of isocitrate 
dehydrogenase 1, served as a negative control. For PD169316 I measured Kd values of 
16.7 ± 1.2 nM, 35 ± 5 nM and 24 ± 9 nM for BLUE-, GREEN- and RED-tris-NTA, 
respectively, which is in accordance with published values51 (Figure 41).  
 
 
Figure 41: The interaction of p38α protein with small molecule inhibitors.  MST traces (top) and dose-
response-curves (bottom) for labeled His6-p38α (BLUE-tris-NTA (B), GREEN-tris-NTA (C) and RED-tris-
NTA (A)) against PD169316 (black) or IDH-C35 (grey). The resulting dose-response curves were fitted to a 
one-site binding model for Kd determination. All measurements were done in triplicates, error bars indicate 
the standard deviation. MST experiments were performed at high MST power and LED power of 60 %,100 
% and 20 % (from left to right). Fnorm = normalized fluorescence. Figure adapted with permission from ref.131, 
Scientific Reports. 
 
 
As a second example, the interaction between maltose-binding-protein (MBP) and MBP-
binding protein was analyzed. This 15 kDa VHH binds MBP of E.coli with high affinity 
(ChromoTek GmbH, unpublished data). For MST affinity analysis, His6-tagged MBP-
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binding protein was labeled with all three DYE-tris-NTA conjugates separately and added 
to a serial dilution of MBP in PBST buffer. The Kd values measured were 6 ± 2 nM for 
BLUE-tris-NTA, 5 ± 4 nM for GREEN-tris-NTA and 7 ± 1 nM for RED-tris-NTA (Figure 
42). No binding was detected for labeled His6-peptide against titrated MBP, which 
underscores the high specificity of the MBP-binding protein for its ligand MBP. Among 
all DYE-tris-NTA candidates, RED-tris-NTA showed the best S/N ratio.  
 
 
Figure 42: MST measurements of MBP towards MBP binding protein.  MST traces (top) and dose-
response curves (bottom) of MBP towards BLUE-tris-NTA-MBP-binding protein (A), GREEN-tris-NTA-MBP-
binding protein (B) and RED-tris-NTA-MBP-binding protein (C). The resulting dose-response curves were 
fitted to a one-site binding model to extract Kd values. All experiments were done in triplicates. Error bars 
indicate the standard deviation. MST experiments were performed at a LED power of 60 % (A), 100 % (B) 
and 40 % (C) and at high MST power. Fnorm = normalized fluorescence. Figure adapted with permission from 
ref.131, Scientific Reports. 
 
 
As is evident from Figure 40 to Figure 42, differences in MST binding curve direction can 
be observed between the three DYE-tris-NTA candidates. For RED-tris-NTA and 
GREEN-tris-NTA, the unbound state of the protein exhibits the smallest changes in 
fluorescence; while for BLUE-tris-NTA, the bound state of the protein exhibits the 
smallest changes in the fluorescence. As mentioned previously, RED- and GREEN-tris-
NTA are highly similar regarding their chemical structures, whereas BLUE-tris-NTA 
belongs to a different family of dyes. These molecular properties likely result in different 
MST signals of labeled proteins in the unbound and bound state and thus reverse the 
direction of the sigmoidal binding curve.  
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4.4 Determination of ligand binding affinity by labeling of His6-tagged target 
proteins in crude cell lysate 
 
The determination of ligand binding affinity directly in complex sample matrices like crude 
cell lysate, cell-free expression systems and blood serum offers several advantages. 
This approach is not only faster and more cost-effective, but it also enables studies with 
proteins in their natural environment. As the degree of autofluorescence from cell lysate 
components is higher for green and blue spectral regions, only RED-tris-NTA was used 
for all ligand binding studies in cell lysates.  
 
As a first example, p38α-mNeonGreen-His6 and mNeonGreen-His6 were both expressed 
in mammalian cells for direct labeling in cell lysate using RED-tris-NTA. Labeling 
products were then used to quantify the interaction between p38α and SB203580. 
Thereby, mNeonGreen-His6 served as a negative control to verify the high specific 
binding of the small inhibitory compound to p38α. Further, the same interaction was 
quantified using mNeonGreen-His6-p38α as a target. Fluorescent proteins like 
mNeonGreen can be used as a fluorescent label for MST affinity analysis, which is 
performed directly in the cell lysate.  
 
To first determine the optimal dye-to-protein ratio for this labeling approach, first the 
concentration of p38α in cell lysate was experimentally determined. Therefore, cell lysate 
was titrated against a constant concentration of RED-tris-NTA and MST was carried out. 
Knowing the Kd value of this interaction from the experiments described above (Figure 
40), the concentration of p38α in the cell lysate could be determined as described in the 
Method section. Assuming the expression level of mNeonGreen-His6 to be like that of 
mNeonGreen-His6-p38α, the same amount of fluorophore was added to cell lysate 
containing mNeonGreen-His6, which served as negative control. For the MST 
experiment, a serial dilution of SB203580 was prepared using PBST buffer and a 
constant amount of labeled p38α-mNeonGreen-His6 or labeled mNeonGreen-His6 was 
added to all dilution steps. Only cell lysate containing labeled p38α showed clear binding 
towards SB203580 with a Kd of 116 ± 0.84 nM, while no binding could be detected for 
the p38α-free measurement (Figure 43 A). When mNeonGreen-His6-p38α was used as 
the target, much higher noise level was observed at simultaneously smaller binding 
amplitude (Figure 44 B), which consequently resulted in a less reliable fit of the Kd value. 
Nevertheless, the estimated Kd of 56.8 ± 39 nM is comparable to the Kd determined with 
RED-tris-NTA labeled His6-p38α. 
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Figure 43: MST analysis of p38α MAPK against SB203580 in HeLa cell lysate.  MST traces (top) and 
dose-response curve (bottom) of the interaction analysis of p38α against SB203580 in HeLa cell lysate in 
two different detection channels. A) His6-p38α was labeled in HeLa cell lysate to determine its binding affinity 
toward SB203580 (black, n=3). MST experiments were carried out at 100 % LED and high MST power. 
mNeonGreen-His6 served as negative control and did not yield a binding curve (grey, n=2). Here, 20 % LED 
and high MST power were used. B) p38α-mNeonGreen-His6 against SB203580 (n=2). Experiments were 
carried out at 20 % LED and high MST power. The extracted Kd value was 56.8 ± 39 nM. Fnorm = normalized 
fluorescence. Figure adapted with permission from ref.131, Scientific Reports. 
 
 
In the next experimental settings, the MST measurements, in which either the purified 
protein or the protein in crude cell lysate was employed, were compared. Therefore, two 
proteins His6-pUL53 and pUL50 were used, which form the core nuclear egress complex 
of human cytomegalovirus (HCMV)132. First, the binding affinity of RED-tris-NTA towards 
His6-pUL53 in E.coli cell lysate was tested. For this purpose, protein-containing cell 
lysate was titrated and a constant amount of RED-tris-NTA was added to all dilution 
steps. Figure 44 A shows the MST data for this interaction. The binding curve was further 
used to roughly estimate the concentration of His6-pUL53 in the cell lysate to further 
determine the optimal dye concentration for protein labeling. To quantify the interaction 
between RED-tris-NTA labeled His6-pUL53 and pUL50, a serial dilution of the ligand was 
prepared using PBST buffer and a constant amount of labeled target protein was added 
to all dilution steps. As a control, pUL53 was purified after expression in E.coli, labeled 
using RED-tris-NTA and added to a serial dilution of pUL50 in HEPES buffer. Kd values 
of 1.2 ± 0.5 M for the purified protein and 1.8 ± 0.2 M for the measurements in crude 
cell lysate were obtained. These two values are in good agreement with each other and 
differ only slightly from the Kd value reported by Sam et al. using ITC measurements (Kd 
= 0.29 µM)139. The likely reason for this is that formation of the heterodimeric His6-
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pUL53:pUL50 complex is preceded by the dissociation of homodimeric His6-pUL53 into 
monomers. Hence, the Kd values measured here represent apparent affinities and are 
thus concentration-dependent.  
 
 
Figure 44: MST analysis of pUL53 against pUL50 in E.coli cell lysate.  MST affinity analysis of RED-tris-
NTA toward His6-pUL53 containing cell lysate and of labeled pUL53 toward pUL50 in E.coli lysate. MST 
traces (top) and dose-response curves (bottom) for His6-pUL53 against RED-tris-NTA (A) and RED-tris-NTA 
labeled pUL53 against pUL50 (B) (n=3). A) The interaction between RED-tris-NTA and His6-pUL53 was 
measured directly in E.coli lysate at LED 40 % and high MST power. B) MST traces of His6-pUL53 RED-tris-
NTA in E. coli lysate (top) and comparison of the binding affinity of pUL50 toward labeled His6-pUL53 
measured either with purified His6-pUL53 (black) or with His6-pUL53 in crude lysate (red) (bottom). 
Measurements were performed at 40 % LED and medium MST power. Fnorm = normalized fluorescence. 
Figure adapted with permission from ref.131, Scientific Reports. 
 
 
These two examples highlight the versatility, specificity and robustness of the RED-tris-
NTA / His-tag system for the use in complex sample matrices such as cell lysate. 
Measured Kd values were in good agreement with published values and indistinguishable 
from the binding affinities determined in MST experiments using purified proteins.  
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5 Discussion 
 
MST is routinely used for the quantification of molecular binding events and can even be 
used with complex biological matrices like cell lysate and serum. With the intention to 
develop a near-native labeling strategy for MST measurements, the tris-NTA / His-tag 
system was exploited, which comprises one of the smallest high-affinity recognition 
elements known to date. The conjugation of BLUE (OregonGreen® 488), GREEN 
(NT547) and RED (NT647) to tris-NTA resulted in fluorescence probes with high affinity 
and selectivity for oligohistidine tags, an ideal tool for site-selective labeling of proteins 
for quantitative characterization of intermolecular interactions by MST. All investigated 
DYE-tris-NTA conjugates displayed a high affinity for oligohistidine-tags. The RED-tris-
NTA conjugate was identified as the optimal dye conjugate, requiring only low LED power 
and yielding the best S/N ratios. This conjugate was also successfully used for the 
labeling of oligohistidine-tagged proteins in crude cell lysate, which allowed the 
determination of binding affinity for a binding partner directly in lysate. As outlined in this 
study, the compatibility of RED-tris-NTA with complex sample matrices such as cell 
lysate has two major benefits: firstly, it permits the study of biomolecular interactions in 
a near-native environment, allowing a more physiologically realistic assessment. And 
secondly, it may eliminate the need for protein purification for many MST assay setups, 
enabling shorter workflows and easier investigation of difficult-to-purify proteins. 
Combined with its high specificity for His-tags, this labeling strategy offers numerous 
advantages for protein labeling.    
 
Conclusion  
  99 
Conclusion 
 
 
Molecular interactions play a major role in nearly every biological process and are 
therefore of enormous interest for basic and for drug discovery research14,97. Several 
methods are available for the characterization of molecular interactions, including 
surface-immobilization based methods, such as SPR, fluorescence-based techniques, 
like FP, and label-free and in-solution methods, such as DLS or label-free MST5. The 
latter method was so far not applicable for affinity quantification of two molecules that 
both fluoresce in the same spectral region. This does not only exclude label-free MST 
from the analysis of PPIs, but in addition restrict its application range to small inhibitory 
compounds that lack privileged structures, such as indole motifs. Thus, so far MST 
affinity analysis of such interactions required the attachment of a fluorophore to one of 
the binding partners. However, applying NHS- or maleimide-based labeling strategies 
can alter the native structure of a target molecule or can interfere with the ligand binding. 
These potential negative effects of a covalent labeling let to a strong demand for 
strategies to increase the application range of label-free MST59,75. Hence, in this 
dissertation three different strategies were presented, to overcome the problem of 
interfering compounds and to allow measurements of PPIs using the Monolith 
NT.LabelFree device.  
 
Regarding protein-small molecule interactions, differences in the emission profile of 
proteins and compounds were used to choose a smaller emission filter that can detect 
enough protein fluorescence while at the same time cuts-off interfering fluorescence from 
compounds. This was possible, as the emission spectra of proteins are highly conserved, 
while the emission profile of compounds can significantly differ from that of proteins. 
Thus, with the use of a smaller emission filter bandwidth, label-free MST was for the first 
time accessible to interactions that were so-far not measurable using the broader 
emission filter. However, spectral separation of proteins and compounds is no longer 
possible if the compound structure is based on privileged scaffolds like indole-motifs, 
which are also present in the Trp residues of proteins59. Furthermore, prediction of the 
degree of interference is difficult, as already slight changes in the chemical structure of 
the substances can change its emission profiles to a significant extent. Besides the fact 
that the smaller filter bandwidth is not an overall solution for interfering compounds, this 
filter decreases the sensitivity of the device and thus increases the required amount of 
sample. To compensate for this effect, further modifications of the optical system would 
be required. Taken all these limitations together, a second solution strategy was 
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developed and presented in Chapter 2. Here, a CGT strategy together with data analysis 
based on a least-mean-square approximation was applied for the quantification of PPIs. 
Obtained Kd values were verified using standard MST experiments, in which one of the 
binding partners was fluorescently labeled. Data from both approaches were in good 
agreement for all tested interactions, while slight deviations in the obtained Kd values 
were shown to arise from the too high freedom of the fitting algorithm for the selection of 
the complex Fnorm value. To define overall limitations of the CGT strategy, various 
experimental conditions were simulated and showed that distinct Kd determination is 
restricted to several requirements that need to be fulfilled, such as the requirement for 
similar fluorescent intensities and Fnorm values of both unbound proteins. In addition, the 
mentioned limitation regarding the similarity of the fluorescence intensities of both 
molecules made this approach not applicable for protein-small molecule interactions, as 
their fluorescence characteristics differ to a too high extent. 
Although a completely label-free assay is preferred as it provides close-to-native 
experimental conditions, it will always have some limitations, regarding binding partners 
or buffer components that interfere with the detection system. Thus, the third Chapter 
describes a compromise between preserving the native structure of the target molecule, 
while taking the advantage of a fluorescence tag, which allows for highly sensitive 
binding assays without signal interference of ligands or buffer additives. To achieve this, 
site-specific labeling of His6-proteins was applied. Using such a site-specific labeling 
approach the protein remains in its native conformation and dye-interference with the 
ligand binding is unlikely, as the tag is mostly located far away from the active site. 
Another advantage of this labeling strategy is that it provides a fast and gentle way to 
label a protein, as no removal of unreacted dye is needed. In addition, it can be used to 
direct label histidine tagged proteins in cell-lysate, what wouldn’t be possible using label-
free MST as many cell components show intrinsic fluorescence in the UV region. 
Consequently, the presented site-specific labeling of proteins using tris-NTA-
fluorophores is a valuable tool for MST affinity analysis under close-to-native 
experimental conditions.  
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1. nanoDSF for protein stability determination 
 
nanoDSF is a label-free differential scanning fluorimetry method, that is used to quantify 
protein stability. Therefore, it determines the unfolding transition midpoint Tm (°C), which 
is the point at where half of the protein is unfolded. For the unfolding procedure, either 
thermal or chemical unfolding of the protein is used. While thermal unfolding experiments 
use a temperature ramp to unfold proteins, chemical unfolding experiments use 
chaotropes such as urea or guanidinhydrochlorid. During both measurement modes, the 
device monitors changes in the intrinsic fluorescence of proteins Trp and Tyr residues, 
as those strongly depend on their local environment1. Trp residues which are located in 
the hydrophobic core of proteins show maximum fluorescence emission at 330 nm, while 
the same amino acid exposed to the solvent, will show maximum emission at 350 nm2. 
To detect both signals, nanoDSF uses and dual-UV detector, giving the option to monitor 
the unfolding event either at 330 nm, 350 nm or at the ratio of 350 nm / 330 nm. This 
fluorescence signal is then plotted against the temperature or against the concentration 
of the denaturant. An example for a resulting unfolding curve is shown in Figure 1.   
 
 
 
Figure 1: The principle of protein unfolding using nanoDSF. Regarding a folded protein, Trp residues 
are mostly located in the hydrophobic core, exhibiting an emission maximum at 330 nm (grey peak). Upon 
unfolding, Trp residues are more and more oriented towards the solvent, which shifts the emission maximum 
towards 350 nm (red peak). For data analysis, fluorescence intensity can be recorded at the ratio of 350 nm 
/ 330 nm, which is plotted against the temperature or against the denaturant concentration. The inflection 
point of the resulting unfolding curve gives the melting temperature (Tm). 
 
In addition, nanoDSF is used to determine colloidal stability using a backreflection optics. 
Here, light passes through the sample-containing glass capillary. In case of no 
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aggregates in the solution, all incident light passes through the capillary and is then 
reflected by the capillary tray and detected by the optical system. If the sample contains 
aggregates, the incident light will be scattered by the particles, leading to loss of detected 
light. This loss of light can be quantified and provides information on protein aggregation 
formation.  
nanoDSF typically is measured in the Prometheus NT.48 (NanoTemper Technologies 
GmbH), which consists of a capillary tray with the option to load 48 glass capillaries for 
one measurement. Thereby, the capillaries are placed on a heatable tray for the thermal 
unfolding of proteins. For the measurement, 10 µL of sample is filled into each glass 
capillary. Thereby the concentration of the sample can range from 5 µg/mL up to  
250 mg/mL (concentrations refer to a standard IgG) in one run. For thermal unfolding, 
samples will be heated from 15 to 95 °C, in either 1 °C/min or faster. Additionally, the 
device can be equipped with a high-temperature upgrade, which allows a maximum 
temperature of 110 °C. 
 
2. Thermal shift assay for maltose binding protein  
 
For the label-free thermal shift assay, the Prometheus NT.48 instrument was used. This 
assay was used to determine if the binding pocket of maltose binding protein (MBP) 
contains maltose as an impurity left from column purification of MBP. First, size exclusion 
chromatography was used to remove any residual maltose from the shipped MBP. 
Briefly, column B was equilibrated using 9 mL MSTP buffer. After equilibration 200 µL of 
25 µM solution was placed onto the column. After the sample entered the resin, the total 
volume was adjusted to 500 µL using assay buffer. For protein elution 600 µL of assay 
buffer was used. The first few µL did not contain protein and were discarded, while the 
residual flow-through was collected (~ 500 µL). The purified MBP was diluted further with 
the MSTP buffer to a final concentration of 5 µM. For the samples in which MBP is bound 
to maltose, 10 mM maltose (dissolved in ddH2O) was mixed 1:1 with 10 µM MBP (purified 
and non-purified) to reach experimental concentrations of 5 µM MBP and 5 mM maltose. 
Samples were filled into Prometheus NT.48 Series nanoDSF Grade Standard Capillaries 
and loaded into the Prometheus NT.48 instrument. Before running the thermal unfolding 
experiment, capillaries were sealed using the sealing paste. Thermal unfolding was 
recorded using 70 % LED power and a heating ramp of 20 °C to 100 °C with 1°C / min. 
Thermal unfolding data were exported with the chart export function in the PR Control 
v1.12.3 software.   
Because it is known that residual maltose remains bound to MBP after the purification 
process, MBP was purified using size exclusion chromatography prior the MST 
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experiment to remove residual maltose from the binding pocket. Thermal shift assay was 
used to determine the success rate of the purification. Therefore, nanoDSF technology 
was used to compare the thermal unfolding data of purified and non-purified MBP, both 
with and without the addition of maltose (Figure 2). After successful removal of maltose 
with size exclusion chromatography, the melting temperature of MBP decreased (green), 
whereas after addition of maltose, the unfolding curve of non-purified MBP nicely 
overlaps with the data of re-purified MBP supplemented with maltose (yellow and red) 
These unfolding data show that binding of maltose stabilizes MBP and thus increases its 
melting temperature. Furthermore, data show that the size-exclusion purification was 
sufficient to reduce any maltose from the MBP binding pocket and that the protein can 
further be used for maltose-binding quantification using MST.  
 
 
Figure 2: Thermal unfolding of MBP with and without the addition of maltose. 350 / 330 nm ratio and 
first derivatives of 5 µM MBP in MSTP buffer prior (blue) and after (green) size exclusion chromatography, 
re-purified MBP with 5 mM maltose (yellow), and non-purified MBP with 5 mM maltose (red), n=3. Samples 
were loaded into Prometheus NT.48 Series nanoDSF Grade Standard Capillaries and sealed. Thermal 
unfolding was run using 70 % LED power and a heating ramp from 20 °C to 100 °C and 1.0 °C / min.    
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3. CGT titration  
 
Table 1: CGT pipetting scheme. 
Vial number Molecule A Molecule B 
1 10.0 µL 0.0 µL 
2 23.4 µL 1.8 µL 
3 21.6 µL 3.6 µL 
4 19.8 µL 5.4 µL 
5 18.0 µL 7.2 µL 
6 16.2 µL 9.0 µL 
7 14.4 µL 10.8 µL 
8 12.6 µL 12.6 µL 
9 10.8 µL 14.4 µL 
10 9.0 µL 16.2 µL 
11 7.2 µL 18.0 µL 
12 5.4 µL 19.8 µL 
13 3.6 µL 21.6 µL 
14 1.8 µL 23.4 µL 
15 0.0 µL 10.0 µL 
 
 
Formulas used for the calculation of free concentrations of [A] and [B] (only shown for 
B), the complex concentration [AB] and for the simulation of Fnorm values for the case of 
an interaction and for the case of no interaction: 
 
  (20) 
         (21) 
 
   (22) 
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4. CGT of DNA Hybridization experiments 
 
Table 2: CGT of DNA Hybridization. Absolute concentration in each tube. 
Vial number Absolute conc. template [nM] 
Absolute conc. perfect match / 
mismatch 1 / mismatch 2 [nM] 
1 0.00000000 100.0000000 
2 7.14285714 92.8571429 
3 14.2857143 85.7142857 
4 21.4285714 78.5714286 
5 28.5714286 71.4285714 
6 35.7142857 64.2857143 
7 42.8571429 57.1428571 
8 50.0000000 50.0000000 
9 57.1428571 42.8571429 
10 64.2857143 35.7142857 
11 71.4285714 28.5714286 
12 78.5714286 21.4285714 
13 85.7142857 14.2857143 
14 92.8571429 7.14285714 
15 100.0000000 0.00000000 
 
 
Table 3: Simulated data summary. Simulated data, using the following values: Fnorm template: 825.635335, 
Fnorm perfect match: 817.940166, Fnorm complex: 874.859182, Kd: 17.8530193, quadratic error: 1.16443823 
Vial 
number 
Free conc. 
template 
[nM] 
Free conc. 
perfect 
match [nM] 
Complex 
conc. [nM] 
Fnorm for 
interaction 
Fnorm for no 
interaction 
Measured 
Fnorm values 
St.dev. 
1 0.00000 100.0000 0.0000000 817.94016 817.9401 817.94016 2.71958 
2 1.21699 86.93127 5.9258659 821.62512 818.4898 822.63069 2.49096 
3 2.77063 74.19920 11.515079 825.58833 819.0394 826.78102 2.88454 
4 4.79461 61.93747 16.633956 829.73974 819.5891 830.52058 3.31007 
5 7.48031 50.33745 21.091113 833.88320 820.1387 834.93548 3.63513 
6 11.0866 39.65811 24.627600 837.67010 820.6884 838.37233 4.23097 
7 15.9205 30.20625 26.936605 840.60153 821.2380 841.95515 4.59336 
8 22.2557 22.25575 27.744246 842.16573 821.7877 843.10298 3.51749 
9 30.2062 15.92053 26.936605 842.10612 822.3374 842.14825 1.99491 
10 39.6581 11.08668 24.627600 840.58711 822.8870 838.82567 1.16394 
11 50.3374 7.480315 21.091113 838.06262 823.4367 835.37182 1.62850 
12 61.9374 4.794615 16.633956 835.01435 823.9863 833.51641 1.69436 
13 74.1992 2.770635 11.515079 831.80018 824.5360 830.75661 1.56357 
14 86.9312 1.216991 5.9258659 828.63646 825.0856 828.15897 2.85521 
15 100.0000 0.000000 0.0000000 825.63533 825.6353 825.63533 2.23997 
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Table 4: Simulated data summary. Simulated data, using the following values: Fnorm template: 833.295444, 
Fnorm mismatch 1: 816.408961, Fnorm complex: 880.293179, Kd: 19.2906922, quadratic error: 0.1403165  
Vial 
number 
Free conc. 
template 
[nM] 
Free conc. 
mismatch 1 
[nM] 
Complex 
conc. [nM] 
Fnorm for 
interaction 
Fnorm for no 
interaction 
Measured 
Fnorm values 
St.dev. 
1 0.0000 100.00000 0.0000000 816.40896 816.40896 816.40896 0.6511364 
2 1.2962 87.010514 5.8466285 820.60845 817.61513 821.58908 1.0251395 
3 2.9423 74.370880 11.343405 825.14322 818.82131 825.85065 0.6338866 
4 5.0717 62.214578 16.356850 829.92576 820.02749 830.67616 1.6884190 
5 7.8715 50.728712 20.699858 834.76097 821.23367 834.03066 0.5595524 
6 11.588 40.160066 24.125648 839.30127 822.43984 838.93687 0.6806615 
7 16.507 30.792972 26.349885 843.04967 823.64602 843.35432 1.0668842 
8 22.874 22.874913 27.125086 845.48812 824.85220 846.10832 0.4384865 
9 30.792 16.507257 26.349885 846.32509 826.05838 846.47944 0.6397446 
10 40.160 11.588637 24.125648 845.66009 827.26455 845.49431 0.4372318 
11 50.728 7.8715698 20.699858 843.88714 828.47073 842.97256 0.7490935 
12 62.214 5.0717208 16.356850 841.46217 829.67691 840.91747 0.6631446 
13 74.370 2.9423093 11.343405 838.74827 830.88308 838.93532 1.2250487 
14 87.010 1.2962285 5.8466285 835.98137 832.08926 835.77715 0.8381949 
15 100.00 0.0000000 0.0000000 833.29544 833.29544 833.29544 0.3060108 
 
 
Table 5: Simulated data summary. Simulated data, using the following values: Fnorm template: 827.872274, 
Fnorm mismatch 2: 803.861025, Fnorm complex: 946.806993, Kd: 85.0505851, quadratic error: 0.15111039 
Vial 
number 
Free conc. 
template 
[nM] 
Free conc. 
mismatch 2 
[nM] 
Complex 
conc. [nM] 
Fnorm for 
interaction 
Fnorm for no 
interaction 
Measured 
Fnorm values 
St.dev. 
1 0.000000 100.00000 0.0000 803.86102 803.86102 803.86102 0.0565020 
2 3.486369 89.200655 3.6564 810.15508 805.57611 810.76565 1.3514143 
3 7.413442 78.842013 6.8722 816.32100 807.29120 816.64699 1.4986118 
4 11.83250 68.975360 9.5960 822.17695 809.00629 822.38911 2.2025124 
5 16.79335 59.650498 11.778 827.51566 810.72138 827.83170 2.1547540 
6 22.34081 50.912246 13.373 832.12158 812.43647 832.12501 2.1714705 
7 28.51081 42.796527 14.346 835.79579 814.15156 836.25987 0.9939388 
8 35.32668 35.326680 14.673 838.38398 815.86664 839.13284 0.1333003 
9 42.79652 28.510812 14.346 839.80050 817.58173 840.29171 0.5398805 
10 50.91224 22.340818 13.373 840.04104 819.29682 839.67665 1.4309383 
11 59.65049 16.793355 11.778 839.18003 821.01191 837.88272 1.3478174 
12 68.97536 11.832503 9.5960 837.35407 822.72700 836.44815 1.923156 
13 78.84201 7.4134425 6.8722 834.73753 824.44209 833.84912 2.1363912 
14 89.20065 3.4863693 3.6564 831.51726 826.15718 831.25164 1.8914184 
15 100.0000 0.0000000 0.0000 827.87227 827.87227 827.87227 1.2767998 
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5. Perfect match DNA Hybridization using different starting concentrations 
 
Table 6: CGT of DNA Hybridization. Absolute concentration in each tube.  
Vial number Absolute conc. template [nM] 
Absolute conc. perfect match 
[nM] 
1 0.00000000 100.0000000 
2 7.14285714 92.8571429 
3 14.2857143 85.7142857 
4 21.4285714 78.5714286 
5 28.5714286 71.4285714 
6 35.7142857 64.2857143 
7 42.8571429 57.1428571 
8 50.0000000 50.00000000 
9 57.1428571 42.8571429 
10 64.2857143 35.7142857 
11 71.4285714 28.5714286 
12 78.5714286 21.4285714 
13 85.7142857 14.2857143 
14 92.8571429 7.14285714 
15 100.0000000 0.00000000 
 
 
Table 7: Simulated data summary. Simulated data, using the following values: Fnorm template: 773.26655, 
Fnorm perfect match: 758.20794, Complex Fnorm 821.66787, Kd: 10.219274, quadratic error: 0.3024734 
Vial 
number 
Free conc. 
template [nM] 
Free conc. 
perfect match 
[nM] 
Complex 
conc. 
Fnorm for 
interaction 
Fnorm for no 
interaction 
Measured 
Fnorm values 
1 0.00000000 100.000000 0.000000000 758.207939 758.207939 758.207939 
2 0.75562359 87.1556236 6.444376408 762.662769 759.283554 762.831529 
3 1.75246507 73.7524651 12.64753493 767.612116 760.359169 768.825269 
4 3.11197549 60.7119755 18.48802451 773.030943 761.434784 773.455082 
5 5.03496552 48.2349655 23.76503448 778.769343 762.510399 777.536562 
6 7.84945266 36.6494527 28.15054734 784.424704 763.586014 782.825506 
7 12.0419499 26.4419499 31.15805008 789.203951 764.661635 787.053121 
8 18.1532043 18.1532043 32.24679571 792.046496 765.737245 791.541288 
9 26.4419499 12.0419499 31.15805008 792.317655 766.812862 795.197098 
10 36.6494527 7.84945266 28.15054734 790.394302 767.888475 791.339404 
11 48.2349655 5.03496552 23.76503448 787.213976 768.964092 787.905469 
12 60.7119755 3.11197549 18.48802451 783.568609 770.039705 783.975059 
13 73.7524651 1.75246507 12.64753493 779.911489 771.115321 779.805644 
14 87.1556236 0.75562359 6.444376408 776.451711 772.190936 776.123565 
15 100.000000 0.00000000 0.000000000 773.266551 773.266551 773.266551 
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Table 8: CGT of DNA Hybridization. Absolute concentration in each tube.  
Vial number Absolute conc. template [nM] 
Absolute conc. perfect match 
[nM] 
1 0.0 50.0 
2 3.6 46.8 
3 7.2 43.2 
4 10.8 39.6 
5 14.4 36.0 
6 18.0 32.4 
7 21.6 28.8 
8 25.2 25.2 
9 28.8 21.6 
10 32.4 18.0 
11 36.0 14.4 
12 39.6 10.8 
13 43.2 7.2 
14 46.8 3.6 
15 50.0 0.0 
 
 
Table 9: Simulated data summary. Simulated data, using the following values: Fnorm template: 760.939848, 
Fnorm perfect match: 744.752061, Complex Fnorm 809.738121, Kd: 4.85606702, quadratic error: 0.2588723 
Vial 
number 
Free conc. 
template [nM] 
Free conc. 
perfect match 
[nM] 
Complex 
conc. 
Fnorm for 
interaction 
Fnorm for no 
interaction 
Measured 
Fnorm values 
1 0.00000000 50.0000000 0.000000000 744.752061 744.752061 744.752061 
2 0.36106724 43.5610672 3.238932755 749.339115 745.908332 748.639451 
3 0.83856555 36.8385656 6.361434449 754.447633 747.064602 752.962325 
4 1.49212576 30.2921258 9.307874242 760.060013 748.220873 761.924103 
5 2.42151075 24.0215108 11.97848925 766.032685 749.377143 765.441753 
6 3.79240745 18.1924075 14.20759255 771.959042 750.533414 771.039652 
7 5.85591514 13.0559151 15.74408486 777.010345 751.689684 775.406297 
8 8.89752323 8.89752323 16.30247677 780.046852 752.845955 779.819703 
9 13.0559151 5.85591514 15.74408486 780.373467 754.002225 781.708092 
10 18.1924075 3.79240745 14.20759255 778.399734 755.158496 779.655696 
11 24.0215108 2.42151075 11.97848925 775.133217 756.314766 774.928314 
12 30.2921258 1.49212576 9.307874242 771.405454 757.471037 772.574006 
13 36.8385656 0.83856555 6.361434449 767.680588 758.627307 767.382229 
14 43.5610672 0.36106724 3.238932755 764.167287 759.783578 763.683941 
15 50.0000000 0.00000000 0.000000000 760.939848 760.939848 760.939848 
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Table 10: CGT of DNA Hybridization. Absolute concentration in each tube.  
Vial number Absolute conc. template [nM] 
Absolute conc. perfect match 
[nM]  
1 0.0 5.00 
2 0.36 4.68 
3 0.72 4.32 
4 1.08 3.96 
5 1.44 3.60 
6 1.80 3.24 
7 2.16 2.88 
8 2.52 2.52 
9 2.88 2.16 
10 3.24 1.80 
11 3.6 1.44 
12 3.96 1.08 
13 4.32 0.72 
14 4.68 0.36 
15 5.00 0.0 
 
 
Table 11: Simulated data summary. Simulated data, using the following values: Fnorm template: 
768.593033, Fnorm perfect match: 755.21791, Complex Fnorm 816.311303, Kd: 1.70864076, quadratic error: 
0.20404395 
Vial 
number 
Free conc. 
perfect match 
[nM] 
Free conc. 
template [nM] 
Complex 
conc.[nM] 
Fnorm for 
interaction 
Fnorm for no 
interaction 
Measured 
Fnorm values 
1 0.00000000 5.00000000 0.000000000 755.217912 755.217912 755.217912 
2 0.10036067 4.42036067 0.259639333 758.816924 756.173276 759.343884 
3 0.22242049 3.82242049 0.497579511 762.565033 757.128642 761.643245 
4 0.37199506 3.25199506 0.708004939 766.351326 758.084008 765.763879 
5 0.55606875 2.71606875 0.883931248 770.001074 759.039374 770.048525 
6 0.78238029 2.22238029 1.017619714 773.275445 759.994742 773.219142 
7 1.05839562 1.77839562 1.101604377 775.900677 760.950106 776.228173 
8 1.38970235 1.38970235 1.130297646 777.634235 761.905471 776.509737 
9 1.77839562 1.05839562 1.101604377 778.345858 762.860837 778.195833 
10 2.22238029 0.78238029 1.017619714 778.063699 763.816203 778.369157 
11 2.71606875 0.55606875 0.883931248 776.952419 764.771569 777.539189 
12 3.25199506 0.37199506 0.708004939 775.243385 765.726935 777.488501 
13 3.82242049 0.22242049 0.497579511 773.165206 766.682301 772.364057 
14 4.42036067 0.10036067 0.259639333 770.903989 767.637667 770.291217 
15 5.00000000 0.00000000 0.000000000 768.593033 768.593033 768.593033 
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6. CGT of IL6 nanobody against IL6 antigen    
 
Table 12: CGT of nanobody antigen interaction. Absolute concentration in each tube.  
Vial number Absolute conc. antigen [nM] Absolute conc. nanobody [nM] 
1 0.00 250.00 
2 25.00 232.14 
3 50.00 214.29 
4 75.00 196.43 
5 100.00 178.57 
6 125.00 160.71 
7 150.00 142.86 
8 175.00 125.00 
9 200.00 107.14 
10 225.00 89.29 
11 250.00 71.43 
12 275.00 53.57 
13 300.00 35.71 
14 325.00 17.86 
15 350.00 0.00 
 
 
Table 13: Simulated data summary. Simulated data, using the following values: Fnorm nanobody: 
958.223794, Fnorm antigen: 949.578126, Complex Fnorm: 928.800717, Kd: 55.3873329, quadratic error: 
0.11457584 
Vial 
number 
Free conc. 
nanobody 
[nM] 
Free conc. 
antigen [nM] 
Complex 
conc. [nM] 
Fnorm for 
interaction 
Fnorm for no 
interaction  
Measured 
Fnorm values 
St.dev. 
1 0.000000 100.0000 0.0000000 949.57812 949.57812 949.57812 3.6989619 
2 5.172467 212.3153 19.827532 948.03062 950.41867 948.06535 1.8987948 
3 11.95604 176.2417 38.043959 946.54116 951.21379 946.94831 2.2721378 
4 20.99961 142.4281 54.000384 945.25287 951.96706 945.69665 0.9039912 
5 33.14539 111.7168 66.854604 944.37069 952.68169 945.01979 0.4512768 
6 49.30852 85.0228 75.69147 944.11982 953.36060 944.12029 1.2208516 
7 70.16446 63.0216 79.83553 944.63892 954.00639 944.06134 1.0380502 
8 95.79511 45.7951 79.20488 945.87578 954.62143 946.08533 0.1044339 
9 125.6388 32.7817 74.36110 947.60718 955.20786 947.03045 2.0446483 
10 158.8026 23.0883 66.19734 949.56823 955.76763 949.32097 0.8070402 
11 194.4092 15.8378 55.59073 951.55589 956.30253 951.82826 1.8641302 
12 231.7618 10.3332 43.23819 953.45204 956.81417 952.57822 1.6735065 
13 270.3583 6.07258 29.64169 955.20277 957.30404 955.88684 3.1565727 
14 309.8508 2.70798 15.14915 956.79219 957.77349 957.09468 2.7785391 
15 100.0000 0.000000 0.0000000 958.22379 958.22379 958.22379 4.2853042 
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7. CGT of MBP binding protein against MBP 
 
Table 14: CGT of MBP binding protein against MBP. Absolute concentration in each tube.  
Vial number Absolute conc. MBP [nM] 
Absolute conc. MBP binding 
protein [nM] 
1 0.00000000 200.000000 
2 7.14285714 185.714286 
3 14.2857143 171.428571 
4 21.4285714 157.142857 
5 28.5714286 142.857143 
6 35.7142857 128.571429 
7 42.8571429 114.285714 
8 50.0000000 100.000000 
9 57.1428571 85.7142857 
10 64.2857143 71.4285714 
11 71.4285714 57.1428571 
12 78.5714286 42.8571429 
13 85.7142857 28.5714286 
14 92.8571429 14.2857143 
15 100.0000000 0.00000000 
 
 
Table 15: Simulated data summary. Simulated data, using the following values: Fnorm MBP: 635.398104, 
Fnorm MBP binding protein: 612.664769, Complex Fnorm: 739.658359, Kd: 5.46473725, quadratic error: 
1.69408839 
Vial 
number 
Free conc. 
MBP [nM] 
Free conc. 
MBP 
binding 
protein 
[nM] 
Complex 
conc. 
Fnorm for 
interaction 
Fnorm for no 
interaction 
Measured 
Fnorm values 
St.dev. 
1 0.0000000 200.0000 0.0000000 612.66476 612.66476 612.66476 6.4000821 
2 0.2118548 178.7832 6.93100228 617.42477 613.50674 605.32272 8.4266407 
3 0.4786894 157.6215 13.8070248 622.92777 614.41348 608.99876 14.700579 
4 0.824637 136.538 20.6039341 629.34740 615.39276 624.242 8.6975715 
5 1.289944 115.575 27.2814844 636.90319 616.45365 637.84466 7.8318194 
6 1.946468 94.8036 33.7678171 645.85980 617.60679 646.85403 9.6458207 
7 2.933875 74.3624 39.9232672 656.48590 618.86476 657.08161 6.0869066 
8 4.552629 54.5526 45.4473700 668.85676 620.24254 677.05541 16.755838 
9 7.515278 36.0867 49.6275781 682.09801 621.75810 677.70054 8.4517613 
10 13.47099 20.6138 50.8147195 692.28100 623.43319 683.15627 11.819692 
11 24.65377 10.3680 46.7747930 692.13700 625.29439 698.79341 4.4100603 
12 40.77883 5.06455 37.7925901 681.13357 627.37457 687.91907 9.5417692 
13 59.54459 2.40173 26.1696910 665.74285 629.71477 664.04428 5.6127766 
14 79.49035 0.91892 13.366785 650.03653 632.36699 646.30674 2.8519700 
15 100.00000 0.000000 0.0000000 635.39810 635.39810 635.39810 9.5434050 
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Table 16: CGT of MBP binding protein against MBP. Absolute concentration in each tube.  
Vial number Absolute conc. MBP [nM] 
Absolute conc. MBP binding 
protein [nM] 
1 0.00000000 400.000000 
2 14.2857143 371.428571 
3 28.5714286 342.857143 
4 42.8571429 314.285714 
5 57.1428571 285.714286 
6 71.4285714 257.142857 
7 85.7142857 228.571429 
8 100.000000 200.000000 
9 114.285714 171.428571 
10 128.571429 142.857143 
11 142.857143 114.285714 
12 157.142857 85.7142857 
13 171.428571 57.1428571 
14 185.714286 28.5714286 
15 200.000000 0.00000000 
 
 
Table 17: Simulated data summary. Simulated data, using the following values: Fnorm MBP: 656.529406, 
Fnorm MBP binding protein: 599.601676, Complex Fnorm783.63247, Kd: 22.6235537, quadratic error: 
1.17179075 
Vial 
number 
Free conc. 
MBP [nM] 
Free conc. 
MBP 
binding 
protein [nM] 
Complex 
conc. [nM] 
Fnorm for 
interaction 
Fnorm for no 
interaction 
Measured 
Fnorm values 
St.dev. 
1 0.000000 400.0000 0.00000000 599.60167 599.60167 599.60167 10.872361 
2 0.849134 357.9919 13.4365802 606.37372 601.71011 604.69699 20.614431 
3 1.907776 316.1934 26.6636519 614.14938 603.98073 606.64063 12.088545 
4 3.261142 274.6897 39.5960005 623.13374 606.43300 621.80241 9.2011455 
5 5.045167 233.6165 52.0976895 633.56373 609.08963 631.74827 9.6376562 
6 7.48739 193.201 63.941179 645.67874 611.97726 647.85796 5.3840424 
7 10.9886 153.845 74.725625 659.61741 615.12742 657.31628 6.0801058 
8 16.2864 116.286 83.713520 675.11734 618.57758 676.86210 2.4931291 
9 24.7404 81.8833 89.545247 690.78579 622.37276 683.95987 4.8412432 
10 38.5481 52.8338 90.023289 703.02488 626.56744 696.94659 3.2091541 
11 59.9017 31.3303 82.955351 706.82183 631.22819 710.66638 4.3381924 
12 88.8277 17.3991 68.315102 700.60224 636.43726 707.51716 8.1116311 
13 123.153 8.86814 48.274716 687.76137 642.29747 692.10629 1.6718194 
14 160.669 3.52652 25.044902 672.28989 648.93904 680.44973 15.039229 
15 200.000 0.00000 0.0000000 656.52940 656.52940 656.52946 22.745405 
 
 
 
Supplementary Data 
124 
Table 18: CGT of MBP binding protein against MBP. Absolute concentration in each tube.  
Vial number Absolute conc. MBP [nM] 
Absolute conc. MBP binding 
protein [nM] 
1 0.00000000 800.000000 
2 28.5714286 742.857143 
3 57.1428571 685.714286 
4 85.7142857 628.571429 
5 114.285714 571.428571 
6 142.857143 514.285714 
7 171.428571 457.142857 
8 200.000000 400.000000 
9 228.571429 342.857143 
10 257.142857 285.714286 
11 285.714286 228.571429 
12 314.285714 171.428571 
13 342.857143 114.285714 
14 371.428571 57.1428571 
15 400.000000 0.00000000 
 
 
Table 19: Simulated data summary. Simulated data, using the following values: Fnorm A: 663.150366, Fnorm 
B: 592.785, Complex Fnorm 794.533639, Kd: 46.6522985, quadratic error: 1.20411805 
Vial 
number 
Free conc. 
MBP [nM] 
Free conc. 
MBP 
binding 
protein [nM] 
Complex 
conc. 
Fnorm for 
interaction 
Fnorm for no 
interaction 
Measured 
Fnorm values 
St.dev. 
1 0.0000000 800.00000 0.00000000 592.785 592.785 592.785 13.33373 
2 1.7476699 716.03338 26.8237586 600.21798 595.39112 595.74808 7.648838 
3 3.9252735 632.49670 53.2175835 608.75389 598.19772 603.91453 9.161531 
4 6.7069084 549.56405 79.0073773 618.61866 601.22884 622.66000 14.65067 
5 10.369616 467.51247 103.916098 630.07386 604.51256 622.98971 0.824207 
6 15.37551 386.8040 127.481630 643.38554 608.08181 644.15719 7.637243 
7 22.53454 308.2488 148.894022 658.71434 611.97555 667.15868 4.025270 
8 33.32569 233.3256 166.674309 675.79713 616.24012 672.81596 13.87884 
9 50.44563 164.7313 178.125792 693.18160 620.93114 690.84148 7.358567 
10 78.19382 106.7652 178.949031 707.11292 626.11596 702.47628 8.6557062 
11 120.8166 63.67379 164.89763 712.33453 631.87687 713.69207 8.7669567 
12 178.3943 35.53723 135.89133 707.039018 638.31553 715.94844 6.829136 
13 246.7437 18.17233 96.113380 694.58543 645.55902 689.59310 2.415099 
14 321.5263 7.240630 49.902226 679.11899 653.76831 680.66891 12.04590 
15 400.00000 0.000000 0.0000000 663.15036 663.15036 663.15036 15.44031 
 
 
Raw data of all 1400 simulated interactions can be obtained upon request.  
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8. EDTA test 
 
In MST experiments exhibiting ligand-dependent changes in initial fluorescence, the 
cause of this effect needs to be determined through specificity tests. In some cases, the 
interaction itself is causing the fluorescence changes, allowing data evaluation via initial 
fluorescence. In other cases, the effect is due to material loss such as adsorption of the 
fluorescent molecule to labware or protein aggregation. 
The EDTA (ethylenediaminetetraacetic acid) test is used for assays with DYE-tris-NTA 
labeled samples and was performed according to instructions given in MO.Control 
software. For this, 7 µL of samples 1-3 and 14-16 were centrifuged for 10 min at  
14 000 g and 4 °C, before 7 µL 50 mM EDTA (pH 7.4) solution was added to all six 
samples. Solutions were mixed by pipetting up and down and incubated for 30 min at  
37 °C using a heating block. Afterward samples were loaded into Monolith NT.115 
Capillaries and sample fluorescence was recorded at 25 °C and 60 % or 100 % LED 
power, for BLUE and GREEN respectively. Fluorescence intensities of duplicate 
measurements for the GREEN and the BLUE channel are illustrated in Figure 3. Here, 
the fluorescence intensities of samples 1-3 and 14-16 are presented before and after the 
addition of EDTA. As the high affinity of this interaction is dependent on the presence of 
Ni(II) ions complexed with the NTA molecule, the addition of a chelating agent like EDTA 
removes the Ni(II) ions from the tris-NTA dye, causing dissociation of the dye from the 
His-tagged protein. In case of a non-specific fluorescence decrease, the difference in 
initial fluorescence intensity will remain after addition of EDTA. In case of a binding 
specific fluorescence decrease, the initial fluorescence of all samples will be nearly 
identical after EDTA addition, as seen in Figure 3. 
In situations where interactions of DYE-tris-NTA labeled proteins with a third molecule 
are analyzed, the EDTA test is followed by the Control Peptide test. This is to detect 
fluorescence changes caused by the direct interaction of the third molecule with either 
the tris-NTA dye or the labeled target protein's His-tag. In this particular assay, only the 
interaction of the dye to the His-tagged protein was investigated, and the Control Peptide 
test was therefore not needed. 
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Figure 3: EDTA test. EDTA test to analyze the ligand-induced fluorescence changes observed for BLUE- 
and GREEN-tris-NTA binding to His6-p38α. Fluorescence intensities before and after addition of EDTA 
solution are illustrated for both fluorophores, each measured in two biological replicates (A and B). Figure 
adapted with permission from ref.131, Scientific Reports. 
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9. Tested buffers and additives 
 
Table 20: Buffers and additives. Tested buffer additives to investigate robustness of tris-NTA labeling 
approach. Table adapted with permission from ref.131, Scientific Reports. 
Buffer additive Tested concentrations 
Maximum allowed assay 
concentration 
Histidine 0.25 mM/0.5 mM/1 mM 1 mM 
Imidazole 0.25 mM/0.5 mM/1 mM 1 mM 
EDTA, EGTA 0.25 mM/0.5 mM 0.5 mM 
TCEP 0.25 mM/0.5 mM 0.5 mM* 
DTT 0.25 mM/0.5 mM/1 mM/5 mM 5 mM 
ß-Mercapto-ethanol 0.25 mM/0.5 mM/1 mM 1 mM 
GSH 0.25 mM/0.5 mM/1 mM/5 mM/10 mM 10 mM 
GTP, GDP 0.25 mM/0.5 mM/1 mM 1 mM 
AMP, ADP, ATP 0.25 mM/0.5 mM/1 mM/5 mM 5 mM 
Glycerol 10% 10 % 
Zn(II), Co(II), Cu(II) 100 nM preloaded protein only** 
Mg(II) 10 mM 5 mM*** 
Polyhistidine-tagged 
ligand 
none none 
*NanoTemper Technologies GmbH recommends to avoid the use of TCEP with the red fluorophores in 
general. 
**Zn2+, Co2+, Cu2+ ions compete for the binding with tris-NTA fluorophores. Thus, only very low nanomolar 
concentrations are tolerated in the assay buffer. Additional pretests are required.  
***Caution is required when using Mg(II), because the magnesium salts might be contaminated with 
significant amounts of divalent heavy metal ions (like Zn(II), Co(II), Cu(II)), which might interfere with the 
labeling. 
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10. Determination of His6 p38α concentration in cell lysate  
 
 
Figure 4: His6-p38α against RED-tris-NTA in HeLa cell lysate. Dose-response curve of the interaction 
analysis of His6-p38α against RED-tris-NTA in HeLa cell lysate, for the determination of protein concentration 
in the cell lysate. A serial dilution of His6-p38α containing cell lysate was prepared and RED-tris-NTA was 
added at a constant concentration of 50 nM. Samples were then filled into Monolith NT.115 MST Premium 
Capillaries and MST experiment was carried out using 50 % LED and medium MST power. Figure adapted 
with permission from ref.131, Scientific Reports. 
 
Concentration of His6-tagged p38α in cell lysate was determined as described. Briefly, a 
1:1 serial dilution of p38α-mNeonGreen-His6 containing HeLa cell lysate was prepared 
using non-transfected HeLa cell lysate as dilution buffer. 50 nM of RED-tris-NTA dye was 
added to all 16 dilution steps, followed by incubation for 30 min at room temperature. 
Samples were then filled into Monolith NT.115 MST Premium Capillaries and MST 
experiment was carried out using 50 % LED and medium MST power. MST data was 
evaluated after 10 sec MST-on time. Resulting dose-response curve is illustrated in 
Figure 4. The data were fitted using a Kd fit model that describes a molecular interaction 
with a 1:1 stoichiometry according to the law of mass action. The Kd is estimated by fitting 
the equation below: 
f(c) = Unbound + (Bound − Unbound) ×
c+ctarget+Kd−√(c+ctarget+Kd)2−4cctarget
2ctarget
  (23) 
 
Where f(c) is the fraction bound at a given ligand concentration c, Unbound is the Fnorm 
signal of the target, Bound is the Fnorm signal of the complex, Kd is the dissociation 
constant or binding affinity, and the ctarget is the final concentration of target in the assay. 
For the data set shown in Figure 4, the Kd of RED-tris-NTA for the His-tagged p38α was 
set to 2.1 nM (as measured for the purified protein) and the ctarget to 25 nM. Taking into 
consideration the 1:1 dilution step, the concentration of the His-tagged p38α was 
estimated to be around 50 nM. 
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11. Overview of experimental parameters 
 
Table 21: Overview of experimental parameters. Table adapted with permission from ref.131, Scientific 
Reports. 
Interaction 
Kd with 
standard 
deviation 
Amplitude* 
S / N 
ratio** 
Reduced 
χ2*** 
Number of 
experiments 
BLUE-tris-NTA against 
His6-peptide 
6.7 ± 4.1 nM 8.8 24.9 1.1 3 
GREEN-tris-NTA against 
His6-peptide 
4.4 ± 3.7 nM 17.2 34.1 5.2 3 
RED-tris-NTA against 
His6-peptide 
3.8 ± 0.5 nM 12.1 61.1 0.2 3 
BLUE-tris-NTA against 
His6-p38α 
2.7 ±1.7 nM 100.3 18.6 3.1 3 
GREEN-tris-NTA against 
His6-p38α 
6.3 ± 1.7 nM 63.6 34.4 0.3 3 
RED-tris-NTA against 
His6-p38α 
2.1 ± 0.8 nM 34.4 91.0 1.4 3 
His6-p38α-BLUE-tris-NTA 
against PD169316 
16.7 ± 1.2 nM 19.3 29.6 1.5 3 
His6-p38α-GREEN-tris-
NTA against PD169316 
35 ± 5 nM 17.1 13.5 1.5 3 
His6-p38α-RED-tris-NTA 
against PD169316 
24 ± 9 nM 13.8 20.1 3.4 3 
BLUE-tris-NTA-MBP-
binding protein against 
MBP 
6 ± 2 nM 6.3 12.7 14.9 3 
GREEN-tris-NTA-MBP-
binding protein against 
MBP 
5 ± 4 nM 18.8 18.4 0.9 3 
RED-tris-NTA-MBP-
binding protein against 
MBP 
7 ± 1 nM 13.0 42.9 3.8 3 
His6-p38α-RED-tris-NTA 
against SB203580 in 
HeLa cell lysate 
116 ± 0.84 nM 16.1 22.4 3.0 3 
mNeonGreen-His6-p38α 
against SB203580 in 
HeLa cell lysate 
56.8 ± 39 nM 4.6 6.3 26.4 2 
RED-tris-NTA toward 
His6-pUL53 containing cell 
lysate 
not determined 11.3 16.2 0.4 4 
RED-tris-NTA labeled 
pUL53 against pUL50 in 
E.coli lysate 
1.8 ± 0.2 M 10.1 42.3 1.5 3 
RED-tris-NTA labeled 
pUL53 against pUL50 
(purified) 
1.2 ± 0.5 M 12.2 26.6 3.8 2 
 
 
*Response Amplitude =  |unbound − bound|      (24) 
Where unbound and bound are the respective estimated values from the fit. “Unbound” 
is the plateau at very low concentrations of ligand (also called baseline), while “bound” 
is the plateau at very high concentrations of ligand (also called saturation). 
 
** The S/N ratio is calculated by dividing the response amplitude by the noise (25). The 
noise is calculated as the standard deviation of the residuals from the fit. 
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S/N =
Response Amplitude
√∑ (ri−r̅)
2
i
n−1
        (25) 
Where ri and ?̅? are the residuals of the fit at a given data point or at an average of all 
residuals, respectively. The number of data points is given by n. 
The S/N ratio is a good parameter from which to judge data quality. A value of more than 
5 is desirable while a value of more than 12 corresponds to an excellent assay. 
 
*** This value is only calculated for merge sets that contain two or more replicates (26). 
χ2 =  ∑
(mi− yi)
2 
σi
i          (26) 
Where 𝑚𝑖 denotes the y-values of the fitted curve, 𝑦𝑖 denotes the averaged raw-data  
y-values and 𝜎𝑖 denotes the standard deviation of the averaged raw-data y-values. 
The reduced χ2 is then defined as (27) 
χ2red =  
χ2
ν
          (27) 
With the residual degree of freedom 𝜈 = 𝑛 − 𝑚; n is the number of data points and m is 
the number of parameters that are fitted (four parameters for both, Kd- and Hill-model, 
except any parameters are fixed). 
In MO.AffinityAnalysis the reduced χ2 can become quite large. The reason for this is that 
replicates are often very similar. This yields a small standard deviation. Since one divides 
by these small values, the number can become quite high. Therefore, the absolute value 
of the reduced χ2 alone is not a useful parameter from which to judge data quality. It is 
however very useful for comparing data quality between replicates or comparable 
samples. In such cases, the smaller χ2 for one particular dataset in comparison to other 
datasets, the better the data quality. 
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